1.
2.
CURRICULUM VITAE
Date of Preparation May 2015
PERSONAL DATA:
a)
NAME:
Janice Jean Phillips Dutcher
b,c)
DATE AND PLACE OF BIRTH:
d)
CITIZENSHIP:
November 10, 1950
Bend, Oregon
USA
3.
EDUCATION:
1968 - 1971 BA, Honors, magna cum laude
University of Utah
1971 - 1975 MD, University of California Davis
Senior Year Rotations: University of Chicago, Northwestern
University, Rush Presbyterian St. Lukes Medical Center
4.
POST DOCTORAL TRAINING:
1975 - 1978 Medical Internship and Residency
Rush University -Presbyterian St. Lukes Hospital; Chicago, IL
1978-1981 – Medical Oncology Fellowship
Clinical Associate, Baltimore Cancer Program,
National Cancer Institute, Balitmore MD
5.
MEDICAL LICENSURE AND BOARD QUALIFICATION:
a)
National Board of Medical Examiners Part 1, 1973; Part 2, 1975; Part 3: July 1, 1976
Certificate: 158946 (initially licensed in Illinois)
Current Licenses:
b)
Maryland (21938); New York (152748);
DEA
AD8285290
American Board of Internal Medicine, 1978
American Board of Internal Medicine, Subspecialty Board of Medical Oncology, 1983
6.
MILITARY SERVICE:
Commissioned Officer, United States Public Health Service, 1978-1982
Inactive Reserve, 1982-
1
7.
PROFESSIONAL ORGANIZATIONS AND SOCIETIES
Eastern Cooperative Oncology Group (member since 1983)
Study Principal Investigator, 1983Hematology Steering Committee, member 1983-1986
Leukemia Core Committee, member 1986Co-Chair, Biological Response Modifiers Committee, 1987-89
Chair, Biologic Response Modifiers Committee, 1989-1995
Bone Marrow Transplant Steering Committee, member 1993-2005
Institutional Principal Investigator, 1993-1997
Member, Scientific Advisory Committee, 1994-1995
Member, Executive Committee, 1994-1997
Member, ECOG Research & Education Foundation Executive Committee, 1995- 1998
BRM co-chair, Lymphoma Committee, 1996-2005
Member, Nominating Committee, 1996-1997
Member, Publication Committee, 2005Chair, Renal Subcommittee of Genitourinary Committee, 1998-2011
Member, ECOG Research & Education Foundation Executive Committee, 2010Member, PrECOG Data Safety and Monitoring Committee, 2014American Society of Clinical Oncology (ASCO) (member since 1980)
Member, Annual Meeting Program Committee, 1988; Co-Chairman, Session on AIDS and
Epidemiology, 1988
Co-Chair, Session on Biologic Therapy, 1996
Member, Annual Meeting Program Committee, 1997; Co-Chair, Session on Immunotherapy and
Gene Therapy, 1997
Chair and participant, Annual Meeting, Educational Session on Renal Cell Cancer, 2002
Participant, Annual Meeting, Categorical Course on Clinical Trial Design, Presentation on Phase II
Trial Design, 2003.
Invited Discussant, Session on New Therapy in Renal Cell Cancer, Annual Meeting, 2004.
Invited Discussant, Session on Health Policy – FDA Drug Approval Process, ASCO Annual
Meeting, 2004
Member, Annual Meeting Program Committee, 2005-2006; Track Leader, Developmental
Therapeutics- Immunotherapy, 2006.
Faculty Member, Joint AACR/ASCO Workshop on Methods in Clinical Cancer Research and
Protocol Development, 1996-2002; Course Program Committee, 1996; 2001
Member, Young Investigator Awards Selection Committee, 1998-2002; Chair, Awards Selection
Committee, 2000-2001
Member, Program Committee and Faculty, FECS/ASCO/AACR European Clinical Methods
Course - planning 1998, held June 23-29, 1999, June 24-29, 2000.
Member, Nominating Committee, 1999-2001
Member, Fellows Task Force Steering Committee, 1999-2000
Member, Task Force on Associate/Junior Active ASCO Members, 2001
Member, Maintenance of Certification Task Force, 2005-2007
Member, In-training Medical Oncology Examination Development Committee, 2009-2011
Member ASCO SEP Exam Committee, 2008 - 2011
2
American Association for Cancer Research (member since 1983)
Member, Subcommittee for Special Conferences, 1997-1999
Faculty, Workshop on Methods in Clinical Research, 1996-2002; Program Committee 1996; 2001
Co-Director, Special Conference on Cytokines and Cancer, Vail Colorado, Sept 20-24, 2000
American Board of Internal Medicine
Member, Medical Oncology Subspecialty Board, 1997-2003
Member, Medical Oncology SEP Update, 2002-2003
American Society of Hematology (member since 1984)
Co-Chairman, Session on Leukemia and Myeloproliferative Disorders, 1983
Member, Program Committee, 1986; Co-Chairman, Session on Transfusion Medicine, 1986.
American Association of Blood Banks (member since 1983)
Workshop Participant, Adoptive Immunotherapy, 1988-89
Session Co-Chair, Apheresis, 1992; Abstract Reviewer, 1992-1996
International Society of Hematology (member since 1986)
Co-Chairman, Session on Leukocytes, 1984
Co-Chairman, Session on Chronic Myelogenous Leukemia, 1988
American Radium Society (member since 1984)
Member, Local Arrangements Committee, 1993; Chair, Local Arrangements Committee, 1994
Moderator and Speaker, Multidisciplinary Panel on Dose Intensification, 1994
Member, Janeway Lecture Committee, 1993-1995; Chair, Janeway Lecture Committee 1996
Member, Local Arrangements Committee, 1997
Member, Public Relations Committee, 1997-1999;
Member, Executive Committee, 1997-1999
Member, Membership and Credentials Committee, 1998-1999
Member, Nominating Committee, 2001-2002
Member, Program Committee, 2004-2005
Member, Executive Committee, 2005
Member, Program Committee, 2006-2007.
Member, Nominating Committee, 2007-2009
National Leukemia Research Association
Member, Medical Advisory Board 1995 - ; Research Grant Reviewer 1995Israel Cancer Research Fund
Scientific Review Committee B, 1996-1998
National Kidney Cancer Association
Medical Advisory Committee, 1996 –
Volunteer Speaker at numerous patient education sessions
Session chair and speaker at annual meetings
European Society for Medical Oncology
Corresponding Member, 1997International Society of Biologic Therapy (member since 1989)
Program Committee, 2002-2003; Development Committee, 2003
Public Affairs Committee, 2003-2006
Board of Directors, 2001-2004
Association for Patient Oriented Research
Board member, 2011 - 2013
Additional Memberships
3
- American Association for the Advancement of Sciences, 1983- American College of Physicians, member, l978, Fellow (044202) l983- American Federation for Clinical Research, l982Chair of Session I, Eastern Division Meeting, April 2012
- American Society for Clinical Pharmacology and Therapeutics, 1984-2013
- New York Academy of Sciences, 1983- New York Cancer Society, Inc 1984- American Society for Apheresis, 1989- International Society for Experimental Hematology, 1993- Kidney Cancer Association, Scientific Adv Board, 10 yr term, continued member, 19888.
ACADEMIC APPOINTMENTS
1978-1981
1978-1982
9.
Clinical Associate
Baltimore Cancer Research Program, Division of Cancer Treatment
National Cancer Institute, NIH
1979-1981
Clinical Associate Cell Component Therapy
Baltimore Cancer Research Program, National Cancer Institute
1982
Senior Investigator, Baltimore Cancer Research Program,
National Cancer Institute
Jul 1982-Dec 1982
Assistant Professor of Internal Medicine
University of Maryland Cancer Center, University of Maryland
Jan 1983-Jun 1986
Jul 1986-Jun 1992
Jul 1992-1998
Assistant Professor of Medicine, Albert Einstein College of Medicine
Associate Professor of Medicine, Albert Einstein College of Medicine
Professor of Medicine, Albert Einstein College of Medicine,
Bronx, New York
Oct 1998-present
Professor of Medicine, New York Medical College
HOSPITAL APPOINTMENTS
Jan 1983-1997
Chief of Service, Oncology, Jack D. Weiler Hospital, Albert Einstein
College of Medicine, Montefiore Medical Center, Bronx,
New York
Jan 1984-1998
Director for Apheresis Research, Blood Bank, Montefiore Medical Center
July 1986-1998
Director of Immunotherapy Clinical Research Program, Montefiore
Medical Center
Jan 1993-1998
Medical Director, Bone Marrow Transplant Program, Montefiore Medical
Center, Albert Einstein Cancer Center, Bronx, New York
Oct 1998-July 2008 Associate Director for Clinical Affairs, Comprehensive Cancer Center
Our Lady of Mercy Medical Center, Bronx, New York
Oct 1998-July 2008
Director of Oncology Apheresis,
Medical Director, Bone Marrow Transplant Program, Our Lady of Mercy
Medical Center, Bronx, New York
July 2008-Nov 2010 Senior Attending, Cancer Center, North Division, Montefiore Medical
Center, Bronx, New York
4
Nov 2010- Nov 2012 Director of Immunotherapy Program, Division of Hematology/ Oncology
St Lukes Roosevelt Hospital Center, Continuum Cancer Centers
New York, NY
10.
HONORS AND AWARDS:
- National Merit Finalist and Scholar, Scholarship Recipient, 1968
Sterling Scholar in General Scholarship, State of Utah, 1968
Presidential Scholar from State of Utah, awarded at the White House by invitation of President Lyndon
B. Johnson, 1968
- Alpha Lambda Delta, Freshman Women Honor Society, President, 1968-70
- Phi Kappa Phi, elected 1971
- Phi Beta Kappa, elected 1971
- Alpha Omega Alpha, elected 1975
- Lange Medical Publishers Award, 1975
- Finalist, Beecham Award in Hematology/Oncology for physicians in clinical research training. Southern
Blood Club of American Federation of Clinical Research, Southern Meeting and Southern Society for
Clinical Investigation, January, 1983
- Leukemia Society of America - Special Fellow, 1983-1985
- First Recipient of the Distinguished Alumnus Award, University of California, Davis School of
Medicine, June 11, 1988.
- Recipient, First Prize for Clinical Research, Henry C. Moses Award, Montefiore Medical Center, 1989
- Recipient, Young Investigator Award, Eastern Cooperative Oncology Group, 1993
- Listed in Who's Who in Science and Engineering, 1992- Listed in Who's Who in America 1995- Listed in Who's Who in the World, 1993- Listed in Who's Who in the East, 1995- Listed in Who's Who in Medicine and Healthcare, 1997- Listed in Who's Who of American Women, 1997- Recipient of the Women of Distinction Health Care Services Award:
from the New Bronx Chamber of Commerce and the Bronx Chamber of Commerce Charitable
Foundation at the second annual luncheon - Women of Distinction – in Celebration of Women’s
History Month , Marina Del Rey, Bronx, NY ; also awarded proclamation from the New York City
Council , March 28, 2008.
11.
FELLOWSHIP AND GRANT SUPPORT
Past Support
- 1982 - Pangborn Research Fund, University of Maryland $1800.
- 1983-85, Leukemia Society of American Special Fellowship - $ 25,000/yr
- 1983-84, National Leukemia Association Fellowship, $ 20,000
- 1986-87, National Leukemia Association Award, $ 20,000
- 1986-87, 5U10CA14958-S2 - ECOG supplement for IL-2/LAK cell studies in melanoma, colon cancer,
and renal cell carcinoma, Co-Principal Investigator.
- 1987-91, RFP/NCI-CM73702-26 - Contract for Clinical Trials of Activated Leukocytes, clinical coprincipal investigator. Co-Principal Investigator,30% effort
- 1986-96, NIH/NCI-P30CA1330 - Albert Einstein Cancer Center, Core Support for Cancer Research
Center, clinical investigator. Program Leader, 1993-1996.
5
- 1996-98, NIH/NCI-P30CA1130 - Albert Einstein Cancer Center, Core Support for Cancer Research,
director of clinical trials and monitoring unit.
- 1986-98, 5U10CA14958 - Participation in Albert Einstein ECOG institutional grant, clinical
investigator, 10% effort and funding. Principal Investigator, 1993-1997.
- 1989-90, American Association of Blood Banks National Foundation Grant -$26,000.
- 1991-92, MAO/RFP NCI-CN-15339-33 - Master Agreement, Phase I Clinical and Pharmacologic
Studies of new Chemopreventive Agents, Principal Investigator.
- 1992-93, Institutional grant from Chiron for IL-2 based clinical and pharmacokinetic trials, $40,000
- 1992-93, PI, Institutional grant from Sandoz for IL-6 based clinical and pharmacokinetic trials, $60,000
- 1992-93, PI, Institutional grant from Sandoz for IL3-based Bone marrow transplantation trial, $40,000
- 1993, PI, Institutional grant from Immunex for GM-CSF studies and peripheral blood stem cells,
$10,000
- 1993-95, PI, Institutional grant from Genetech, Inc for studies of gamma interferon in renal cell,
$60,000
- 1994-6, PI, unrestricted grant from Immunex for GM-CSF/IL2 study in renal cell cancer, $25,000
- 1994-96, PI, Institutional grants from Chiron/Schering, for studies of IL2/IF in renal cell cancer,
$50,000
- 1995-96, PI, Institutional grant from Genetics Institute for phase I/II studies of IL12, $60,000
- 1996-97, PI, Institutional grant from Chiron/Schering for studies of 5FU/IL2/IF in renal cell cancer,
$20,000
- 1997, PI, Institutional grant from Genetics Institute for Phase II study of IL12, $40,000
- 1996-97. PI, Institutional grant from Ligand for studies of Targeting in renal cell cancer, $20,000.
- 1997-98-PI, Institutional grant from Chiron for studies of high dose IL2 in renal cell cancer.
- 1998-99, PI, RO3, Phase II study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia,
$50,000/yr.
- 1998-2003, PI, FDA Orphan Drug Award, Phase II Clinical and Biological Study of Arsenic Trioxide in
Relapsed/Refractory Acute Leukemia, $198,000/yr
- 1998-2000, Co-Invest, Leukemia Society of America Transnational Research Award, Study of Biology
of Arsenic Trioxide in Acute Leukemia, P Wiernik, PI, $100,000/yr
- 1998-2000, PI, Institutional Grant from Immunex for Phase I/II study of CD40 Ligand in solid tumor
and renal cell cancer. $ 100,000.
- 2000, PI, Institutional grant from Wyeth-Ayerst for phase II study of CCI-779 in renal cell cancer,
$75,000.
- 2000, PI, Institutional grant from Chiron/Schering for IL2/IFN studies in renal cell cancer, $5,000.
- 2000-2001, PI, Institutional grant from Bayer for Phase I trial of bayer IL2 in solid tumor, $10,000.
- 2001-2004, PI, Institutional grant from Wyeth-Ayerst (CCI-779)
- 2001-, PI, Institutional grant from Abgenix (ABG-EGF)
- 2002-2003, PI, Institutional grant from Novartis (EPO)
- 2002-2003, PI, Institutional grant from Eisai (E7070)
- 2001-2007 Co-PI, Minority-Based CCOP Grant from NCI.
- 2004- 2010 PI, Institutional grant from Genentech (Avastin)
- 2004 –2010 PI, Institutional grant from Wylex (Vaccine)
- 2004 –2009 PI, Institutional grant from Bayer (Bay 43-9006)
- 2006 –2010 PI, Institutional grant from Novartis, (IL2)
- 2007 – 2010 PI, Institutional Grant from Genentech (Avastin)
- 2010- 2012 PI, Institutional Grant from Exelixis (XL184)
- 2011 -2012 PI, institutional grant from BMS (Anti-PD1)
- 2012
PI, institutional grant – Prometheus (Registry)
- 2011 - 2012 Support of IL2 Clinical Research, ACKC philanthropic grant, $ 10,000
6
- 2011, 2012
12.
LILAC – grants for equipment, freezer component, refrigerated centrifuge
DEPARTMENTAL AND UNIVERSITY COMMITTEES
Albert Einstein College of Medicine
Committee on Clinical Investigations, 1983-1998
Am Cancer Society Institutional Research Grant Review Committee, 1983-86
Experimental Clinical Procedures Committee, Dept of Medicine, 1984-88
Practice Plan Committee, Dept. of Medicine, 1984-1985
Departmental Research Committee, Dept of Medicine, 1986-1987
Clinical Oncology Committee, 1986-1990
Committee on Appointments & Promotions for Associate Professors, main committee
1986-1988; ad hoc committees, 1989-1991
Audio-Visual Committee, 1986-1993
Faculty Committee for the Dean's Letter, 1991-1993
Patent Committee, 1991-1992
Search Committee for Chairman of Radiation Oncology, 1992
Committee on Appointments & Promotions to Professor, main committee 1992 -1994
Associate Director for Clinical Research, Albert Einstein Cancer Center, 1993-1995
Program Leader, Hematologic Malignancies and General Oncology, Albert Einstein Cancer
Center, 1993-1995
Acting Chief, Division of Oncology, 1993-1997
Hospital of Albert Einstein College of Medicine
Tissue Review Committee, 1983-1984
Quality Assurance Committee, 1984-1985
Pharmacy and Therapeutics, 1985-1995
Chair, Pharmacy and Therapeutics, 1993-1995
Transfusion Committee, 1987- 1998
Credentials Committee, 1988-1990
Chief of Service, 1984-1997
Physician's Publication Committee, 1990-1994
Medical and Executive Committee, 1991-1993
Montefiore Medical Center
MMC Division Council, 1994-1995
MMC Medical and Executive Committee, 1996-1997
Acting Chair, Dept Oncology, 1993-1997
Staff and Alumni Association Executive Committee, 1996
Institutional Review Board, 7/2006-9/2010, Consultant, 9/2010
Transfusion Committee, Montefiore North Division, 2008-2010
Medical Council, Montefiore North Division, 2009-2010
Our Lady of Mercy Medical Center
Investigational Review Committee, 1998-2008
7
Transfusion Committee, 1998-2008
Cancer Committee, 1999-2008, Chair, 2005-2008
New York Medical College
Member, Surgery Chair Search Committee, 2001-2002
St Luke’s Roosevelt Hospital, Continuum Cancer Centers
GU Tumor Board, 2010 -2012
Melanoma Tumor Board, 2011 –2012
Leukemia tumor Board – 2011 - 2012
13.
EDUCATIONAL RESPONSIBILITIES:
1984-96, Course Co-Director, Advances in Cancer Treatment Research Symposium – 2 day
course held in Manhattan, sponsored by Albert Einstein College of Medicine
1996-2002, Faculty Member, Joint AACR/ASCO Workshop on Methods in Clinical Cancer
Research and Protocol Development; Course Program Committee, 1996; 2001
1998-2000, Member, Program Committee and Faculty, FECS/ASCO/AACR European Clinical
Methods Course - planning 1998, held June 23-29, 1999, June 24-29, 2000.
See participation in National Meetings – ASCO, AACR, program committees and course
development.
Participation in educational program of oncology dept/division throughout academic career.
14.
OTHER PROFESSIONAL ACTIVITIES
a)
EDITORIAL RESPONSIBILITY
Cancer Investigation, Co-editor, Controversies in Oncology, 1988-1992
Co-editor, Handbook of Oncologic and Hematologic Emergencies, Plenum Press, 1987
Your Patient and Cancer, Consultant, Queries in hematologic malignancies
Editor, Modern Transfusion Therapy, Volumes I & II CRC Press, Inc, 1990.
Editorial Board, Journal of Biologic Response Modifiers, now J Immunotherapy 1990 -1997;
Guest Editor, Intravenous Allopurinol and Tumor Lysis Syndrome, Seminars in Oncology, April
2001
Guest Editor, Interleukin-2 Therapy, Oncology, November 2002.
Section Editor, Chronic Leukemia, Current Treatment Options in Oncology, 2000-2009
Section Editor, Leukemia, Current Treatment Options in Oncology, 2010 –
Associate Editor, Medical Oncology , 1992 – 2014; Reviewer, ongoing
Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 3rd Edition, 1996.
Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 4th Edition, 2003.
Section Editor, Supportive Care, Neoplastic Diseases of the Blood, 5th Edition, 2012
Editorial Board, J. Clinical Oncology, 1996-1998
Editorial Board, Annals of Internal Medicine, 2000 - 2003
Editorial Board, J. Clinical Pharmacology, 1997-1998; 2001-2002, 2004-2005.
Editorial Board, Kidney Cancer Journal, 2006-present
Editorial Board, J Immunotherapy, 2001-present
8
Editorial Board, J Clinical Oncology 2013 -
Manuscript Reviewer for:
American Journal of Medicine; Annals of Internal Medicine
Blood; Bone Marrow Transplantation
Cancer ; Cancer Investigation; Cancer Research
Cancer Treatment Reports; Clinical Cancer Research
Journal of the American Medical Association
Journal of Applied Physiology
Journal of Apheresis
Journal of Biologic Response Modifiers/ now Journal of Immunotherapy
Journal of Clinical Oncology
Journal of Nuclear Medicine
Journal of the National Cancer Institute
Journal of Interferon Research
Journal of Neurologic and Neurosurgical Research
Medical Oncology
New England Journal of Medicine; Transfusion
Kidney Cancer Journal
International Journal of Immunotherapy
Annals of Oncology
b)
CONSULTATIVE ACTIVITY - FEDERAL
National Cancer Institute
Member, Phase I Working Group, 1983-1998
Member, Phase II Working Group, 1983-1998
Member, IL-2/LAK Working Group, 1986-1991
Member, Study Section for Review of BRMP Task B Grants for clinical/laboratory studies
of new biologic therapies, 1988, 1994.
Member, Study Section for Review of New Initiative Grants for Laboratory Correlations of
Clinical Trials, NCI, March 1990.
Member, Site Visit Team, Program Project Grant in Acute Leukemia, 1991
Member, Site Visit Team, Program Project Grant in Chronic Myelogenous Leukemia, 1994
PDQ External Advisory Board, protocol reviewer, 1994- 1998
Member, Site Visit Teams, Cancer Center Reviews, 1994, 1997, 1998
Member, Subcommittee D, Research Programs Review Committee, 1994 -1998
Member, Informed Consent Working Group, 1995-1998
Member, Subcommittee A, Cancer Centers Review Committee, 1998-2002
Member, NCI Central IRB, 1999-2001
Member and Section Leader, PRG Report on Kidney and Bladder Cancer, 2001-2002
Ad Hoc member, Cancer Biomarker Study Section, Oct 2007, February 2008.
Ad Hoc Member, Cancer Immune Therapy Study Section, March 2008.
Member, Cancer Biomarker Study Section, 2008-2012
Ad Hoc member, Cancer Biomarker Study Section, 2012 –
Member, GU Steering Committee, 2008-2012
Member, Renal Cancer Task Force, 2010 Med Onc Co-Chair, Renal Cancer Task Force, 20159
National Heart, Lung and Blood Institute
Member, Data Safety and Monitoring Committee for the
Trial to reduce Alloimmunization to Platelets
(TRAP study), 1990-1995
Member, Site Visit Team, National Marrow Donor Program, 1994
Member, Ad Hoc panel to review T-cell Depletion Trial in Bone Marrow Transplant from
Unrelated Donors, 1995
National Institutes of Health
Panel Member, Consensus Development Conference, Early Melanoma, Diagnosis and
Management, January 27-29, 1992
Member, National Bone Marrow Donor Registry Advisory Committee of the National
Institutes of Health, appointed by Secretary Louis B. Sullivan, M.D., 1993
Food and Drug Administration
Observer, Oncology Drug Advisory Committee, January 1995-July 1995
Member, Oncology Drug Advisory Committee, July 1995-1999
Chair, Oncology Drug Advisory Committee, July 1996-1999
Ad Hoc Consultant, 1999-present
CONSULTATIVE ACTIVITY – PRIVATE
Member, Data Safety and Monitoring Committee, Sanolfi, Oxaliplatin Colorectal phase III
studies, 2000-2002.
Pfizer Visiting Professorship in Oncology, Academic Advisory Board. 2007-2010; Chair,
2009-2010.
Member, Scientific Advisory Board, Univ Pittsburgh Cancer Institute, 1998-2010
Chair, Data Safety and Monitoring Committee, TRIST – Oxford Biomedica - TROVAX
phase III clinical trial, 2007-2010.
Member, Medical Advisory Board, Meniscus Medical Education Ltd, 2006- 2010
Member, Data Safety and Monitoring Committee, Medarex/BMS, Ipilimumab, multiple
clinical trials, 2005-present
Speaker’s Bureau: Pfizer, Novartis, Prometheus, GSK
Consultant, Prometheus Labs, 2012-present
Member, Data Safety and Monitoring Committee, Merck, Anti-PD1, 2013-2015
acknowledged on manuscript – Pembrolizumab in Ipilimumab-refractory melanoma.2015
Member, Data Safety and Monitoring Committee, Tracon, 2014-present
Member, Data Safety and Monitoring Committee, PrECOG, 2014-present
Chair, Data Safety and Monitoring Committee, BMS, Nivolumab randomized adjuvant
trial, 2015PHILANTHROPIC LEADERSHIP
Associate Director, Cancer Research Foundation, 1998-present
10
RESEARCH PROTOCOLS:
- Co-Chairman, Phase III Study of Mitoxantrone and Cytosine Arabinoside versus Daunorubicin and
Cytosine Arabinoside in Acute Non-Lymphocytic Leukemia, 1983-1986
- Co-Chairman, Phase III Study of Mitoxantrone and Cytosine Arabinoside in relapsed ANLL or Blast
Crisis of CML, 1983-1985
- Co-Chairman, Low-dose Cytosine Arabinoside in elderly patients with leukemia, 1983-1986
- Co-Chairman, Phase II Study of Deoxydoxorubicin in refractory acute leukemia, with pharmacology,
1983-1987
- Co-Chairman, Phase II study of Homoharringtonine in refractory acute leukemia, with pharmacology,
1983-1986
- Co-Chairman, Phase III Study of MOAD in adult acute lymphocytic leukemia, 1983-1989
- Chairman, Phase III study of autologous frozen platelet transfusion in alloimmunized patients with
acute non-lymphocytic leukemia, 1984- Chairman, Indium-111-labeled granulocyte migration in infected neutropenic patients, 1983-1991
- Chairman, Ethiodized Oil Emulsion in the identification of hepatic and splenic metastases, 1983-1989
- Co-Chairman, institutional Phase III study of Idarubicin and Cytosine Arabinoside versus Daunorubicin
and Cytosine Arabinoside in ANLL, 1986-1988
- Co-Chairman, Phase II study of mitoxantrone and 5-azacytadine in chronic myelogenous leukemia,
blast crisis. (EST 5484).
- Co-Principal Investigator, Phase II study of Interleukin-2 and Activated Autologous Leukocytes in
Patients with Untreatable Malignancy, 1986-1989.
- Co-Chairman, Indium-111-labeled LAK cells and platelets in patients treated with interleukin-2, 19871989.
- Co-Chairman, ancillary clinical studies in patients treated with interleukin-2
- Chairman, Phase I study of menogaril in relapsed/refractory acute leukemia with pharmacology.
- Co-Chairman, Phase II study of mitoxantrone, CCNU, vinblastine in relapsed Hodgkin's disease. (EST
PH484).
- Chairman, Phase II study of menogaril in acute leukemia (EST 8490)
- Chairman, Phase II studies of interleukin-2 alone and with alpha interferon in patients with renal cell
and melanoma, 1990-92.
- Chairman, phase I-II studies of interleukin-6 in patients with advanced malignancy, 1992-1994
- Chairman, Phase II study of carboplatin in blast crisis of chronic myelogenous leukemia (EST 1992)
- Principal Investigator, Master Agreement for Phase I Clinical and Pharmacological Studies of
Chemopreventive Agents 1990-92.
- Chairman, Phase II study of all-trans retinoic acid in chronic myelogenous leukemia (E1993) 1994-97
- Co-Chairman, Phase II study of IL-4 in CLL and non-Hodgkins lymphoma (E5Y92), 1995-1998
- Co-Chair, Phase II study of Arsenic Trioxide in relapsed/refractory acute leukemia and blast crisis of
CML, and myelodysplasia (funded by NCI-RO3 and FDA Orphan Grant) 1998-2002
- Co-Chair, Phase II study of Arsenic Trioxide plus Ascorbic Acid in relapsed/refractory acute leukemia
and blast crisis of CML, and myelodysplasia (funded by FDA Orphan Grant) 2002- Institutional Chair, Phase III study of high dose IL2 versus outpatient subcutaneous IL2 plus interferon
in metastatic renal cell cancer. 1998-2000
- Institutional Chair, Phase II study of peptide vaccine plus IL2 in metastatic melanoma. 1998- Chair, Phase III study of adjuvant high dose IL2 versus observation in high risk, resected renal cell
cancer, 1998-2002
- Institutional Chair, Phase I and Phase II studies of CD40 Ligand. Phase II in renal cell cancer, 19982001
- Institutional Chair, Phase I study of IL2 plus DENSPM. 2000.
11
-
Institutional Chair, Phase II study of CCI-779 for renal cell cancer. 2000-2001
Institutional Chair, Phase I study of CCI-779 plus Interferon for RCC, 2002-2004
Institutional Chair, Phase I trial of Bayer IL2, 2000-2002
Institutional Chair, Phase I trial of PEG interferon plus IL2 in renal cell cancer, 2000-2003
Institutional Chair, Phase II trial of ABX-EGF in metastatic RCC, 2001-2004
Institutional Chair, Phase II trial of Epothilone 906 in metastatic RCC, 2002.
Institutional Chair, Phase II trial of E7070 in metastatic RCC, 2002-2003
Chair, Pilot study of Adriamycin plus Gemcitabine in sarcomatoid RCC, 2001-2003
Institutional Chair, Phase II trial of IFN plus genesense (anti-bcl 2) in RCC, 2003-2005
PI, Multicenter trial of IL2 plus thalidomide in RCC 2003-2006
Institutional Chair, Randomized Phase II trial of Avastin +/- Tarceva in RCC, 2004
Institutional Chair, Randomized Phase II trial of Bay 43-9006 vs placebo in RCC, 2004-2005
Institutional Chair, Adjuvant g250 Mab vs placebo following nephrectomy in RCC, 2004Institutional Chair, Phase II trial of temodar + thalidomide in melanoma, 2003-2004
Institutional Chair, Phase III trial of SU11248 vs IFN in RCC, 2005-2007
Institutional Chair, Phase II trial of IMOxine in RCC, 2005-2007
Institutional Chair, Phase II open label trial of SU11248 in GIST, 2005-2007
Institutional Chair, Phase II trial of Sutent +/- Avastin in RCC, 2007-2008.
Institutional Chair, Phase II trial of Axitinib following Sorafenib, 2007-2008.
Institutional Chair, Phase II trial of Axitinib vs Sorafenib following Sunitinib, 2008-2009.
Institutional Chair, Phase II trial of Temsirolimus vs Sorafenib, following sunitinib, 2008-2010.
Institutional Chair, Phase I of XL184 drug-drug interaction study in renal cell cancer 2010-2012
Institutional Chair, Phase II dose-finding study of Anti-PD-1 antibody in renal cell cancer, 2011-2012
HOME/ WORK ADDRESS
750 Kappock Street, Apt 511
Riverdale, New York 10463
Email: jpd4401@ aol.com
12
15.
PUBLICATIONS
A)
Original Peer Reviewed Articles
1.
Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Alloimmunization following platelet transfusion: The
absence of a dose-response relationship. Blood 1981; 57; 395-398.
2.
Dutcher JP, Schiffer CA, Johnston GS: Rapid migration of Indium-111-labelled granulocytes to sites of
infection. N Engl J Med 1981; 304; 586-589.
3.
Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long-term follow-up of patients with leukemia
receiving platelet transfusions: Identification of a large group of patients who do not become
alloimmunized. Blood 1981; 58; 1007-1011.
4.
Schiffer CA, Dutcher JP, Hogge DE, Aisner J: Histocompatible platelet transfusion for patients with
leukemia. Plasma Therapy and Transfusion Technology 1982; 3; 272-28l.
5.
Schiffer CA, Aisner J. Dutcher JP: Platelet cryopreservation using dimethylsulfoxide. Annals N Y
Academy of Science 1983; 411; 161-169.
6.
Hogge DE, Dutcher JP, Aisner J, Schiffer CA: Lymphocytotoxic antibody is a predictor of response to
random donor platelet transfusion. Amer J Hematol 1983; 14; 363-369.
7.
Mirvis S, Dutcher JP, Haney PJ, Whitley NO, Aisner J: Serial CT of malignant pleural mesothelioma.
Am J Radiology 1983; 140; 665-670.
8.
Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH: Potential HLA matched platelet
donor availability for alloimmunized patients. Transfusion 1983; 23; 286-289.
9.
Wiernik PH, Riggs C Jr, Dutcher JP: Adriamycin or Daunorubicin in combination with cytosine
arabinoside for the treatment of acute nonlymphocytic leukemia. Drugs Exper Clin Res 1983; 9; 403-406.
10.
Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Aisner J, Wiernik PH. Alloimmunization
prevents the migration of transfused Indium-111-labeled granulocytes to sites of infection. Blood 1983;
62; 354-360.
11.
Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomized trial of leukocytedepleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62;
815-820.
12.
Schiffer CA, Aisner J, Dutcher JP, Wiernik PH: Sustained post-transfusion granulocyte count increments
following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia. Am J
Hematol 1983; 15; 65-74.
13.
Dutcher JP, Haney PJ, Whitley NO, Finley R, Pearl P, Didolkar MS, Wiernik PH: Ethiodized oil
emulsion 13 in computed tomography of hepatoma. J Clin Oncol 1984; 2; 118-123.
14.
Hogge DE, Dutcher JP, Aisner J, Schiffer CA: The ineffectiveness of random donor platelet transfusion
in splenectomized alloimmunized recipients. Blood 1984; 64; 253-256.
13
15.
Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D: High dose intravenous
gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64; 937-940.
16.
Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of
thrombocytopenia and bleeding among patients with solid tumors. Cancer 1984; 53; 557-562.
17.
Dutcher JP: Decreased sensitivity of early imaging with In-111 oxine-labeled leukocytes in detection of
occult infection. J Nuc Med 1984; 25; 1150-1151. (letter to editor).
18.
Paietta E, Dutcher JP, Wiernik PH: Terminal transferase positive acute promyelocytic leukemia: In vitro
differentiation of a T-lymphocytic/promyelocytic hybrid phenotype. Blood 1985; 65; 107-114..
19.
Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and
pharmacokinetic study of taxol. Cancer Res 1987; 47; 2486-2493.
20.
Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as
a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clinical Oncology
1987; 5; 1232-1239.
21.
Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H:
Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin-2
and lymphokine-activated killer cells. Cancer Research 1987; 47; 4208-4212.
22.
Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF: Mitoxantrone and Ara-C in
previously treated patients with acute myelogenous leukemia. Leukemia 1987; 1; 565-567.
23.
Dutcher JP, Schiffer CA, Wiernik PH: Hyperleukocytosis in adult acute nonlymphocytic leukemia:
Impact on remission rate and duration and survival. J Clin Oncol 1987; 5; 1364-1372.
24.
Lipton RB, Galer BS, Dutcher JP, Portenoy RK, Berger A, Arezzo JC, Mizruchi M, Wiernik PH,
Schaumburg HH: Quantitative sensory testing demonstrates that subclinical sensory neuropathy is
prevalent in patients with cancer. Arch Neurol 1987; 44; 944-946.
25.
Wadler S, Einzig AI, Dutcher JP, Ciobanu N, Laudau L, Wiernik PH: Phase II trial of recombinant
alpha-2b-interferon and low dose cyclophosphamide in advanced melanoma and renal cell carcinoma. Am
J Clin Oncol 1988; 11; 55-59.
26.
Dutcher JP, Wiernik PH, Markus S, Weinberg V, Schiffer CA, Harwood KV: Intensive maintenance
therapy improves survival in adult acute non-lymphocytic leukemia: An eight year follow-up. Leukemia
1988; 2; 413-419.
27.
Dutcher JP, Wadler S, Wiernik PH: Biological response modifiers in gynecologic malignancies. Yale
Journal of Biology and Medicine 1988; 61; 367-378.
28.
Dutcher JP, Wiernik PH: Extension of remission in acute non-lymphocytic leukemia. (letter to the
editor) J Clin Oncol 1988; 6; 1783-1784.
14
29.
Dutcher JP, Riggs CE, Strauman JJ, Link B, Wiernik PH: A phase I-II trial of 4'deoxydoxorubicin
(esorubicin) in refractory or relapsed acute leukemia. Clinical Pharmacology and Therapeutics 1989; 45;
424-430.
30.
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D, Ciobanu N,
Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M: A phase II study of interleukin-2
and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin
Oncol 1989; 7; 477-485.
31.
Margolin K, Rayner AA, Hawkins M, Atkins M, Dutcher JP, Fisher RI, Weiss GR, Doroshow J, Jaffe H,
Roper MA, Parkinson D, Wiernik P, Creekmore SP, Boldt DH. Toxicity of interleukin-2 and lymphokineactivated killer (LAK) cell therapy. J Clin Oncol 1989; 7; 486-498.
32.
Walewski J, Paietta E, Dutcher J, Wiernik PH: Evaluation of in-vivo natural killer and lymphokineactivated killer (LAK) cell activity in patients treated with high-dose interleukin-2 and adoptive transfer of
autologous LAK cells. J Cancer Res Clin Oncol 1989; 115; 170-174.
33.
Lipton RB, Apfel S, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik PH, Schaumburg
HH: Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39; 368-373.
34.
Dutcher JP, Kendall J, Norris D, Schiffer C, Aisner J, Wiernik PH: Granulocyte transfusion therapy and
amphotericin B - Adverse reactions? Am J Hematol 1989; 31; 102-108.
35.
Paietta E, Gucalp R, Papenhausen P, Dutcher JP, Wiernik PH: TDT+/non-lymphoid antigen+ acute
leukemias: Immunologic and karyotypic monitoring during therapy and at relapse suggests the
transformation of a bipotential stem cell. Leukemia 1989; 3; 485-491.
36.
Baker H, Marcus SL, Frank O, Petrylak DP, DeAngelis BA, Dutcher JP, Wiernik PH: Interleukin-2
enhances biopterins and catecholamine production during adoptive immunotherapy for various cancers.
Cancer 1989; 64; 1226-1231.
37.
Dutcher JP, Riggs C, Fox JJ, Johnston GS, Norris D, Wiernik PH, Schiffer CA: The effect of
histocompatibility factors on pulmonary retention of Indium-111-labeled granulocytes. Am J Hematol
1990; 33; 238-243.
38.
Wiernik PH, Schwartz B, Dutcher JP, Turman N, Adinolfi C: Successful treatment of hairy cell leukemia
with beta-ser interferon. Am J Hematol 1990; 33; 244-248.
39.
Weisfuse IB, Graham DJ, Will M, Parkinson D, Snydman DR, Atkins M, Karron RA, Feinstone S, Rayner
AA, Fisher RI, Mills BJ, Dutcher JP, Weiss GR, Glover A, Kuritsky JN, Hadler SC. An outbreak of
hepatitis A among cancer patients treated with interleukin-2 and lymphokine activated killer cells. J Infect
Dis 1990; 161; 647-652.
40.
Dutcher JP, Salva KM, Wiernik PH: Successful treatment of hairy cell leukemia with 2'deoxycoformycin after failure of interferons alpha or beta. Am J Clin Oncol 1990; 13; 290-293.
41.
Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH: Acute
renal failure during interleukin-2 treatment - Evidence for an intrinsic renal lesion. J Clin Oncol 1990;
15
8; 1839-1846.
42.
Dutcher JP, Marcus SL, Tanowitz HB, Wittner M, Fuks JZ, Wiernik PH: Disseminated strongyloidiasis
with central nervous system involvement diagnosed antemortem in a patient with the acquired
immunodeficiency syndrome and Burkitts lymphoma. Cancer 1990; 66; 2417-2420.
43.
Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, Sznol M, Dutcher JP,
Aronson FR, Doroshow JH, Atkins MB, Hawkins MJ: Interleukin-2 therapy in patients with metastatic
malignant melanoma: A phase II study. J Clin Oncol 1990; 8; 1650-1656.
44.
Sznol M, Mier JW, Sparano J, Gaynor E, Weiss GR, Margolin K, Bar MH, Hawkins MJ, Atkins M,
Dutcher JP, Fisher RI, Boldt DH, Doroshow JH, Louie A, Aronson FR: A phase I study of high dose
interleukin-2 in combination with interferon-alfa 2B. J Biol Response Modifiers 1990; 9; 529-537.
45.
Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ: A phase II
study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9; 59-64.
46.
Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss
G, Margolin K, Aronson FR, Hawkins M, Atkins M. A phase II study of high dose continuous infusion
interleukin-2 with lymphokine activated killer cells in patients with metastatic melanoma. J Clin Oncol
1991; 9; 641-648.
47.
Sklarin NT, Dutcher JP, Wiernik PH: Lymphomas following cardiac transplantation. Am J Hematol
1991; 37; 105-111.
48.
Wiernik PH, Dutcher JP, Paietta E, Hittelman WN, Vyas R, Strack M, Castaigne S, Degos L, Gallagher
RE: Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid.
Leukemia 1991; 5; 504-509.
49.
Gucalp R, Paietta E, Weinberg V, Papenhausen P, Dutcher JP Wiernik PH: Terminal transferase
expression in acute myeloid leukemia: Biology and prognosis. Br J Haematology 1991; 77; 48-54.
50.
Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R,
Ciobanu N, Grima K, Wiernik PH, Brandt LJ. Colonic ischemia complicating immunotherapy with
interleukin-2 and alpha-interferon. Cancer 1991; 68; 1538-1544.
51.
Lipton RB, Galer BS, Dutcher JP, Portnoy RK, Pahmer V, Meller F, Arezzo JC, Wiernik PH: Large and
small fiber type sensory dysfunction is prevalent in patients with cancer. J Neurol Neurosurg Psychiatry
1991; 54; 706-709.
52.
Marcus SL, Petrylak DP, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank
O, Baker H: Hypovitaminosis C in patients treated with high-dose interleukin-2 and lymphokine-activated
killer cells. Am J Clinical Nutrition 1991; 54 (suppl); 1292S-1297S.
53.
Moskowitz C, Dutcher JP, Wiernik PH: Association of thyroid disease with acute leukemia. Am J
Hematol 1992; 39; 102-107.
54.
Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH,
Doroshow JH, Bar MH, Hawkins MJ, Demchak PA, Gucalp R, Fisher RI, Clark GM: A randomized
16
phase II trial of continuous infusion interleukin 2 or bolus injection interleukin 2 plus lymphokineactivated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10; 275-281.
55.
Wiernik PH, Dutcher JP: Clinical importance of anthracyclines in the treatment of acute myeloid
leukemia. Leukemia 1992; 6 (Suppl 1); 67-69.
56.
Dutcher JP Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M,
Oken M, Cassileth PA: Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of
chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 1992;
6; 770-775.
57.
Baker H, Marcus LS, Frank O, Petrylak DP, DeAngelis B, Baker ER, Dutcher JP, Wiernik PH: Effect of
interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers. J Am Coll Nutr
1992; 11; 482-486.
58.
Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G,
Cavasotto G, Wiernik PH: Survival after phase II treatment of advanced renal cell carcinoma with taxol or
high dose interleukin-2. J Immunotherapy 1993; 13; 275-281.
59.
Sparano JA, Wiernik PH, Leaf A, Dutcher JP: Infusional cyclophosphamide, doxorubicin and etoposide
in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule dependent effect favoring
infusional administration of chemotherapy. J Clin Oncol 1993; 11; 1071-1089.
60.
Mazurek C, Dutcher JP, Schwartz EL, Garl S, Benson L, Wiernik PH: Phase I clinical and
pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute
leukemia. Invest New Drugs 1994; 11; 313-322.
61.
Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan R, Raschko J, Somlo G, Dutcher J,
Hawkswoth K, Yonemoto L, Caliendo G, Cavasotto G: Phase I trial of interleukin-2 plus doxorubicin. J
Immunotherapy 1993; 14; 70-76.
62.
Sparano JA, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP: Phase I trial of
cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha2B in patients with advanced
breast cancer. Cancer Res 1993; 53; 3509-3512.
63.
Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L: Long
term followup of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A Nonanthracycline containing regimen. Leukemia 1993; 7; 1236-1241.
64.
Sparano JA, Micetich KC, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP,
Fisher RI, Weiss GR, Doroshow JH, Aronson FR, Rubinstein LV, Mier JW: Randomized phase III trial
of treatment with high dose interleukin-2 either alone or in combination with interferon-alpha2A in
patients with advanced melanoma. J Clin Oncol 1993; 11; 1969-1977.
65.
Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M,
Parkinson DR, Paietta E, Gaynor ER, Boldt DH, Doroshow JH, Aronson FR: A phase II clinical trial of
interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunotherapy
1994; 15; 74-78.
17
66.
Oleksowicz L, Zuckerman D, Puszkin E, Dutcher JP: Effects of interleukin-2 administration on platelet
function in cancer patients. Am J Hematol 1994; 45; 224-231.
67.
Vlock DR, Snyderman C, Johnson J, Myers E, Rubin J, Dutcher J, Adams G: Phase Ib trial of the effect
of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell
carcinoma of the head and neck: An Eastern Cooperative Oncology Group. J Immunotherapy 1994; 15;
134-139.
68.
Margolin K, Aronson F, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Stewart M, Doroshow
JH, Ernest ML, Mier JW, Dutcher JP, Gaynor ER, Weiss GR. Phase II studies of recombinant human IL4 in advanced renal cancer and malignant melanoma. J Immunotherapy 1994; 15; 147-153..
69.
Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Sarta C, Carney D, Elkind R, Shah M, Valentine
ES, Dutcher JP: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's
lymphoma: A followup report of a highly active regimen. Leukemia and Lymphoma 1994; 14; 263-271.
70.
Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L: Polyethylene glycolated interleukin-2 as
maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematology 1994; 47;
41-44.
71.
Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E: Platelet activation induced by
interleukin-6: Evidence for a thromboxane sensitive mechanism. Thrombosis and Haemostasis 1994;
72; 302-308..
72.
Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP,
Gaynor ER, Boldt DH, Doroshow JH, Ernest ML, Sznol M, Mier JW: Phase II trials of high-dose
interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the
lung, ovary, pancreas and other tumors. J Immunotherapy 1994; 16; 216-223.
73.
Sagayadan GE, Wiernik PH, Sun N, Ahern G, Thompson D, Hallam S, Hu XP, Dutcher JP, Gallagher
RE: Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in
chronic myelogenous leukemia: Increased inhibition by all-trans and 13-cis retinoic acids in advanced
stage disease. Leukemia Res 1994; 18; 741-748.
74.
Oleksowicz L, Strack M, Dutcher JP, Sussman I, Caliendo G, Sparano J, Wiernik PH: Short Report: A
distinct coagulopathy associated with interleukin-2 therapy. Br J Haematology 1994; 88; 892-894.
75.
Oleksowicz L, Mrowiec Z, Issacs R, Dutcher JP, Puszkin E: Morphologic and ultrastructural evidence
for interleukin-6 induced platelet activation. Am J Hematology 1995; 48; 92-99.
76.
Mrowiec ZR, Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Lalezari P, Puszkin EG: A novel
technique for preparing improved buffy coat platelet concentrates. Blood Cells, Molecules and Diseases
1995; 21; 25-33.
77.
Khalil A, Ciobanu N, Sparano JA, Gucalp R, Dutcher JP, Wiernik PH: Pilot study of high dose
mitoxantrone and busulfan plus autologous bone marrow transplantation in patients with advanced
malignancies. Bone Marrow Transplantation 1995; 15; 93-97.
78.
Bennett RT, Lerner SE, Taub HC, Caliendo G, Dutcher JP, Fleischman J: Cytoreductive surgery for
18
stage IV renal cell carcinoma. J Urology 1995; 154; 32-34..
79.
Weiss GR, Margolin KA, Sznol M, Atkins MB, Oleksowicz L, Isaacs R, Sosman JA, Doroshow JH, Trehu
EG, Dutcher JP, Fisher RI: A phase II study of the continuous intravenous infusion of interleukin-6 for
metastatic renal cell carcinoma. J Immunotherapy 1995; 18; 52-56.
80.
Oleksowicz L, Dutcher JP: Adhesive receptors expressed by tumor cells and platelets: Novel targets for
therapeutic anti-metastatic strategies. Medical Oncology 1995; 12; 95-102.
81.
Dutcher JP, Leong T, Makary AZ, Bennett J, Frontiera M, Miller H, Wiernik PH: A phase II study of
menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: A Study of
the Eastern Cooperative Oncology Group. Leukemia 1995; 9; 1638-1642.
82.
Paietta E, Nelson DL, Andersen J, Dutcher JP, Wiernik PH: Levels of soluble interleukin-2 receptors are
predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells. Medical
Oncology 1995; 12; 121-124.
83.
Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E: Characterization of tumorinduced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast
cancer cells. Thrombosis Research 1995; 79; 261-264.
84.
Mrowiec ZR, Oleksowicz L, Zuckerman D, DeLeon-Fernandez M, Khorshidi M, Dutcher JP, Puszkin
EG: Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: Combined
strategies for reducing platelet activation during storage. Transfusion 1996; 36; 5-10.
85.
O'Boyle KP, Colletti D, Mazurek C, Wang Y, Ray SK, Diamond B, Rosenblum MG, Epstein AL, Shochat
D, Dutcher JP, Wiernik PH, Klein RS: Potentiation of antiproliferative effects of monoclonal antibody
Lym-1-gelonin on human Burkitt's lymphoma cells with gamma interferon and tumor necrosis factor. J
Immunotherapy 1996; 18; 221-230.
86.
Oleksowicz L, Puszkin E, Mrowiec Z, Isaacs R, Dutcher JP: Alterations in platelet function in patients
receiving interleukin-6 as cytokine therapy. Cancer Investigation 1996; 14; 307-316.
87.
Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H,
Dutcher JP: Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and
filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J.
Clinical Oncology 1996; 14; 3026-3035.
88.
Sparano JA, Lipsitz S, Wadler S, Hansen R, Bushunow PW, Kirkwood J, Flynn PJ, Dutcher JP, Benson
AB: Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon- in patients with
advanced pancreatic cancer. ECOG Protocol 3292. Am J. Clin Oncol 1996; 19; 546-551.
89.
Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher
RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH: Concurrent phase I trials of
intravenous interleukin-6 in solid tumor patients: Reversible dose-limiting neurologic toxicity. Cancer
Clin Res 1997; 3; 39-46.
90.
Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Paietta E, Etkind P: Human breast carcinoma cells
synthesize a protein immunorelated to platelet GPIb with different functional properties. J Lab Clin Med
19
1997; 129; 337-346.
91.
Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA,
Eckardt JR, Ernest ML, Doroshow J, Atkins MB: Outpatient subcutaneous interleukin-2 and alpha
interferon for metastatic renal cell cancer: Five year follow-up of the cytokine working group study. The
Cancer Journal from Scientific American 1997; 3; 157-162.
92.
Dutcher JP, Coletti D, Paietta E, Wiernik PH: A pilot study of alpha interferon and plicamycin for
accelerated phase of chronic myeloid leukemia. Leukemia Res 1997; 21; 375-380.
93.
O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, Wiernik PH, Horwitz SB:
Development of two radioimmunoassays to detect taxol in sera and in cerebrospinal, ascitic, and pleural
fluids from patients. Cancer 1997; 79; 1022-1030..
94.
Leaf AN, Neuberg D, Schwartz EL, Wadler S, Ritch PS, Dutcher JP, Adams GL: An ECOG phase II
study of Amonifide in unresectable or recurrent carcinoma of the head and neck (PB390). Invest New
Drugs 1997; 15; 165-172.
95.
Oleksowicz L, Dutcher JP, DeLeon-Fernandez M, Etkind P: A GPIb -related protein is expressed by
fresh human breast carcinoma tissue and is regulated by a PKC-sensitive mechanism. Experimental Cell
Research 1997; 237; 110-117.
96.
Malik UR, Dutcher JP, Caliendo G, LaSala P, Mitnick R, Wiernik PH. Phase II trial of merbarone in
patients with malignant brain tumors. Medical Oncology 1997; 14; 159-162.
97.
Mrowiec ZR, Oleksowicz L, DeLeon-Fernandez M, Puszkin EG, Dutcher JP: Apyrase, ascorbic acid and
aprotinin ameliorate the storage lesion in pelleted platelet preparations. Biotechnic & Histochemistry
1997; 72; 259-267.
98.
Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M,
Logan T, Mier J, for the Cytokine Working Group: Interleukin-2-based therapy for metastatic renal cell
cancer: The Cytokine Working Group Experience, 1989-1997. Cancer Journal of Scientific American
1997; 3(Suppl 1); S73-S78.
99.
Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP,
Vogelzang NJ, Ryan JL: Effects of single-dose IL-12 exposure on IL-12-associated toxicity and IFNgamma production. Blood 1997; 90; 2541-2548.
100.
Schiller JH, Neuberg D, Burns D, Ritch P, Larson M, Levitt M, Dutcher JP: An Eastern Cooperative
Oncology Group phase I trial of all-trans retinoic acid and interferon-alpha: E2Y92. Investigational New
Drugs 1997; 15; 319-324.
101.
Wu JJ, Caliendo G, Hu X-P, Dutcher JP: Impact of histology on the treatment outcome of metastatic or
recurrent renal cell carcinoma. Medical Oncology 1998; 15; 44-49.
102.
Dutcher JP, Lee S, Paietta E, Bennett JM, Stewart JA, Wiernik PH: Phase II study of carboplatin in blast
crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992. Leukemia 1998;
12; 1037-1040.
20
103.
Wiernik PH, Dutcher JP, Einzig AI, Sparano J, Frank M, Friedenberg W: Mitoxantrone, vinblastine and
lomustine (CCNU) (MVC): A highly active regimen for advanced and poor prognosis Hodgkin's disease.
Cancer Journal for Scientific American 1998; 4(July/Aug); 254-260.
104.
Wadler S, Atkins M, Haynes H, Karp D, Neuberg D, Dutcher JP: Clinical trial of weekly intensive
therapy with 5-fluorouracil on two different schedules combined with interferon- -2a and filgrastim in
patients with advanced solid tumors: Eastern Cooperative Oncology Group study PZ991. Cancer Journal
for Scientific American 1998; 4(July/Aug); 261-268.
105.
Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuckter L, Weiner LM, Dutcher JP:
Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha interferon.
Medical Oncology 1998; 15; 191-198.
106.
AML Collaborative Group: A systematic collaborative overview of randomized trials comparing
idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia.
Br J Haematology 1998; 103; 100-109.
107.
Oleksowicz L, Dutcher JP: A phase II pilot trial of dose-intensive interleukin-2 in metastatic renal cell
carcinoma. J. Cancer Research and Clinical Oncology, 1999; 215; 101-108.
108.
Atkins MB, Lotze MT, Dutcher JP, Fisher R, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D,
Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin-2 therapy for
metastatic melanoma: Analysis of 270 patients treated between 1985-1993. J Clin Oncol 1999; 17;
2105-2116.
109.
Moadel A, Morgan C, Fatone A, Grennan J, Carter J, LaRuffa G, Skummy A, Dutcher JP: Seeking
meaning and hope: Self-reported spiritual and existential needs among an ethnically-diverse cancer patient
population. Psycho-Oncology 1999; 8; 378-385.
110.
Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt AJ: Phase II protocol for the evaluation of
new treatments in patients with advanced gastric carcinoma: Results of ECOG Study E5282. Medical
Oncology 1999; 16; 261-266.
111.
Dutcher JP. Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J,
Atkins M: Phase II trial of interleukin-2, interferon-alpha and 5-fluorouracil in metastatic renal cell cancer:
A Cytokine Working Group study. Cancer Clinical Research 2000; 6; 3442-3450.
112.
Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S:
Torsade de Pointes in three leukemia patients treated with arsenic trioxide. Blood 2001; 97; 1514-1516.
113.
Vonderheide RH, Dutcher JP, Eckhardt G, Anderson JE, Stephans KF, Razvillas B, Garl S, Butine MD,
Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG: Phase I study of recombinant human CD40
ligand (rhuCD40L) (AVREND) in cancer patients. J Clin Oncology 2001; 19; 3280-3287.
114.
Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Wiernik PH, Chiaramida S: Monitoring the
cardiac toxicity with arsenic trioxide (letter to editor). Blood 2001; 98; 1633-1634.
115.
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier
J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferone
21
alfa-2b in patients with metastatic melanoma: Results of two phase II Cytokine Working Group trials. J
Clin Oncol 2001; 19; 3194-3202.
116.
Vonderheide RH, Dutcher JP, Anderson JE, Caron DA, Gribben JG: CD40 Ligand therapy of lymphoma
patients. (Letter to Editor response) J Clin Oncol 2001; 19; 4351-4353.
117.
Margolin K, Atkins MB, Thompson JA, Ernstoff MS, Weber J, Flaherty L, Clark JJ, Weiss G, Sosman J,
Smith JA, Dutcher JP, Gollob J, Longmate J, Johnson D: Temozolomide and whole brain irradiation in
melanoma metastatic to the brain: a Phase II trial of the Cytokine Working Group. J Cancer Res Clin
Oncol 2002; 128; 214-218. (Online - DOI 10.1007/s00432-002-0323-8) (Springer-Verlag)
118.
Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP,
Loehrer PJ: A phase II study of 13-cis-retinoic acid plus interferon alpha-2a in advanced stage penile
carcinoma: An Eastern Cooperative Oncology Group Study (E3893). Cancer Invest
2003; 21(1);
41-46.
119.
Radin AI, Kim HT, Grant BW, Bennett JM, Kirkwood JM, Stewart JA, Hahn RC, Dutcher JP, Wiernik
PH, Oken MM: Eastern Cooperative Group Study. Phase II study of alpha 2 interferon in the treatment of
the chronic myeloproliferative disorders (E5487): A trial of the Eastern Cooperative Oncology Group.
Cancer 2003; 98; 100-109.
120.
Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G,
Dorner AJ, Slonim DK, Trepicchio WL, Burczynski ME: Disease-associated expression profiles in
peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 2003;
63; 6069-6075.
121.
King M-C, Marks JH, Mandell JB, for the New York Breast Cancer Study Group (including Ben-Yishay
M, Dutcher HP, Gross SJ, Runowicz CD, Venkataraj U, at Albert Einstein College of
Medicine/Montefiore Medical Center): Breast and ovarian cancer risks due to inderited mutations in
BRCA1 and BRCA2. Science 2003; 302; 643-645.
122.
Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ: Stratification by risk
factors predicts survival on the active treatment arm in a randomized phase II study of interferon gamma
plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Medical Oncology 2003; 20; 271281.
123.
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF,
White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, Gordon MS, Margolin KA:
Adjuvant high dose bolus interleukin-2 for patients with high-risk renal cell carcinoma – A Cytokine
Working Group Randomized Trial. J Clin Oncol 2003; 21; 3133-3140.
124.
Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK, Benson III AB, Eastern
Cooperative Oncology Group: Phase II study of interferon gamma in malignant carcinoid tumors
(E9292): A trial of the Eastern Cooperative Oncology Group. Invest New Drugs 2004; 22; 75-81.
125.
Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R, Wiernik PH: Cardiac monitoring of
patients receiving arsenic trioxide therapy. Br J Haematology 2004; 124; 610-617.
126.
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marshall B,
22
Boni JP, Dukart G, Sherman ML: Randomized phase II study of multiple dose-levels of CCI-779, a novel
mTOR kinase inhibitor in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22;
909-918.
127.
Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP,
Vogelzang NJ, Gollup J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical
and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J
Radiant Oncol Biol Phys 2004; 48; 984-990.
128.
Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancerIV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Prostate 2004; 60; 1-17.
129.
Adiga GU, Dutcher JP, Larkin M, Garl S, Koo J: Characterization of bone metastases in patients with
renal cell cancer. Br J Urology, 2004; 93; 1237-1240.
130.
Rowinsky EK, Schwartz G, Gollob J, Thompson J, Vogelzang N, Figlin R, Bukowski R, Haas N,
Lockbaum P, Li YP, Roskos L, Foon KA, Schwab G, Dutcher JP: Safety, pharmacokinetics and activity
of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody, in patients with
metastatic renal cell cancer. J Clin Oncol 2004; 22; 909-918.
131.
Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP: Idarubicin and standard dose
cytosine arabinoside in relapsed and refractory adult acute lymphocytic leukemia (ALL). Cancer 2004;
101; 1414-1419.
132.
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP: Active chemotherapy for sarcomatoid and
rapidly progressing renal cell cancer. Cancer 2004; 101(7); 1545-1551.
133.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan T, Kirkwood JM, Gordon MS,
Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollop JA, Dutcher
JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2
and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1); 133-141.
134.
Dutcher JP, Lee S, Makary AZ, Londer H, Farnen JP, Bennett JM, Paietta E, Gallagher RE, Rowe JM,
Goloubeva O, Wiernik PH: Phase II study of all-trans retinoic acid (ATRA) in accelerated phase or early
blastic phase of chronic myeloid leukemia: A Study of the Eastern Cooperative Oncology Group (E1993).
Leukemia/Lymphoma 2005; 46 (3); 377-385.
135.
Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes
G, Trepicchio WL, Strahs A, Immermann F, Slonim DK, Dorner AJ: Transcriptional profiles in peripheral
blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Clin Cancer Research 2005; 11(3); 1181-1189.
136.
Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G: Phase II study of
carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy, E4896,
an Eastern Cooperative Group Study. Cancer 2005; 104; 2392-2399.
137.
Koulova L, Novik Y, Caliendo G, Wiernik PH, Dutcher JP: A phase II study of moderate dose IL2 and
GM-CSF in patients with metastatic or unresectable renal cell carcinoma. J Immunotherapy 2005;
23
28; 576-581.
138.
Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP: The role of carbonic anhydrase IX
overexpression in kidney cancer. Eur J Cancer 2005; 41 (18): 2935-2945.
139.
O’Boyle KP, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaleya R, Steinberg JJ, Dutcher
JP, Wiernik PH: Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and
cellular immune responses to Tn and sialylated Tn. Cancer Immun 2006; 6; 5-9.
140.
Kunthur A, Wiernik PH, Dutcher JP: Renal parenchymal tumors and lymphoma in the same
patient: A case series and review of literature. Am J Hematol 2006; 81; 271-280.
141.
Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C,
Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Future Phase II Clinical Trials Design:
Methods in Translational Research from the Eastern Cooperative Oncology Group. Clinical
Cancer Research, 2006; 12; 1966-1969.
142.
Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU
(MVC): Long-term follow-up of patients treated with advanced and poor-prognosis Hodgkin’s
disease. Leukemia and Lymphoma 2006; 47; 641-656.
143.
Moadel AB, Morgan C, Dutcher JP: Psychosocial needs assessment among an underserved,
ethnically diverse cancer patient population. Cancer 2007; 109; 446-454.
144.
Hudes G, Carducci M, Tomczak P, Dutcher JP, Figlin R, Kapoor A, Staroslawska E, Sosman J,
Atkins M, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, Galand
L, Thiele A, O’Toole T, Kong S, Park Y, Moore L, Motzer R. Temsirolimus, interferon, or the
combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and
poor risk features. N Engl J Med 2007; 356; 2271-2281.
145.
Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC,
Goldstein L, Weiner LM: Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2
trial of 2B1 bispecific monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated
by the Eastern Cooperative Oncology Group. J Immunotherapy 2007; 30; 455-467.
146.
Margolin KA, Synold TW, Lara P, Frankel P, Lacey SF, Quinn D, Baratta T, Dutcher JP, Xi B,
Diamond DJ, Gandara DR: Oblimersen and Alpha Interferon in metastatic renal cancer: A Phase
II study of the California Cancer Consortium. J Cancer Res and Clin Oncol 2007; 133; 705-711.
147.
Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, FlahertyLE, Baar J,
Sosman J, Weber J, Lathia C, Smith J, Schwartz B, Cihon F: Phase I trial of Bay 50-4798, an IL-2Specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007; 13; 3312-3319.
148.
Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L,
O’Toole T, Boni JP, Dutcher JP: Phase I/II trial of temsirolimus combined with interferon alfa
for advanced renal cell carcinoma: J Clin Oncol, 2007; 25(25); 3958-3964.
149.
Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, Dutcher JP, Ghavamian R:
Renal medullary carcinoma: The Bronx experience. Urology 2007; 70; 878-882.
24
150.
Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin H,
Dutcher JP, Ryba S, Xia Q, Scappaticci FA, McDermott D: Randomized phase II study of
erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cancer.
J Clin Oncol, 2007; 25:4536-4541.
151.
Clark JI, Mehrabi J, Sosman JA, Logan RF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS,
McDermott DF, Lau AM, Atkins MB: Phase I/II trial of outpatient PEG-interferon with
interleukin-2 in advanced renal cell carcinoma: A cytokine working group study. J Immunotherapy
2007; 30; 839-846.
152.
Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark J, Dutcher J, Margolin KA, Mier
J, Gollob J, Kirkwood J, Panka D, Crosby NA, O’Boyle K, LaFleur B, Ernstoff M: Three phase II
Cytokine Working Group (CWG) trials of gp100 (210M)-peptide plus high-dose Interleukin-2 in
HLA-A2+ advanced melanoma patients. J Clin Oncol, 2008; 26; 2292-2298.
153.
Atkins M, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G,
Curti B, Margolin K: Temozolomide, thalidomide and whole brain radiation therapy for patients
with brain metastasis from metastatic melanoma: A phase II trial of the Cytokine Working Group.
Cancer 2008; 113; 2139-2145. PMID. 18792064
154.
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, Archer L, Atkins JN,
Czaykowski P, Dutcher J, Small EJ: Bevacizumab plus interferon alfa compared with interferon
alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol
2008; 26; 5422-5428.
155.
Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov
I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management
of multi-targeted kinase inhibitor-associated hand-foot skin reaction. Oncologist, 2008; 13;
1001-1011.
156.
Dutcher JP, deSouza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs
A, Feingold J, Hudes G: Effect of Temsirolimus versus interferon-α on outcome of patients with
advanced renal cell carcinoma of different tumor histologies. Med Onc 2009; 26; 202-209.
157.
Figlin RA, deSouza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs
A, Feingold J, Boni J, Hudes G: Analysis of PTEN and HIF-1α and correlation with efficacy in
patients with advanced renal cell carcinoma treated with temsirolimus versus interferon- α. Cancer
2009; 115 (16); 3651-3660.
158.
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L,
Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J
Clin Oncol, 2009; 27; 1-8.
159.
Gordon M, Hussey M, Nagle R, Lara Jr, P, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn
DI, Pan C-X, Crawford D: Phase II study of erlotinib in patients with locally advanced or
metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol, 2009; Dec 1; 27
(34); 5788-5793.
25
160.
Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD,
Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti
BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, on behalf of the ARCCS study
investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded
access program in North America. Cancer, Epub Jan 15, 2010; Cancer 2010; 116:1272-1280.
PMID: 20082451.
161.
Dutcher JP, Morris EL, Gaynor B, Paietta E, Wiernik PH: A pilot study of carboplatin and
mitoxantrone in blast crisis of chronic myeloid leukemia. Medical Oncology, 2010; 27:728-735.
Epub 2009, August 21. PMID:19697165.
162.
Rini BI, Halabi S, Roseberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J,
Czaykowski P, Dutcher JP, Small EJ: Phase III trial of bevacizumab and interferon – alpha versus
interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Final results of
CALGB 90206. J Clin Oncol 2010; 28; 2137-2143. PMID: 20368558.
163.
Malouf GG, Camparo P, Oudard S,Schleiermacher G, Theodore C, Rustine A, Dutcher J,
Billemont B, Bompas E, Guillot A, Couturier J, Molinie V, Escudier B: Targeted agents in
metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma : A Report from the Juvenile
RCC Network. Ann Oncol, 2010; 21 (9):1834-1838. Epub ahead of print, Feb 12 2010. PMID
20154303
164.
Bukowski R, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller Jr, WH, Hainsworth JD,
Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L,
Ryan CW, Hotte SJ, Xia C-H, Cupit L, Figlin RA., for the AARCS trial: Safety and efficacy of
sorafenib in elderly patients treated in the North American Advanced Renal Cell Carcinoma
Sorafenib (ARCCS) Expanded access program. Oncology 2010; 78; 340-347.
165.
Wiernik PH, Dutcher JP, Yao X-P, Venkatraj U, Falkson CI, Rowe JM, Cassileth. Phase II study
of interleukin-4 in indolent B-cell non-Hodgkins lymphoma and B-cell chronic lymphocytic
leukemia: A study of the Eastern Cooperative Oncology Group (E5Y92). J Immunotherapy,
2010; 33(9); 1006-1009.
166.
Lee SH, Baig M, Rusciano V, Dutcher JP. Novel management of pruritis in patients treated with
IL-2 for metastatic renal cell carcinoma and malignant melanoma. J Immunotherapy. 2010;
33(9); 1010-1013.
167.
Dutcher JP, Tannir N, Bellmunt J, Escudier B: Experience with sorafenib in the elderly patient.
Med Oncol 2010; 27 (4) : 1359-1370. Epub 2009, Dec 31
168.
Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell carcinoma
treated with chemotherapy, Med Oncol, 2011 28(4):1530-1533. Epub 2010 Aug 18
169.
Malouf GG, Caparo P, Molinie V, Dedet G,Oudard S, Schleiermacher G, Theodore C, Dutcher J,
Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturieer J, Escudier B. TFE3 and TFEB
renal cell carcinomas: Clinical features, biological behaviour and prognostic factors. J Urology,
2011; 185; 24-29. Epub Nov 12, 2010. PMID 21074195
170.
Moroto JP, Hudes G, Dutcher JP, Logan TF, White C, Krygowski M, Cincotta M, Shapiro M,
26
Duran I, Berkenblit A: Drug-related pneumonitis in patients with advanced renal cell carcinoma
treated with temsirolimus. J Clin Oncol, 2011; 29:1750-1756.
170.
Manola J,Bacik J, Elson P,Royston P,Mazumdar M, Motzer R, Negrier S, Escudier B, Eisen T,
Dutcher J, Atkins M, Heng D, Choueiri TK, Bukowski R: Prognostic factors for survival in
patients with metastatic renal cell carcinoma: Results from the International Kidney Cancer
Working Group. Clin Cancer Res 2011; 17 (16): 5443-5450; epub 2011 Aug 9;
171.
Haas NB, Lin C, Manola J, Pins M, Liu G,McDermott D, Nanus D, Heath E, Wilding G, Dutcher,
J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid
features: ECOG 8802. Med Oncol, 2012; 29 (2): 761-767. Epub 2011, Feb 6;
172.
Dutcher JP, Mourad W, Ennis RD: Integrating innovative therapeutic strategies into the
management of renal cell carcinoma. Oncology June 2012; 526-534.
173.
Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B,
Hutson T: Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results
from a large pooled analysis. In Press, Br J Cancer, 2013
174.
Rini BI, Garrett M, Poland B, Dutcher J, Rixe O, Wilding G, Stadler WM, Pithavala Y, Kim S,
Tarazi J, Motzer R. Axitinib in metastatic renal cell carcinoma: Results of a pharmacokinetic and
pharmacodynamic analysis. J Clin Pharmacology 53 (5):491-504, 2013
175.
Dandamudi UB, Ghebremichael M, Sosman J, Clark J, McDermott D, Atkins M, Dutcher JP,
Urba W, Regan M, Puzanov I, Crocenzi T, Curti BD, Vaishampayan UN, Crosby NA, Margolin
KA, Ernstoff MS: A phase II study of Bevacizumab and high dose Interleukin-2 in patients with
metastatic renal cell carcinoma: A Cytokine Working Group (CWG) Study J Immunotherapy,
36:490-495, 2013.
176.
Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Steward JA, Chachoua A, Schuchter
LM: Report of a phase I trial of Interleukin-1 Alpha and cyclophosphamide in patients with
advanced tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1
based studies of hematopoietic reconstitution. In press, J Interferon and Cytokine Research
34:376-384, 2014. EPUB 2014 Jan 15 PMC 4015471
177.
Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin Jr WG,
Dutcher JP: A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann
Oncol 2014, Aug 25 (8): 1603-1608. Epub May 2014 DOI:10.1093. 00:1-6.
178.
Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins
MB: High dose Interleukin-2 (Aldesleukin) – expert consensus on best management practices –
2014. J ImmunoTherapy of Cancer 2014; 2:26
179.
McDermott DF, Cheng S-C, Signoretti S, Margolin KA, Clark J, Sosman J, Dutcher J, Logan T,
Curti B, Ernstoff M, Appleman L, Wong M, Kushalani N, Oleksowicz L, Vaishampayan U, Mier J,
Panka D, Bhatt RS, Bailey A, Leibovich B, Kwon E, Kabbinavar F, Belldegrun A, Figlin R,
Pantuck A, Regan M, Atkins MB: The high dose Aldesleukin (HD IL-2) “Select” trial: A trial
designed to prospectively validate predictive models of response to HD IL-2 treatment in patients
with metastatic renal cell carcinoma. Clin Cancer Res 2015; 21(3):561-568.
27
181.
Flaherty K, Manola J, Pins M, McDermott DF, Atkins MB, Dutcher JP, George DJ, Margolin
KA, DiPaola RS: ECOG E2804: A randomized phase II study of VEGF, RAF Kinase and mTOR
combination targeted therapy with Bevacizumab, Sorafenib, and Temsirolimus in advanced renal
cell carcinoma In Press, J Clin Oncol 2015.
182.
Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher J, Wilding G. Atrasentan in patients
with advanced renal cell carcinoma: A phase II trial of the Eastern Cooperative Oncology Group.
Submitted, 2013.
183.
Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood CG, Atkins MB,
Dutcher JJ, Hariharan S, DiPaola RS. Effects of sorafenib and sunitinib on cardiac function in a
population without overt metastases: Cardiac substudy of a phase III trial of sunitinib or sorafenib
or placebo in patients with high risk resected renal cell carcinoma (E2805). In press, Clin Cancer
Res 2015.
184.
Mowla M, Bojanapally P, Rustine A, Graham S, Dutcher JP. Real practice experience with
temsirolimus in metastatic renal cell carcinoma. Manuscript in preparation, 2012.
185.
Logan TF, Szczylik C, Tannir N, Benedetto P, Makhson A, McDermott D, Ruff P, Mikulas J,
Dutcher JP, Berkenblit A, Galand L, Krygowski M, Hudes G: Effect of nephrectomy status on
temsirolimus efficacy in patients with advanced poor-prognosis renal cell cancer. 2012, Submitted
Urology
28
B.
Case Reports
1.
Dutcher JP, Aisner J, Hogge D, Schiffer CA: Brief Report: Donor reaction to hydroxyethyl starch
during granulocytopheresis. Transfusion 1984; 24; 66-67.
2.
Dutcher JP and Wiernik PH - Case Report: Long term survival of a patient with multiple myeloma A Cure? Cancer 1984; 53; 2069-2072.
3.
Dutcher JP, Wiernik PH, Gray WC: Tonsillectomy for recurrent throat infections in acute leukemia
patients. N Engl J Med 1984; 311; 408. (letter to the editor).
4.
Paietta E, Papenhausen P, Ciobanu N, Dutcher JP, Wiernik PH: Biphenotypic leukemia with unusual
chromosomal translocation in a patient treated for melanoma. Cancer Genetics and Cytogenetics
1986; 21; 355-360.
5.
Paietta E, Papenhausen P, Dutcher JP, Wiernik PH: Cytogenetic and phenotypic evolution in a case
of acute promyelocytic leukemia. Cancer Genetics and Cytogenetics 1986; 21;181-182. (letter to the
editor).
6.
Gelman KM, Ben-Ezra JM, Steinschneider M, Keefe DL, Dutcher JP, Factor SM: Lymphoma with
primary cardiac manifestations. Am Heart Journal 1986; 111; 808-811.
7.
Dutcher JP, Fisher M, Spivack M, Wiernik PH: Porphyria cutanea tarda in a patient with acute
leukemia. Am J Hematol 1986; 23; 69-75.
8.
Dutcher JP, Wiernik PH: Acute leukemia in a patient cured of diffuse histiocytic lymphoma. Cancer
Res and Clinical Oncol 1986; 112; 67-70.
9.
Lauer SA, Fischer J, Jones J, Gartner S, Dutcher J, Hoxie J: Orbital involvement in systemic adult Tcell leukemia/lymphoma (ATLL) associated with human T-cell leukemia virus-I (HTLV-I) infection.
Ophthalmology 1988; 95; 110-115.
10.
Catanese J, Dutcher JP, Dorfman HD, Andres DF, Wiernik PH: Mediastinal osteosarcoma with
extension to lungs in a patient treated for Hodgkin's disease. Cancer 1988; 62; 2252-2257.
11.
Simon KE, Dutcher JP, Runowicz CD, Wiernik PH: Adenocarcinoma arising in vulvar breast tissue.
Cancer 1988; 62; 2234-2238.
12.
Feinfeld DA, D'Agati V, Dutcher JP, Werfel SB, Lynn RI, Wiernik PH: Interstitial nephritis in a
patient receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine activated
killer cells. Am J Nephrology 1992; 11; 489-492.
13.
Gucalp R, Motyl M, Carlisle P, Dutcher J, Fuks J, Wiernik PH: Clostridium cadaveris bacteremia in
the immunocompromised host. Med Ped Oncol 1993; 21; 70-72.
14.
Sparano JA, Brandt LJ, Dutcher JP, DuBois JS, Atkins MB: Symptomatic exacerbation of Crohns
disease after treatment with high-dose interleukin-2. Ann Intern Med 1993; 118; 617-618.
29
15.
Dutcher JP, Benchabbat A, Jones JG, Wiernik PH: Unique dermatological complication of rhM-CSF
treatment. Leukemia and Lymphoma 1994; 15; 347-349.
16.
Merer DM, Dutcher JP, Mercando A, Brodman R, Suhrland MJ, Bhandari A, Zimmerman D,
Mitchell MS, Wiernik PH: Clinical findings and successful resection of melanoma metastatic to the
right atrium. Cancer Investigation 1994; 12(4); 409-413.
17.
Wiernik PH, Dutcher JP, Leaf AN, Liao Z, Paietta E, Rosenstreich DL: Objective response of
multiple myeloma to cyclosporin A. Leukemia and Lymphoma 1994; 6; 167-170.
18.
Wiernik PH, Sklarin NT, Dutcher JP, Sparano JA, Greenwald ES: Adjuvant radiotherapy for breast
cancer as a risk factor for the development of lung cancer. Medical Oncology 1994; 11; 121-125.
19.
Einzig AI, Dutcher JP, Wiernik PH: Life-threatening hyperleukocytosis and pulmonary compromise
after priming with rh-GMCSF in a patient with AML. J Clin Oncol 1995; 13; 304. (letter)
20.
Gucalp R., Carlisle P, Gialanella P, Mitsudo S., McKitrick J., Dutcher JP: Paecilomyces sinusitis in
an immunocompromised adult patient: Case report and review. Clinical Infectious Diseases 1996;
23;
391-393.
21.
Makower D, Venkatraj U, Dutcher JP, Wiernik PH: Occurrence of myeloma in a chronic
lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leukemia
and Lymphoma 1996; 23; 617-619.
22.
Wiernik PH, DeBellis R, Muxi P, Dutcher JP: Extramedullary acute promyelocytic leukemia.
Cancer 1996; 78; 2510-2514.
23.
Malik UR, Oleksowicz L, Dutcher JP, Ratech H, Borowitz MJ, Wiernik PH: Atypical clonal T-cell
proliferation in infectious mononucleosis. Medical Oncology 1996; 13; 207-213.
24.
Suh J-G, Oleksowicz L, Dutcher JP: Leukocytoclastic vasculitis associated with nizatidine therapy.
Am J Med 1997; 102; 216-217.
25.
Malik U, Dutcher JP, Oleksowicz L: Acquired Glanzmann's thrombasthenia associated with
Hodgkin's lymphoma: A case report and literature review. Cancer 1998; 82; 1764-1768.
26.
Bhagwati N, Seno R, Dutcher JP, Oleksowicz L: Fulminant metastatic melanoma complicated by a
microangiopathic hemolytic anemia. Hematopathology and Molecular Hematology 1998; 11; 101108.
27.
Deshpande H, Dutcher JP, Novik Y, Oleksowicz L: Successful treatment of a patient on adrenal
steroid replacement therapy with high-dose interleukin-2 for metastatic renal cell carcinoma. (Letter)
The Cancer Journal from Scientific American 1999; 5(Jan-Feb); 52-53.
28.
Blokh I, Oiseth SJ, Fuks J, Jain D, Eapen S, Koulova L, Alexandrescu D, Li YY, Dutcher JP, Wiernik
PH: Metastatic choriocarcinoma in a middle-aged man presenting as a right thigh mass with venous
thrombosis: A case report. Medical Oncology 2003; 20(2); 189-194.
29.
O’Boyle KP, Murigeppa A, Jain D, Dauber L, Dutcher JP, Wiernik PH: Probable veno-occlusive
30
disease after treatment with Gemtuzumab Ozogamicin in a patient with acute myeloid leukemia and a
history of liver transplantation for familial hemochromatosis. Medical Oncology 2003; 20; 379-383.
38.
30.
Alexandrescu DT, Dutcher JP, O’Boyle K, Albulak M, Oiseth S, Wiernik PH: Fatal intra-alveolar
hemorrhage after rituximab in a patient with non-Hodgkin’s lymphoma. Leukemia/ Lymphoma
2004; 45 (11); 2321-2325.
31.
Koulova L, Alexandrrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH: Rituximab in the
treatment of refractory idiopathic throbocytopenic purpura (ITP) and thrombotic thrombocytopenic
purpura (TTP): A report of three cases. Am J Hematology, 2005; 78; 49-54.
32.
Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH: Strokes after intravenous gamma
globulin: Thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol
2005; 78(3); 216-220.
33.
Alexandrescu DT, Maddukauri P, Wiernik PH, Dutcher JP: Thrombotic thrombocytopenic
purpura/Hemolytic uremic syndrome (TTP/HUS) associated with high-dose interleukin-2 for the
treatment of metastatic melanoma. J Immunotherapy 2005; 28(2); 144-147.
34.
Alexandrescu DT, Dutcher JP: Capecitabine-induced pancolitis, Internatl J Colorectal Dis, 2005; Jul
20. (epub)
35.
Dasanu CA, Alexandrescu DT, Dutcher JP: Case Report: Yellow skin discoloration associated with
sorafenib use for treatment of metastatic renal cell carcinoma. Southern Medical Journal 2007; 100;
328-330. Erratum in May 2007; 100;485, with correction of authorship.
36.
Wiernik PH, Baig MA, Lee SH, Dutcher JP, Paietta E, Racevskis J: Survival more than 19 years
after the diagnosis of accelerated phase of chronic myelocytic leukemia. Clinical Advances in
Hematology and Oncology 2011; 9:242-248.
37.
Nagubandi R, Wang J, Dutcher J, Rao S,: A Classic Case of Unicentric Mixed Type Castleman’s
disease. 2013, In Press 2013 J Clin Oncol; Diagnosis in Cancer ; Epub ahead of print
October 14, 2013 as 10.1200/JCO.2012.45.9941
Cabot JC, Hussein S, Lee SH, DiNorcia J, Dutcher JP, Chabot JA: Renal cell cancer with
metachronous metastasis to the gallbladder: A case report and review of the literature. Manuscript
in preparation, 2012.
31
C.
Reviews, Chapters, Editorials and Commentaries
1.
Dutcher JP and Wiernik PH: Adult leukemia: How to recognize the early signs. Your Patient & Cancer
1981; 1; 37-40.
2.
Dutcher JP and Wiernik PH: Adult leukemia: Treatment of choice, maintenance therapy, supportive
care. Your Patient and Cancer 1981; 1; 32-46.
3.
Schiffer CA, Aisner J, Dutcher JP, Daly PA, Wiernik PH: A clinical program of platelet
cryopreservation. WR Vogler, Ed; In Cytapheresis and Plasma Exchange: Clinical Indications; Alan
R. Liss, Inc; Phila; 1982; pp. 165-80.
4.
Dutcher JP, Schiffer CA: Platelet and granulocyte transfusion therapy. PH Wiernik (ed); In Supportive
Care of the Cancer Patient; Futura; Mt. Kisco, NY; 1983; pp. l09-l44.
5.
Schnaper N, Legg-McNamara C, Dutcher JP, Kellner TK: Emotional support of the patient and his
survivors. PH Wiernik (ed); In Supportive Care of the Cancer Patient; Futura; Mt. Kisco, N.Y.; 1983;
pp. l-l6.
6.
Dutcher JP and Wiernik PH: The Leukemias. In Spittell JA (ed);
16; 1983; pp. 1-25.
7.
Dutcher JP and Wiernik PH: Acute Non-Lymphocytic Leukemia. American Society of Hematology
Educational microfishe and manual - 1983.
8.
Wiernik PH, Dutcher JP: Some new drugs in acute nonlymphocytic leukemia (ANLL). Proc 13th Int
Cong Chemother 1983; 237; 52-55.
9.
Dutcher JP and Wiernik PH: The Leukemias. J Spivak (ed); . In
Fundamentals of Clinical
Hematology, Second Edition; Harper and Row, Phila, PA; 1984; pp 229-254.
10.
Park CM, Amare M, Wiernik PH, Dutcher JP, Morrison FS, Maloney TR: In vitro drug sensitivity of
leukemia colony forming cells in acute non-lymphocytic leukemia. Clinical correlation update with
various drug exposure methods. Salmon SS, Trent JM (eds); In Human Tumor Cloning; Grune and
Stratton, New York, 1984; pp 619-626.
11.
Dutcher JP: Labelled cells in patients with malignancy. Seminars in Nuclear Medicine 1984; 14; 251261.
12.
Dutcher JP: Granulocyte transfusion therapy. Am J Med Sci 1984; 287; 13-19.
13.
Dutcher JP, Wiernik PH: Combined modality treatment of Hodgkin's disease confined to lymph
nodes. Results 14 years later. Cavalli F, Bonadonna G, Rozencweig M (eds); In Malignant Lymphomas
and Hodgkin's Disease: Experimental and Therapeutic Advances; Martinus Nijhoff Pub; Boston, MA;
1985; pp 317-328.
14.
Dutcher JP and Wiernik PH: Hodgkin's disease. PH Wiernik (ed); In Contemporary Issues in Clinical
Oncology, Leukemias and Lymphomas; Churchill Livingstone; New York; 1985; pp 63-96.
32
Clinical Medicine, Vol. 5, Chap.
15.
Dutcher JP: Platelet transfusion therapy. PH Wiernik, GP Canellos, RA Kyle, CA Schiffer (eds),
In Neoplastic Diseases of the Blood; Churchill Livingstone; New York; 1985; pp 1039-1059.
16.
Dutcher JP: Transfusion supportive care. JA Spittell, Jr (ed); In Clinical Medicine, Vol 10, Ch 66;
Harper & Row; Phila, PA; 1985; pp 1-22.
17.
Dutcher JP: Granulocyte transfusion therapy. Wiernik PH (ed); In Mediguide to Oncology 1986;
6:1A.
18.
Dutcher JP: Hematologic complications of malignancy. Schimpff SC, Moossa AR, Robson MC
(eds); In Comprehensive Textbook of Oncology; Williams and Wilkins; Phila; 1986; pp 417-424..
19.
Dutcher JP: Platelet and granulocyte transfusions. In Ray PK (ed); Advances in Immunity and
Cancer Therapy, Volume 2; Springer-Verlag; NewYork; 1986; pp 23-61.
20.
Paietta EP, Stockert RJ, Khorshidi M, Ciobanu N, Dutcher JP, Wiernik PH: Activation-associated
antigen expression by human lymphokine-activated killer (LAK) cells. AJ McMichael (ed); In Proc
Second Internatl Conf on Immunophenotyping, Leukocyte Typing III; Oxford Univ Press; Oxford, UK;
1987; pp528-530.
21.
Dutcher JP, Ciobanu N, Paietta E, Marcus S, Strauman JJ, Wiernik PH: The clinical importance of
Interleukin-2 -- 1986. The Einstein Quarterly Journal of Biology and Medicine 1987; 5; 1-9.
22.
Dutcher JP: Hematologic abnormalities in patients with non-hematologic malignancies.
Hematologic/Oncologic Clinics of North America 1987; 1:1-19.
23.
Dutcher JP: Hyperleukocytosis in leukemia - An emergency; Dutcher JP, Wiernik PH (eds); In
Handbook of Hematologic and Oncologic Emergencies; Plenum Press; New York; 1987; pp 103111.
24.
Dutcher JP: Transfusion reactions; Dutcher JP, Wiernik PH (eds); In Handbook of Hematologic
and Oncologic Emergencies; Plenum Press; NewYork; 1987; pp 139-151.
25.
Dutcher JP: Thrombocytosis; Dutcher JP, Wiernik PH (eds); In Handbook of Hematologic and
Oncologic Emergencies; Plenum Press; NewYork; 1987; pp 113-121.
26.
Dutcher JP: Bleeding and coagulopathy. Dutcher JP, Wiernik PH (eds);
In Handbook of
Hematologic and Oncologic Emergencies; Plenum Press; NewYork; 1987; pp 123-138.
27.
Gucalp R and Dutcher JP: Fever and infection. Dutcher JP, Wiernik PH (eds); In Handbook of
Hematologic and Oncologic Emergencies; Plenum Press; , NewYork; 1987; pp 153-183.
28.
Wadler S and Dutcher JP: Renal insufficiency due to drugs and disease; Dutcher JP, Wiernik PH
(eds); In Handbook of Hematologic and Oncologic Emergencies, Plenum Press; NY, 1987; pp 4154.
29.
Dutcher JP: Commentary: Progress toward predictive models for ANLL. by H.D. Preisler, A Raza.
Oncology 1987; 1; 59-60.
33
30.
Dutcher JP: Controversies in Oncology: Editorial Comment: Perioperative blood transfusion and
solid tumor recurrence - a review. Cancer Investigation 1987; 5; 613-614.
31.
Dutcher JP: Hematologic and immunologic abnormalities associated with multisystem failure. V.
Kvetan, J Askanazi (eds); In Anesthesia Clinics of North America, W.B. Saunders Co; Phila, PA;
1988; pp 23-37.
32.
Dutcher JP: IL-2: It's role in transfusion medicine. In Transfusion Medicine Applications for
Growth Factors and Biologic Response Modifiers, AABB Technical Workshop, AABB National
Office,
Arlingtion VA. 1988;
33.
Dutcher JP and Wiernik PH: Lymphomas involving the mediastinum and lungs.
Roth JA,
Ruckdeschel JC, Weisenburger TH (eds); In Thoracic Oncology; WB Saunders; Philadelphia, PA,
1988, pp 448-465.
34.
Dutcher JP: Granulocyte collection. AA Pineda, M Valbonesi, I Sniecinski (eds);
Hemapheresis, Wichtig Editore; Milan; 1988, pp 55-64.
35.
Sznol M, Dutcher JP, Rayner AA, Atkins MB, Margolin K, Fisher RI, Weiss GR, Parkinson DR,
Hawkins MJ. NCI Extramural IL-2/LAK Working Group. Review of IL-2 alone and IL2/LAK clinical
rials in metastatic malignant melanoma. Cancer Treatment Reviews 1989; 16(Suppl A); 29-38.
36.
Dutcher JP: The potential benefit of granulocyte transfusion therapy. Cancer Investigation 1989; 7;
457-462.
37.
Dutcher JP: Meeting report: American Society of Clinical Oncology. J Cancer Res Clin Oncol
1989; 115; 485-490.
38.
Dutcher JP: Lymphokine-activated killer cells/Tumor-infiltrating lymphocytes therapy: Efficacy,
Toxicity, Controversies. J Clinical Apheresis 1990; 5; 80-82.
39.
Dutcher JP: Therapy for acute leukemia in adults. Current Opinion in Oncology 1990; 2; 41-48.
40.
Dutcher JP: Platelet transfusion therapy in patients with malignancy. Dutcher JP (ed); In Modern
Transfusion Therapy. CRC Press, Inc; Boca Raton, FL; 1990; pp 25-50.
41.
Dutcher JP: Granulocyte transfusion therapy in patients with malignancy. Dutcher JP (ed); In
Modern Transfusion Therapy. CRC Press; Boca Raton, FL; 1990; pp 135-156.
42.
Dutcher JP: Platelet transfusion therapy. Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (eds); In
Neoplastic Diseases of the Blood, Second Edition Churchill Livingstone; NY; 1991;pp 881-897.
43.
Dutcher JP: Oncologic emergencies. Kelly WN (editor in chief) In Textbook of Internal Medicine,
Second Edition; J.B. Lippincott; Phila; 1991; pp 1231-1234.
44.
Dutcher JP: Principles of Transfusion Medicine (Book Review). Annals of Internal Medicine 1991;
115:238-239.
45.
Dutcher JP: Future directions of biologic therapy in cancer. Hospital Formulary 1992; 27:694-707.
34
In Donor
46.
Dutcher JP: Interferons and interleukins in cancer therapy. Mediguide to Oncology 1992; 12(3):111.
47.
Sklarin NT, Dutcher JP, Wiernik PH: Hodgkin's disease and the non-Hodgkin's lymphomas. A Bank
(ed); In Cardinal Topics in Internal Medicine; InforMed, Columbia Univ; New York; 1992;.
48.
Rao SV, Dutcher JP: Biological therapy of hematological malignancies. Resident and Staff
Physician Nov, 1992. pp 21-26.
49.
Paietta E and Dutcher JP: LAK cell production and quality assurance. G. Rock (ed), In Blood
Transfusion Methods and Quality Assurance; CRC Press, Inc; Boca Raton, FL; 1993. pp 207-228.
50.
Dutcher JP, Wiernik PH: The role of recombinant interleukin-2 in therapy for hematologic
malignancies. Sem Oncol 1993; 20 (suppl 9); 33-40.
51.
Dutcher JP and Wiernik PH: Hodgkin Disease. Spivak J and Eichner ER (eds); In Fundamentals of
Clinical Hematology, Third Edition; John's Hopkins University Press; Baltimore, MD; 1993; pp 271286.
52.
Dutcher JP and Wiernik PH: Leukemias. Spivak J and Eichner ER (eds); In Fundamentals of
Clinical Hematology, Third Edition; John's Hopkins University Press; Baltimore, MD; 1993; pp 231258.
53.
Leaf AW and Dutcher JP: Transfusion Therapy in Oncology, Contemporary Oncology 3(1): 26-33,
1993.
54.
Dutcher JP: Interleukin-2 as a single agent in advanced renal cell cancer. Klein L, Bukowski R,
Finke J (eds); In Renal Cell Cancer; Marcell Dekker, Inc; New York, NY; 1993; pp 195-200.
55.
Sparano J and Dutcher JP: High dose IL-2 Treatment of Melanoma. Atkins MB and Mier JW (eds);
In Therapeutic Applications of Interleukin-2; Marcel Dekker, Inc; New York, NY; 1993; pp 99-117.
56.
Dutcher JP and Horwitz SB: Taxol: Mechanism of action and clinical studies. Internal Medicine for
the Specialist; 1993; 14:20-26..
57.
Dutcher JP: Interferons and interleukins in cancer therapy. Cancer Research, Therapy and Control;
1993; 3:181-184.
58.
Sparano JA, Dutcher JP: Interleukin-2 for the Treatment of Advanced Melanoma. RH Blum and R
Oratz, Eds; In Heme/Onc Annals, Vol 1, No 4, Nov/Dec 1993; pp 289-295.
59.
Dutcher, JP: Oncologic Emergencies. W.N. Kelley, (ed); In Essentials of Internal Medicine; J.B.
Lippincott; Phila, PA; 1994;
60.
Oleksowicz L, Sparano J, O'Boyle K, Venkatraj U, Wiernik PH, Dutcher JP: Interleukins in Cancer
Therapy: Rationale and Current Status. Clinical Immunotherapy 1994; 1:271-281.
61.
Oleksowicz L and Dutcher JP: A Review of the New Cytokines: IL4, IL6, IL11 and IL12. Am J
35
Therapeutics
1994; 1:107-115.
62.
Benson L, Dutcher JP, Wiernik PH: Acute Leukemia. Booklet for the Leukemia Society of America.
1994
63.
Gucalp R, Sparano J, Dutcher JP, Wiernik PH: Introduction to Bone Marrow Transplant Symposium
held at the Albert Einstein Cancer Center, Bronx, NY March 1994. (Editor for Symposium). Medical
Oncology Volume 11. 1994.
64.
Oleksowicz L and Dutcher JP: Cytokines and Hematopoietic Growth Factors; Brain MC and
Carbone PP (eds); In Current Therapy in Hematology/Oncology - Fifth Edition,), Mosby Pub: Phila,
PA; 1995; pp 25-33.
65.
Sparano JA, Dutcher JP, Wiernik PH: Low-dose Interleukin-2 for Advanced Renal Cell Carcinoma.
NJ Vogelzang, PT Scardino, WU Shipley, DS Coffey (eds); In Comprehensive Textbook of
Genitourinary Oncology; Williams & Wilkins; NY; 1995; pp 248-255.
66.
Dutcher JP: Adoptive Immunotherapy; LD Petz, S Swisher, S Kleinman, R Spence, R Strauss (eds);
In Clinical Practice of Transfusion Medicine, 3rd Edition; Churchill Livingstone; New York, NY; ,
1995; pp 1053-1063.
67.
Dutcher JP: Therapeutic Strategies for Cytokines; Steven Rosen (ed); In Current Opinion in
Oncology, Vol 7 (number 6); 1995; pp 566-571.
68.
Dutcher JP: Platelet and Granulocyte Transfusion Therapy. PH Wiernik, R Kyle, G Canellos, JP
Dutcher (eds); In Neoplastic Diseases of the Blood, Third Edition; Churchill Livingstone; New
York; 1996; pp 1089-1110.
69.
Frishman WH, Sung HM, Yee HCM, Liu LL, Keefe D, Einzig AI, Dutcher JP: Cardiovascular
Toxicity With Cancer Chemotherapy; , R.A. O'Rourke (editor in Chief); In Current Problems in
Cardiology, Vol XXI; Mosby; St. Louis, Mo; 1996; pp: 225-288.
70.
Gucalp R and Dutcher JP: Oncologic Emergencies; RC Bone, WC Koller, J Faucett, J Palek, D
Ettinger (eds), In Current Practice of Medicine, Oncology, Vol 3:XII; Churchill-Livingstone; New
York, NY; 1996; pp 1-10.
71.
Dutcher JP: Approach to the Patient with Superior Vena Cava Syndrome. WN Kelley, (editor-inchief); In Textbook of Internal Medicine, Third Edition; J.B. Lippincott; Philadelphia, PA; 1996;
pp 1272-1274.
72.
Dutcher JP: Approach to the Patient with a Pathologic Fracture. WN Kelley, (editor-in-chief); In
Textbook of Internal Medicine, Third Edition; J.B. Lippincott; Philadelphia, PA; 1996; pp 1293-1295.
73.
Frishman WH, Sung HM, Yee HCM, Keefe D, Einzig A, Dutcher J: Cardiovascular Toxicity with
Cancer Chemotherapy.
WH Frishman and E Sonnenblick (eds);
In Cardiovascular
Pharmacotherapeutics; McGraw-Hill; New York; 1997; pp 1479-1504.
74.
Oleksowicz L, Malik U, Dutcher JP: Autologous Adoptive Immunotherapy. BC McLeod (ed); In
Apheresis: Principles and Practice; AABB Press; Alexandria VA; 1997; pp 475-500.
36
75.
Frishman WH, Sung HM, Yee HCM, Keefe D, Einzig A, Dutcher J: Cardiovascular Toxicity with
Cancer Chemotherapy. S D. Williamss (ed); In Current Problems in Cancer, Vol 21(6); MosbyYear Book; St Louis, Mo; Nov/Dec 1997; pp 301-360.
76.
Gucalp R., Dutcher JP, Wiernik PH: Overview by an oncologist: What are the imaging needs of the
oncologist and oncologic surgeon? Sem Nuclear Med 1997; 27; :3-9.
77.
Atkins MB, Dutcher JP: Renal Cell Cancer (letter to editor) N Engl J Med 1997; 336; 809.
78.
Dutcher JP, Venkatraj U, Makower D, Wiernik PH: Interleukin-4 is a pleotropic cytokine with effects
on B-cell malignancies (Commentary). Leukemia Research 1997; 21; 17-19.
79.
Gucalp R, Dutcher JP: Oncologic Emergencies; AS Fauci, E Braunwald, KJ Isselbacher, JD Wilson,
JB Martin, DL Kasper, SL Hauser, DL Longo (eds). In Harrison's Principles of Internal Medicine,
14th Edition; McGraw Hill; NewYork; 1998; pp 627-634.
80.
Wiernik PH, Dutcher JP: Therapy of Acute Myeloid Leukemia. E Freireich (ed); In Medical
Management of Hematologic Malignant Disease; Marcel Dekker; New York; 1998; pp5-18.
81.
Dutcher JP and Wiernik PH: Novel Biologic Approaches to Hematologic Malignancies; M. Tallman,
L. Gordon (eds);
In Diagnostic and Therapeutic Advances in Hematologic Malignancies; Kluwer
Internatl Press; Norwell, MA; 1999; pp 275-306.
82.
Oleksowicz J, Dutcher JP: Unanswered questions in IL-2-based therapy for renal cell carcinoma.
Biotherapy in Cancer 1998; 2; 88-99.
83.
Gucalp R and Dutcher JP: Oncologic Emergencies; RC Bone, WC Koller, J Faucett, J Pake, DS
Ettinger (eds); In Current Practice of Medicine, Vol 3 Second Edition ;
Churchill Livingstone;
NY; 1999; pp 1313-1325.
84.
Bukowski R and Dutcher JP: Low-dose Interleukin-2 for Advanced Renal Cell Carcinoma. NJ
Vogelzang, PT Scardino, WU Shipley, DS Coffey (eds); In Comprehensive Textbook of
Genitourinary Oncology, Second Ed; Williams & Wilkins; New York; 2000; pp 218-233.
85.
Dutcher JP: Approach to the Patient with Superior Vena Cava Syndrome. H. David Humes (Editor
in Chief); In Kelley’s Textbook of Internal Medicine, 4th Ed; Lippincott, Willliams & Wilkins;
Phila; 2000; pp 1540-1543.
86.
Dutcher JP: Approach to the Patient with a Pathologic Fracture. H. David Humes (Editor in Chief);
In Kelley’s Textbook of Internal Medicine, 4th Ed; Lippincott, Willliams & Wilkins; Phila; 2000; pp
1567-1570.
87.
Dutcher JP and Wiernik PH: Accelerated and Blastic Phase of Chronic Myeloid Leukemia. In
Current Treatment Options in Oncology; 2000; 1; 51-62.
88.
Dutcher JP, Novik Y, O’Boyle K, Marcoullis G, Secco C, Wiernik PH: Twentieth Century Advances
in Drug Therapy in Oncology - Part I. J Clin Pharm 2000; 40; 1007-1024.
37
89.
Dutcher JP, Novik Y, O’Boyle K, Marcoullis G, Secco C, Wiernik PH: Twentieth Century Advances
in Drug Therapy in Oncology - Part II. J Clin Pharm 2000; 40; 1079-1092.
90.
Dutcher JP: Book Review: Aplastic Anemia: Pathophysiology and Treatment (ed) H. Schrezenmeier
and A. Bacigalupo. Published by Cambridge University Press 2000. Medical Oncology 2000; 17;
248.
91.
Dutcher JP: Immunotherapy: Are we making a difference? Current Opinion in Urology 2000; 10;
435-439.
92.
Dutcher JP. Book Review, Transfusion Therapy: Clinical Principles and Practice , P.D. Mintz (ed),
AABB Press, 2000. Annals of Internal Medicine, 2000; 133; 572.
93.
Dutcher JP, Kirkwood JM: Efficacy of high dose interferon as adjuvant therapy in high risk
melanoma:
Overview of ECOG studies 1684 and 1690. Symposium on Melanoma, RuhrUniversity, Bochum . In
Zeitschrift fur Hautkrankh, H+G 2000; 4(75); 220-223.
94.
Gucalp R. and Dutcher JP: Oncologic Emergencies; Braunwald, Fauci, Kasper, Hauser, Longo,
Jameson (eds); In Harrison, Principles of Internal Medicine, 15th Ed; McGraw-Hill; NewYork;
2001; pp 642-650.
95.
Dutcher JP: Supportive Care in Adult Leukemias. P Wiernik (ed); In Adult Leukemias; BC Decker
Pub; Ontario, Canada; 2001; pp 307-342.
96.
Dutcher JP: Angiogenesis and melanoma. Current Oncology Reports 2001; 3; 353-358.
97.
Nelson MA, Frishman WH, Seiter K, Keefe D, Dutcher J: Cardiovascular considerations with
anthracycline use in patients with cancer. Heart Disease 2001; 3; 157-168.
98.
Dutcher JP: Introduction and Guest Editor: Intravenous Allopurinol in the prevention and treatment
of tumor lysis syndrome. Seminars in Oncology, 2001; 28 (Suppl 5); 1-2.
99.
Gucalp R, Dutcher JP: Oncologic Emergencies. In Best Practice of Medicine Praxis.MD, Online
Series. 2001-2002.
100.
Atkins MB, Dutcher JP, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier. for the
Cytokine Working Group: Kidney Cancer - The Cytokine Working Group Experience (1986-2001)
Part I. IL2 Based Clinical Trials. Medical Oncology 2001; 18; 189-196..
101.
Dutcher JP, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J for the
Cytokine Working Group: Kidney Cancer -The Cytokine Working Group Experience (1986-2001):
Part II: Management of IL-2 Toxicity and Studies with Other Cytokines: Medical Oncology 2001;
18; 197-208.
102.
Dutcher JP, Wiernik PH: Commentary. Clinical impact of multidrug resistance in acute leukemia.
Leukemia Res 2002; 26: 323-325.
103.
Dutcher JP: Introduction: High dose Interleukin-2 in metastatic disease: Renal cell carcinoma and
melanoma. Oncology 2002; 16 (11) Suppl, pp 1-2.
38
104.
Dutcher JP: Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic
melanoma. Oncology 2002; 16 (11) Suppl, pp 3-10, November.
105.
Schwartz RN, Stover L, Dutcher JP: Managing toxicities of high-dose interleukin-2. Oncology
2002; 16 (11) Suppl, pp 11-22, November.
106.
Dutcher JP, Wiernik PH: Oncologic Disorders in Older Adults. Dharmarajan T, Norman C, (eds);
In Clinical Geriatrics for Primary Care; Parthenon Publishing; A CRC Press Company; 2003; pp 501515.
107.
Dutcher JP: Platelet and Granulocyte Transfusion. PH Wiernik, R Kyle, Goldman JM, JP Dutcher
(eds); In Neoplastic Diseases of the Blood, Fourth Edition; Cambridge Pub; New York; 2003; pp.
1028-1048.
108.
Dutcher JP: Hematopoietic Growth Factors; PH Wiernik, R Kyle, Goldman JM, JP Dutcher (eds);
In Neoplastic Diseases of the Blood, Fourth Edition; Cambridge Pub; New York; 2003. pp11231136.
109.
Dutcher JP: Interleukin-2 Based Therapy for Kidney Cancer; R. Figlin (ed); In Kidney Cancer;
Series ed, Steven Rosen; Kluwer Academic Publishers Series on Cancer Treatment and Research.
Boston; 2003; pp 155-172.
110.
Dutcher JP: Editorial: The role of Epstein Barr Virus and elevated levels of tumor necrosis factor in
determining prognosis in Asian peripheral T-cell lymphomas. Leukemia Research, 2003; 27:467469.
111.
Dutcher JP: Editorial: The prognostic role of detection of circulating melanoma cells in the blood. J
Clin Oncol 2003; 21:757-759.
112.
Dutcher JP: Is high dose interleukin-2 the treatment of choice for metastatic renal cell carcinoma?
Kidney Cancer Journal 2003; (1):5-11.
113.
Gucalp R, Dutcher JP: Oncologic Emergencies; DL Kasper, E Braunwald, AS Fauci, SL Hauser, DL
Longo, JL Jameson (eds); In Harrison’s Principles of Internal Medicine, 16th Edition; McGraw-Hill;
New York; 2004, pp 575-583.
114.
Dutcher JP, Alexandrescu DT: Interleukin-2 in the treatment of metastatic renal cell carcinoma. Case
Studies in Oncology, Physicians Education Resources, 2004; Vol 6 (No 1) February.
115.
Dutcher JP: Mammalian target of rapamycin (mTOR) inhibitors. R Bukowski (section editor); In
Current Oncology Reports, Evolving Therapies; Current Science, Inc; Phila; 2004; 6(2): 111-115.
116.
Dutcher JP: Mammalian target of rapamycin inhibition. Clinical Cancer Research 2004; 10(18);
6382S-6387S.
117.
Dutcher JP: Book Review: Biologic Therapy of Leukemia M.Kalaycio (ed). Medical Oncology 2004;
21: 209-210.
39
118.
Dutcher JP: New Results in Treatment of Metastatic Renal Cell Cancer with IL-2. 2004; CME
Monograph sponsored by University of Wisconsin, Madison, WI.
119.
Alexandrescu DT, Dutcher JP: Case Studies in Oncology: Interleukin-2 in the Treatment of
Metastatic Renal Cell Carcinoma. 2004; CME Monograph sponsored by Baylor Cancer Center,
Dallas, TX.
120.
Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH,
Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin Jr, WG, Linehan WM,
Lipton A, Motzer RJ, Novick AC, Stadler WM, Tehe BT, Yang JC, King L: Innovations and
challenges in renal cancer: Consensus Statement. Clinical Cancer Research 2004; 10 (18);
6277S-6281S.
121.
Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP: The role of carbonic anhydrase IX
overexpression in kidney cancer. Eur J Cancer 2005; 41;2935-2947.
122.
Alexandrescu DT, Dutcher JP, Wiernik PH: Metastatic Melanoma: Is Biochemotherapy the future?
Review Article. Medical Oncology 2005; 22; 101-112.
123.
Dutcher JP: Book Review: Chronic Lymphocytic Leukemia, Editor Guy B. Faguet.
Contemporary Hematology Series, Humana Press. Medical Oncology 2005; 22:211-212.
124.
Morris EL and Dutcher JP: Blastic Phase of Chronic Myelogenous Leukemia. Clinical
Advances in Hematology and Oncology 3:1-6, 2005.
125.
Alexandrescu DT, Wiernik PH, Dutcher JP: Chemotherapy Toxicities and Complications.
Young NS, Gerson SL, High KA (Eds); In Clinical Hematology; Elsevier; Phila; 2006; pp
1144-1154.
126.
Hugec V and Dutcher JP: Chemotherapy for Rapidly Progressing RCC: To What Extent Do
Combinations of Agents Show Potential Activity? Kidney Cancer Journal 2006; 3:5-10.
127.
Karbasian-Esfahani M, Morris EL, Dutcher JP, Wiernik PH: Blastic phase of chronic
myelogenous leukemia. Curr Treat Options Oncol 2006; May 7 (3) 189-199.
128.
Dutcher JP: Book Review: From Melanocytes to Melanoma: The Progression to Malignancy.
Editors Vincent J. Hearing and Stanley P.L. Leong. Medical Oncology 2006; 23: 10.
129.
Dutcher JP, Green RI, Moore SH: Renal Cell Carcinoma – Today’s Targeted Therapies
Improving Tomorrow’s Outcomes. Continuing Education Newsletter for Nurses. Meniscus
Educational Institute., 2006.
130.
Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP: Role of carbonic anhydrases in the
progression of renal cell carcinoma subtypes: Proposal of a unified hypothesis. Cancer Investigation
2006; 24; 1-26.
131.
Rustine A and Dutcher JP: Case Studies in Oncology: A Patient with Metastatic Renal Cell
Carcinoma Treated with Bevacizumab/Interferon Alfa Case Studies in Oncology, 2007; vol 8,
no 6, PER Publications.
40
132.
Hugec V and Dutcher JP: Management of Patients with Variants of Renal Cell Carcinoma:
Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid
Dedifferentiation; Bukowski R, Novick A (eds); In Clinical Management of Renal Tumors;
Humana Press; Totawa NJ; 2008; pp 529-544.
133.
Gucalp R, Dutcher JP: Oncologic Emergencies; DL Kasper, E Braunwald, AS Fauci, SL Hauser,
DL Longo, JL Jameson (eds); In Harrison’s Textbook of Internal Medicine, 17th edition;
McGraw Hill; New York; 2008; pp 1730-1739.
134.
Dutcher JP: Book Review: Clinical Management of Renal Tumors, Editors: Ronald
Bukowski, Andrew Novick. Medical Oncology, 2008.
135.
Dutcher JP: mTOR Inhibition in the Clinic, Kidney Cancer Journal, (Suppl) 2008; p9-12.
136.
Hudes G, Berkinblit A, Feilngold J, Atkins MB, Rini BI, Dutcher JP: Clinical trial experience
with temsirolimus in patients with advancec renal cell carcinoma. Sem Oncology 2009; Dec; 36
(Suppl 3); S25-36.
137.
Dutcher JP: Introduction: History of the management of advanced renal cell cancer. Med Oncol
2009; 26 (Suppl 1); S1-2. (Editor of Supplement)
138.
Gucalp R. and Dutcher JP: Oncologic Emergencies. DL Kasper, E Braunwald, AS Fauci, SL Hauser,
DL Longo, JL Jameson (eds); In Harrison, Principles of Internal Medicine, 18th Edition; , McGrawHill; New York; 2010-2012; pp 2266-2278
139.
Gucalp R. and Dutcher JP: Oncologic Emergencies; D.Longo (ed); In Harrison’s Hematology and
Oncology; McGraw-Hill; NewYork; 2010; Ch 51, pp 642-656.
140.
Gucalp R. and Dutcher JP: Oncologic Emergencies. J. Loscalzo (ed); In Harrison’s Pulmonary
and Critical Care Medicine; McGraw-Hill; New York; 2010; Ch 45, pp 475-490.
141.
Dutcher JP: High dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic
Melanoma: Still the Standard. Oncology 2011; Apr 30; 25:427-428.
142.
Dutcher JP: mTOR Pathway-Directed Agents in Renal Cell Carcinoma. WM Stadler (ed); In Renal
Cancer, Demos Medical Publishing; 2011; Emerging Cancer Therapeutics 2:1 2011; 137-144.
143.
Escudier B, Dutcher JP, Hutson TE, Wilhelm S, Lewis J, Eisen T, Riedl B, Bukowski RM:
Sorafenib: The First Targeted Therapy Demonstrating Clinical Benefit in RCC - Insight on its
Clinical Development. Clin Cancer Res (Submitted) 2011
144.
Dutcher JP: Commentary: Perceptions of Patient-Oriented Research Amonst House Staff and
Faculty in a Clinically -Oriented Internal Medicine Program. Clinical and Translational Science,
2011; Oct; 4 (5):310-311.
145.
Adiga GU, Dutcher JP. Colorectal Cancer;
CS Pitchumoni, TS Dharmarajan, (eds)
Geriatric Gastroenterology. Springer New York; 2012; Ch 63, pp 587-595.
41
In
146. Dutcher JP and Gore M: Reaching Further with Nexavar: Efficacy and safety in RCC in open
label, non-comparative expanded access programs. In Nexavar 5-Year Anniversary Book. 2011;
(in press )
147. Dutcher JP: Progress in Renal Cell Carcinoma: Historical Perspective and Targeted Therapies.
In Advances in Oncology for Community-Based Oncologists. 2011; In Press.
148.
Dutcher JP: Platelet and Granulocyte Transfusion. In PH Wiernik, R Kyle, Goldman JM, JP Dutcher
(eds); In Neoplastic Diseases of the Blood, Fifth Edition; Cambridge/Springer; New York; 2012;
Ch 56, pp. 1265-1288
149.
Dutcher JP: Therapeutic Cytapheresis, Plasmapheresis and Plasma Exchange in Neoplastic Diseases
of the Blood In PH Wiernik, R Kyle, Goldman JM, JP Dutcher (eds); In Neoplastic Diseases of
the Blood, Fifth Edition; Cambridge/Springer; New York; 2012; Ch 54 pp. 1241-1249.
150.
Dutcher JP: Book Review: Targeted Therapeutics in Melanoma. Thomas F Gajewski and F.
Stephen Hodi (eds) Current Clinical Oncology Series (series editor, Maurie Markman) Humana
Press, 2013. In Medical Oncology 2013; 30:399-400.
151. Bellmunt J and Dutcher JP: Targeted therapies and the treatment of non-clear cell renal cell
carcinoma.
Ann Oncology 24:1730-1740, 2013.
152. Dutcher JP: Book Review: Renal Cell Carcinoma: Clinical Management. Steven C Campbell and
Brian I Rini (eds) Current Clinical Urology Series (series Editor Eric A Klein) Humana Press, 2013.
In Medical Oncology, 30:1-2, 2013.
153. Geller D, Morris J, Dutcher J: Revisiting the orthopedic management of metastatic renal cell
carcinoma: Rationale for a more aggressive approach. Current Orthopaedic Practice Sept/Oct
2013; 24:536-541.
154.
Dutcher JP, Wiernik PH: Deconstructing and Reinventing the IL-2 paradigm: Can alternative
dosing schedules enhance tumor effect? Kidney Cancer Journal, June, 2013.
155.
Dutcher J: Perspective: Results of AXIS trial indicate a significant improvement over historical
survival data in renal cell carcinoma. The ASCO Post 4:77, 2013. (July 10, 2013).
156.
Dutcher JP: Recent developments in the treatment of renal cell carcinoma – 2013. Ther Adv in
Urology , 61:338-353, 2013.
157.
Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins
MB: High dose Interleukin-2 (Proleukin) - Update on best management practices - 2014.
Submitted, J Immunotherapy 2014
157.
Gucalp R. and Dutcher JP: Oncologic Emergencies. DL Kasper, E Braunwald, AS Fauci, SL
Hauser, DL Longo, JL Jameson (eds); In Harrison, Principles of Internal Medicine, 19th Edition;
McGraw-Hill; New York; 2015; Ch 331, pp1787-1798.
158.
Dutcher JP: Guest Editor, Kidney Cancer Journal, Volume 12, Number 4, Winter 2014,
published online Genitourinary Publishing, Sarasota FL,
42
159.
Wiernik PH, Wickramasinghe D, Dutcher JP: Families with both Hodgkin’s lymphoma and
myeloma in their pedigrees. Clinical Advances in Hematology and Oncology, 2015 in press
160.
Dutcher JP, Wiernik PH. Renal cell carcinoma (RCC) in patients with a personal or family
history of hematologic malignancies (HM). Clinical Advances in Hematology and Oncology,
2015 in press
43
E.
Abstracts * = presented
1.
*Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Alloimmunization following platelet transfusion: The
absence of a dose response relationship. Proc Am Soc Clin Oncol; 1980; 21:351.
2.
*Dutcher JP, Schiffer CA, Johnston GS: Localization of infection using Indium-labelled granulocytes in
granulocytopenic patients. Rad Soc North Amer; 1980; 66:320.
3.
Dutcher JP, Schiffer CA, Wesley M, Wiernik PH: Effect of hyperleukocytosis in acute leukemia on
remission rate, duration, and survival. Proc Amer Soc Clin Oncol; 1981; 22:491.
4.
*Dutcher JP, Schiffer CA, Johnston GS, Sorandes TP: Localization of infection using Indium-111labeled granulocytes in granulocytopenic patients. Proc Soc Nuc Med Mideastern Chapter; 1981; April
10.
5.
*Schiffer CS, Aisner J, Dutcher JP, Reilly J, Wiernik PH: A clinical program of autologous frozen
platelet transfusion. Proc Am Assoc Blood Banks Transfusion; 1981; p 618.
6.
*Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long-term follow-up of patients with leukemia
receiving platelet transfusions: Identification of a large group of patients who do not become
alloimmunized. Proc Am Assoc Blood Banks, Transfusion; 1981; pg 618
7.
*Dutcher JP, Schiffer CA, Johnston GS, Papenberg D. Daly PA, Aisner J, Wiernik PH: The effect of
histocompatibility factors on the migration of transfused Indium-111-labeled granulocytes. Blood; 1981;
58 (Suppl): 181a.
8.
*Schiffer CA, Aisner J, Dutcher JP, Wiernik PH: Short-term engraftment following transfusion of
leucocytes from patients with chronic myelogenous leukemia. Blood; 1981; 58 (suppl):186a.
9.
*Dutcher JP, Schiffer CA, Aisner J, O'Connell BA, Levy C, Kendall JA, Wiernik PH: Incidence of
thrombocytopenia and bleeding among patients with solid tumors. Proc Am Soc Clin Oncol; 1982; 1:62.
10.
*Hogge DE, Dutcher JP, Aisner J, Schiffer CA: Lymphocytotoxic antibody is a predictor of response to
random donor platelet transfusion. Proc Am Soc Clin Oncol; 1982; 1:59.
11.
*Dutcher JP, Fox JJ, Riggs C, Johnston GS, Schiffer CA: Pulmonary retention of Indium-111-labeled
granulocytes in alloimmunized patients. Blood; 1982; 60 (Suppl I):177a.
12.
*Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP: A randomized trial of leukocyte
depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood; 1982; 60
(Suppl I):182a.
13.
*Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Fox JJ, Aisner J, Wiernik PH: Indiumlabeled granulocytes to evaluate histocompatibility factors in granulocyte transfusions. Proceeding of 3rd
International Symposium on Therapy of Acute Leukemia, Rome; 1982; p125.
14.
*Sutherland J, Dutcher JP, Wiernik PH: Morphologic study of spleens taken from patients with acute
non-lymphocytic leukemia (ANLL) in complete remission. Proceedings of 3rd International Symposium
on Therapy of Acute Leukemia, Rome; 1982; p45.
44
15.
*Dutcher JP, Wiernik PH, Van Sloten K, Schiffer CA, Schimpff SC, Aisner J, Angelou JE: Intensive
maintenance therapy (IMT) in acute non-lymphocytic leukemia. Proceeding of 3rd International
Symposium on Therapy of Acute, Leukemia Rome; 1982; p39.
16.
*Dutcher JP, Schiffer CA, Johnston GS, Papenberg D, Daly PA, Fox JJ, Aisner J, Wiernik PH: Indiumlabeled granulocytes to evaluate histocompatibility factors in granulocyte transfusions. Clin Res; 1982;
30:847a.
17.
*Dutcher JP, Wiernik PH, Van Sloten K, Schiffer CA, Schimpff SC, Aisner J, Angelou JE: Intensive
maintenance therapy (IMT) in acute non-lymphocytic leukemia. Clin Pharm and Ther; 1983; 33:22l.
18.
Forsthoff CA, Dutcher JP and Wiernik PH: Incidence of central nervous system leukemia (CNSL) in
acute nonlymphocytic leukemia (ANLL). Proc Amer Soc Clin Oncol; 1983; 2:177.
19.
Brown GE, Karpetsky TP, Testa JR, McFarland E, Dutcher J: Differences in individual species of
intracellular acidic Dnase correlate with specific chromosomal abnormalities and with leukemia subtype.
Proc Amer Assoc Cancer Res; 1983; 24:40.
20.
*Park CH, Amare M, Wiernik PH, Morrison FS, Dutcher JP, and Myers JA: Versatile drug exposure
times for improved clinical chemotherapy correlation by clonic assay in acute nonlymphocytic leukemia.
Proc Amer Soc Clin Oncol; 1983; 2:28.
21.
*Kadakia AS, Dutcher JP, Wiernik PH: Association of thyroid disease (TD) with acute leukemia (AL).
Clin Res; 1983; 31:695A.
22.
*Dutcher JP, Whitley NO, Pearl P, Finley R, Smardon C, Wiernik PH: Ethiodized oil emulsion-l3 (EOE13) for improved CT visualization of liver and spleen metastases. Clin Res; 1983; 31:695A.
23.
*Dutcher JP, Schiffer CA, Johnson GS, Papenberg D, Wiernik PH: Indium-labelled granulocytes to
evaluate histocompatibility factors in granulocyte transfusions. Exptl Hemat; 1983; 11:171.
24.
*Whitley NO, Dutcher JP, Pearl P, Finley RF, Whitley JE: Ethiodized oil emulsion-13 (EOE-13) for
improved CT visualization of liver and spleen metastases. Proc 4th Asian-Oceanic Congress of
Radiology; 1983.
25.
*Dutcher JP, Markus S, Wiernik PH, Weinberg V, Schiffer CA, Aisner J, VanSloten K: Intensive
maintenance therapy in acute nonlymphocytic leukemia (ANLL). Blood; 1983; 62 (Suppl 1):201a.
26.
*Paietta E, Dutcher JP, Wiernik PH: TdT-positive acute progranulocyte leukemia: loss of TdT activity
during differentiation with retinoids. Blood; 1983; 62 (Suppl 1):179a.
27.
*Schiffer CA, Hogge DE, Aisner J, Dutcher JP, Lee EJ, Papenberg D: High dose intravenous gamma
globulin in alloimmunized platelet transfusion recipients. Blood; 1983; 62 (Suppl 1):237a.
28.
*Park CH, Amare M, Wiernik PH, Morrison FS, Dutcher JP, Maloney TR: In vitro drug sensitivity of
leukemic colony forming cells in acute nonlymphocytic leukemia: Clinical correlation update with various
drug exposure methods. Proc. 4th Internatl Conf on Human Tumor Cloning; 1984.Tucson,AZ
Dutcher JP, Moorehouse H, Pollack S, Wiernik P: Ethiodized oil emulsion-13 (EOE-13). A new
45
29.
contrast agent for CT demonstration of hepatic and splenic metastases. Proc. Amer Soc Clin Onc; 1984;
3:17.
30.
*Dutcher J, Wiernik P, Goldstein M, Berensweig M, Camacho F, Ryan J. Low dose cytosine arabinoside
(LD AraC) for treatment of acute nonlymphocytic leukemia (ANLL) and myelodysplastic syndrome
(MOS) in elderly patients (pts). Proc Amer Assoc Cancer Res; 1984; 25:189.
31.
*Paietta E, Dutcher JP, Wiernik PH: Retinoic acid induces maturation of leukemic lymphocytes in vitro.
Proc Amer Soc Clin Onc; 1984; 3:65.
32.
*Dutcher JP and Wiernik PH: Combined modality treatment of Hodgkin's disease confined to lymph
nodes. Proc Second Internatl Conference on Malignant Lymphoma; 1984; Lugano, Sz.
33.
*Dutcher JP, Wiernik PH: Treatment of acute non-lymphocytic leukemia in patients older than 60 years
of age. Proc Internatl Soc of Hematology; 1984; (abst 426) Buenos Aires, Argent.
34.
*Paietta E, Dutcher JP, Papenhausen P, Wiernik PH: Acute promyelocytic leukemia (APL) as diagnosed
by cytogenetics and in vitro induction of differentiation. Clin Res; 1984; 32:706A.
35.
Markman HD, Wiernik PH, Dutcher JP, Charbonneau D: The unfulfilled obligation of many medical
schools to teach colorectal cancer detection in clinical medicine. Med Pediatr Oncol; 1984; 12:29A.
36.
*Paietta E, Reed J, Dutcher JP, Ciobanu N, Jacobson G, Wiernik PH: Estradiol receptors (ER) in chronic
lymphocytic leukemia (CLL): Effect of hydrocortisone in vivo and in vitro. Blood; 1984; 64:171a.
37.
*Dutcher JP, Strauman JJ, Wiernik PH: Treatment of acute nonlymphocytic leukemia in patients older
than 60 years of age. Blood; 1984; 64:163a.
38.
*Dutcher JP, Wiernik PH, Strauman JJ, Spielvogel A, Dukart G: Mitoxantrone (MITOX) and cytosine
arabinoside (ARA-C) in acute non-lymphocytic leukemia (ANLL) and blast crisis of chronic myelogenous
leukemia (CML-B). Proc. Am. Soc. Clin. Oncol; 1985; 4:170.
39.
Lipton RE, Dutcher JP, Berger A, Arezzo J, Wiernik PH, Schaumburg HH: Early detection of peripheral
neuropathy in cancer patients. Proc. Am. Soc. Clin. Oncol; 1985; 4:261.
40.
*Dutcher JP, Spivack M, Mohandas K, Wiernik PH: A clinical program of platelet cryopreservation.
Proc VIIIth Int Society of Haematology, Warsaw, Poland; 1985.
41.
*Paietta E, Papenhausen P, Dutcher JP, Wiernik PH: CML-blast crisis: immunologic and karyotypic
heterogeneity. Blood; 1985; 66:181a.
42.
*Dutcher JP, Markus S, Schiffer CA, Wiernik PH: Intensive maintenance therapy (IMT) in acute nonlymphocytic leukemia. Proc Am Soc Clin Oncol; 1986; 5:152.
43.
*Wiernik PH, Strauman JJ, Engel SI, Schwartz EL, Dutcher JP: Taxol (T) phase I and pharmacokinetic
study. Proc Am Soc Clin Oncol; 1986; 5: 32.
44.
*Dutcher JP, Strauman JJ, Paciucci PH, Holland JF, Wiernik PH: Mitoxantrone (MITOX) and
cytarabine for treatment of chronic myelogneous leukemia-blast crisis (CML-BC). Proc Am Soc Clin
46
Oncol; 1986; 5:166.
45.
*Dutcher JP, Kendall J, Papenberg D, Schiffer CA, Aisner J, Wiernik PH: Concurrent administration of
Amphotericin B (Ampho) and granulocyte transfusions (Gran Tx): Lack of detrimental effect. Clin Res;
1986; 34:561A.
46.
*Lipton RB, Dutcher J, Arezzo J, Kaplan J, Wiernik P, Schaumburg HH:
predominantly sensory neuropathy. Ann Neurol; 1986; 20:132.
47.
*Paietta E, Stockert RJ, Khorshidi M, Ciobanu N, Dutcher JP, Wiernik PH: Activation-associated
antigen expression by human lymphokine-activated killer (LAK) cells. Proc Second Internatl Conf on
Immunophenotyping, Oxford; 1986.
48.
*Dutcher JP, Paciucci PA, Wiernik PH, Strauman JJ, Cuttner J, Holland JF: Mitoxantrone (M) + Ara-C
in patients with relapsed or refractory acute myelocytic leukemia. Blood; 1986; 67(Suppl):221a.
49.
*Ciobanu N, Paietta E, Lalezari P, Dutcher JP, Thompson D, Wiernik PH: L-Leucyl-Leucine methyl
ester prevents the generation and inhibits the activity of lymphokine activated killer (LAK) cells. Blood;
1986; 67 (Suppl):93a.
50.
*Dutcher JP, Paciucci PA, Wiernik PH, Strauman JJ, Cuttner J, Holland JF: Mitoxantrone and Ara-C in
the treatment of relapsed or refractory ANLL. Proc 4th International Symposium on Therapy of Acute
Leukemia, Rome; 1987.
51.
*Dutcher JP, Strauman JJ, Wiernik PH: Phase I-II study of deoxydoxorubicin (DxDx) for relapsed and
refractory acute non-lymphocytic leukemia (ANLL). Proc 4th International Symposium on Therapy of
Acute Leukemia, Rome; 1987.
52.
*Dutcher JP, Ryan J, Spivack M, Wiernik PH: Decreased anticoagulant requirement in
thrombocytopenic patients (pts) undergoing lymphocytapheresis (LP). Proc Haemonetics 12th
International Apheresis Symposium; 1987.
53.
*Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D: Phase II
study on high dose interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells in patients (pts) with
melanoma. Proc Am Soc Clin Oncol; 1987; 6:246.
54.
*Dutcher JP, Strauman JJ, Riggs CE, Link B, Wiernik PH: Phase I-II clinical and pharmacologic study
on deoxydoxorubicin (DxDx) for relapsed and refractory acute non-lymphocytic leukemia (ANLL). Proc
Am Soc Clin Oncol; 1987; 6:160.
55.
*Paietta E, Gucalp R, Papenhausen P, Radel E, Dutcher JP, Wiernik PH: Lineage promiscuity in acute
leukemia. Proc Am Soc Clin Oncol; 1987; 6:161.
56.
*Wadler S, Einzig A, Dutcher JP, Ciobanu N, Landau L, Wiernik PH: Phase II trial of recombinant
alpha-2b-interferon (IFN) and low dose cyclophosphamide (cy) in advanced melanoma and renal cell
carcinoma (RCC). Proc Am Soc Clin Oncol; 1987; 6:246.
57.
*Marcus SL, Dutcher J, Ciobanu N, Paietta E, Strauman J, Wiernik PH, Baker H, Frank O:
Micronutrient depletion in patients treated with high-dose interleukin-2 (IL-2) and lymphokine-activated
47
Taxol produces a
killer (LAK) cells. Proc Am Soc Clin Oncol; 1987; 6: 247.
58.
Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Wiernik PH: Plasma free catecholamines in patients
during immunotherapy with high-dose interleukin-2 (IL-2). Proc Am Assoc Cancer Res; 1987; 28:369.
59.
*Riggs CE, Dutcher JP, Strauman JJ, Link B, Wiernik PH: Pharmacokinetics of esorubicin in a phase I
trial in patients with acute leukemia. Clin Pharmacol and Therapeutics; 1988; 43:193.
60.
*Einzig AI, Trump DL, Sasloff J, Gorowski E, Dutcher J, Wiernik PH: Phase II pilot study of taxol in
patients (pts) with malignant melanoma (mm). Proc Am Soc Clin Oncol; 1988; 7:249.
61.
*Wiernik PH, Dutcher JP, Benson L, Gucalp R: Aggressive treatment of acute non-lymphocytic
leukemia (ANLL) in patients older than 60 years of age. Proc International Soc Hematology; 1988; p. 69.
62.
*Wiernik PH, Dutcher JP, Gucalp R, Garl S, Benson L: MOAD therapy in adult patients (pts) with acute
lymphocytic leukemia (ALL). Proc International Soc Hematology; 1988; p. 250.
63.
*Dutcher JP, Arlin Z, Paietta E, Rowe J, Kellermeyer R, Wiernik PH: Phase II study of mitoxantrone
(mitox) and 5-azacytidine (5aza) for blast crisis (BC) chronic myeloid (my) leukemia (CML). Proc
International Soc Hematology; 1988; p. 172.
64.
*Wiernik PH, Dutcher JP: Treatment of relapse in acute non-lymphocytic leukemia (ANLL).
Haematologica; 1988; 73:120.
65.
*Dutcher JP, Adinolfi C, Garl S, Salva K, Azar C, Wiernik PH: Treatment of hairy cell leukemia (HCL)
with B-ser interferon (B-IFN) in previously treated patients or deoxycoformycin (DCF) in patients failing
interferons. Haematologica; 1988; 73:190.
66.
*Sznol M, Dutcher JP, Rayner AA, Atkins MB, Margolin K, Fisher RI, Weiss G, Parkinson DR, Hawkins
MJ. NCI Extramural IL-2/LAK Working Group. Phase II trials of IL-2/LAK or IL-2 alone in melanoma Experience of the IL-2/LAK Working Group (ILWG). Proc EuroCetus Meeting; 1988..
67.
*Einzig AI, Wiernik PH, Dutcher JP, Sasloff J, Gorowski E. Phase I/II trials of Taxol: Responses
observed in malignant melanoma. Proc EORTC New Drug Development Conference; 1989.
68.
*Sznol M, Atkins MB, Dutcher J, Fisher RI, Weiss G, Margolin K, Aronson F, Hawkins MJ. NCI IL2/LAK Extramural Working Group. Experience of the NCI IL-2/LAK Extramural Working Group
(ILWG) in renal cell carcinoma (RCC) and melanoma. Proc of EORTC New Drug Development
Conference; 1989.
69.
*Fisher RI, Weiss GR, Margolin KA, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP. NCI
Extramural IL-2/LAK Working Group. Interleukin-2 plus lymphokine activated killer cell (IL-2/LAK)
treatment of metastatic renal cancer. Proc 2nd International Symposium on Advances in Urologic
Oncology; 1989.
70.
*Dutcher JP, Moore R, Wagner B, Ryan J, Holmes M, Schuyler B: Lymphocytopheresis for killer cell
generation and in patients with chronic lymphocytic leukemia. J Clin Apheresis; 1989; 5:38.
48
71.
*Dutcher JP: LAK/TIL cell therapy: Efficacy, toxicity, controversies. Proc Am Soc Apheresis; 1989.
72.
*Dutcher JP, Wiernik PH, Arlin Z, Paietta E, Rowe J, Kellermeyer R, Andersen J: Mitoxantrone (Mitox)
and 5-Azacytidine (5AZA) for patients (pts) with accelerated (AC) or blast crisis (BC) Ph1 chronic
myeloid leukemia (CML). Proc Am Soc Clin Oncol; 1989; 8:205.
73.
*Dutcher JP, Gaynor E, Boldt DH, Doroshow J, Rayner AA, Sznol M, Mier J: Phase II study of high
dose intravenous continuous infusion (IVCI) interleukin-2 (IL2) and lymphokine activated killer (LAK)
cells in patients (pts) with metastatic melanoma (mm). Proc Am Soc Clin Oncol; 1989; 8:282.
74.
Gucalp R, Dutcher JP, Sparano J, Grima K, Sessa G, Ciobanu N, Wiernik PH: Phase I pilot study of
moderate dose continuous infusion (IVCI) recombinant interleukin-2 (rIL2) in patients (pts) with
refractory malignancy. Proc Am Soc Clin Oncol; 1989; 8:190.
75.
*Ciobanu N, Dutcher J, Gucalp R, Sparano J, Goldman M, Adinolfi C, Fitzgerald E, Wiernik PH. High
dose chemotherapy with autologous bone marrow transplantation (ABMT) for malignant melanoma after
failure of interleukin-2 (IL2) and lymphokine activated killer (LAK) cells. Proc Am Soc Clin Oncol;
1989; 8:281.
76.
*Wiernik PH, Schwartz B, Dutcher JP, Turman N, Adinolfi C: Treatment of patients (pts) with hairy cell
leukemia (HCL) with B-ser-interferon (bIFN). Proc Am Assoc Cancer Res; 1989; 30:388.
77.
*Gallagher R, Pua I, Shao WB, Papenhausen P, Dutcher J, Wiernik PH: Multiple bcr rearrangements
during the clinical course of a patient with chronic myelogenous leukemia. Proc Am Assoc Cancer Res;
1989; 30:56.
78.
*Lipton RB, Galer B, Portenoy RK, Dutcher JP, Meller F, Pahmer V, Arezzo J, Wiernik PH, Schaumburg
HH. Large and small fiber type sensory dysfunction in patients with cancer. Neurology; 1989; 39(Suppl
1):320.
79.
*Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH:
Acute renal failure during interleukin-2 (IL2) treatment - an intrinsic renal lesion. Clin Res 1989;
37:862A.
80.
Ryan J, Caliendo G, Wagner B, Grima K, Dutcher JP: Three year experience with lymphocytopheresis
(LK) for adoptive immunotherapy in malignant diseases. Transfusion;
1989; 29(Suppl):44S.
81.
*Wagner B, Ryan J, Grima K, Ciobanu N, Caliendo G, Mohandas K, Spivack M, Dutcher JP: Platelet
transfusion support for autologous bone marrow transplantation. Proc Am Soc for Apheresis; 1990;
abst #45.
82.
*Moskowitz C, Dutcher JP, Wiernik PH: Association of thyroid disease (TD) with acute leukemia (AL).
Clin Res; 1990; 38:397A.
83.
*Wiernik PH, Dutcher JP, Gucalp R, Markus S, Esterhay R, Schiffer C, Weinberg V, Paietta E, Garl S,
Benson L. MOAD therapy for adult acute lymphocytic leukemia. Proc Am Soc Clin Oncol; 1990; 9:205.
84.
*Sparano JA, Wiernik PH, Reilly J, Salva K, Dutcher JP. Infusional cyclophosphamide (C), Adriamycin
(A), and etoposide (E) in relapsed/refractory Hodgkins (HD) and non-Hodgkin's lymphoma (NHL). Proc
49
Am Soc Clin Oncol; 1990; 9:267.
85.
Wallerstein Jr R, Davidson W, Dutcher J, Freireich E, Hester J, Wiernik P, Deisseroth A, Block J.
Safety, efficacy and preliminary anti-cancer activity of blood tryptophan depletion (BTD) therapy using a
new extracorporeally placed device. Proc Am Soc Clin Oncol; 1990; 9:82.
86.
Sznol M, Mier J, Gaynor E, Dutcher J, Weiss G, Margolin K, Hawkins M, Louie A, Bar M. A Phase I
study of high dose IL-2 (Cetus) with interferon-alfa 2B. Proc Am Assoc Cancer Res; 1990; 31:264.
87.
*Strack M, Grima K, Sussman I, Dutcher J, Wiernik PH: Coagulation abnormalities associated with
interleukin-2 therapy for metastatic cancer. Clin Res; 1990; 38: 776A.
88.
Sparano J, Dutcher J, Caliendo G, Kaleya R, Fiorito J, Wiernik PH: Colonic ischemia complicating
treatment with interleukin-2 and alpha-interferon. Clin Res; 1990; 38:776A.
89.
*Sparano J, Walpole E, Paietta E, Dutcher J, Pellone C, Wiernik PH: Cytotoxicity of peripheral blood
mononuclear cells in patients treated with interleukin-2 and alpha-interferon. Clin Res; 1990; 38:776A.
90.
*Grima K, Dutcher J, Gale B, Paietta E, Chun J. Indium-111 LAK cells localize to tumor and
myocardium. Proc Am Assoc Blood Banks; Transfusion 1990; 30: 54S.
91.
Ryan J, Dutcher JP, Wagner B, Grima K, Wiernik PH. Therapeutic leukopheresis (LP) in chronic
lymphocytic leukemia (CLL). Proc Am Assoc Blood Banks; Transfusion; 1990; 30:43S.
92.
*Gallagher R, Ahearn G, Thompson D, Strack M, Paietta E, Dutcher J, Wiernik PH: Retinoic acidenhanced neutrophilic differentiation of granulocyte-macrophage progenitors in blastic crisis chronic
myelogenous leukemia (CML). Blood; 1990; 76(Suppl 1):272a.
93.
*Gallagher R, Paietta E, Strack M, Dutcher J, Wiernik P: Cell culture studies of a chronic myelogenous
leukemia blast crisis patient responsive to clinical treatment with trans-retinoic acid. In Proc Fourth
Conference on Differentiation Therapy; F. Takaku, G Rossi, S Waxman (eds), Chiba, Japan, Ares Serono
Symposium, 1990, p 117.
94.
*Wagner B, Moore R, Grima K, Dutcher J: Granulocytopheresis efficiency: Comparison of COBE 2997
to the COBE Spectra automated granulocyte protocol. J Clin Apheresis; 1991; 6:186.
95.
*Dutcher JP, Schwartz El, Wiernik PH, Brechbuhl AB, Benson L, Garl S: Phase I study of menogaril
(M) with pharmacokinetics (PK) in acute leukemia (AL). Proc Am Assoc Cancer Res; 1991; 32:179.
96.
*Walpole E, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G,
Cavasotto G, Wiernik PH: Survival after phase II treatment of advanced renal cell cancer (RCC) with
taxol (T) or high dose interleukin-2 (IL2). Proc Am Assoc Cancer Res; 1991; 32:186.
97.
*Volterra F, Wiernik PH, Dutcher JP, Sklarin NT: Breast cancer (BC) and lymphoma (LY) in the same
patients. A possible relationship. Proc Am Assoc Cancer Res; 1991; 32:195.
98.
*Sagayadan G, Dutcher J, Wiernik P, Gallagher R: Effect of trans-retinoic acid and interferon- on
clonogenic chronic myelogenous leukemia blast crisis cells. Proc Am Assoc Cancer Res; 1991; 32:32.
50
99.
Dutcher JP, Martin K, Wiernik PH. Mitoxantrone (M), Vinblastine (V), and CCNU (C): An active
regimen in Hodgkin's disease. Proc Am Soc Clin Oncol; 1991; 10:286.
100.
*Sparano JA, Wiernik PH, Trager M, Dutcher JP: Infusional cyclophosphamide (C), doxorubicin (D),
and etoposide (E): An active regimen in relapsed (RL) non-Hodgkin's lymphoma. Proc Am Soc Clin
Oncol; 1991; 10:286.
101.
*Krigel R, Lynch E, Kucuk O, Tester W, Chang A, Bonomi P, Huberman M, Padavic K, Dutcher J, Blum
R, Comis R: Interleukin 2 (IL2) therapies prolong survival in metastatic non-small cell lung cancer
(NSCLC). Proc Am Soc Clin Oncol; 1991; 10:246.
102.
*Dutcher JP, Wiernik PH, Gucalp R, Markus S, Esterhay R, Paietta E, Benson L, Azar C. MOAD
therapy for adult lymphocytic leukemia (ALL). Haematologica; 1991; 76 (suppl 4):66.
103.
Strack M, Sussman I, Grimma K, Solomon T, Merer D, Caliendo G, Wiernik P, Dutcher J. Unique
pattern of change of coagulation factors (CF) during interleukin-2 (IL2) therapy. Blood; 1991; 78 (suppl
1):485a.
104.
*Gaynor B, Dutcher JP, Paietta E, Wiernik PH: Carboplatin (carbo) plus mitoxantrone (mitox) therapy in
relapsed/refractory acute leukemia (AL) and blast crisis of chronic myeloid leukemia (CMLBC). Blood;
1991; 78 (Suppl 1):31a.
105.
*Wiernik PH, Dutcher JP, Todd M, Duffy T, Caliendo G, Benson L: Polyethylene glycolated (PEG)
interleukin-2 (IL2) as maintenance therapy for acute myelogenous leukemia (AML) in second remission
(CR). Blood; 1991; 78 (Suppl 1):42a.
106.
Venkatraj U, Beitler J, Dutcher J, Wiernik PH: Pulmonary leucostasis in acute leukemia. Proc Am
Radium Soc; 1992.
107.
Sosman J, Fisher RI, Weiss G, Margolin KA, Aronson FR, Sznol, Atkins MB, Dutcher J. Phase IA/IB
trial of anti-CD3 monoclonal antibody (OKT3) with high dose IL2 in renal cell (RCC) and melanoma.
Proc Am Soc Clin Oncol; 1992; 11:254.
108.
Margolin K, Doroshow J, Akman S, Leong L, Morgan R, Raschko J, Somlo G, Dutcher J, Gucalp R,
Hawksworth K, Caliendo G: Phase I study of interleukin-2 (IL2) with Adriamycin (ADR). Proc Am Soc
Clin Oncol; 1992; 11:250.
109.
*Mrowiec ZR, Puzhkin E, Dutcher JP: Metabolism of cryopreserved platelets. Proc Am Assoc Blood
Banks; Transfusion 1992; 32:45S.
110.
*Coletti D, Dutcher JP, Paietta E, Wiernik PH: Alpha-interferon and plicamycin for accelerated phase
chronic myelogenous leukemia. Blood; 1992; 80 (Suppl): 211a.
111.
*Coletti D, Dutcher JP, Paietta E, Wiernik PH: Alpha interferon + plicamycin for accelerated phase
chronic myelogenous leukemia. Proc Am College of Physicians regional meeting; 1993.
112.
*Oleksowicz L, Zuckerman D, Mrowiec Z, Puszkin E, Dutcher J: Functional platelet aberrations in
patients receiving IL-2 as immunotherapy. Proc XIVth Congress of International Society of Thrombosis
and Haemostasis; 1993.
51
113.
*Ciobanu N, Sparano JA, Gucalp R, Dutcher J, Walewski J, Marcoullis G, Wiernik PH: High-dose
cisplatin, carmustine and thiotepa plus autologous bone marrow transplantation in advanced cancer. Proc
Am Soc Clin Oncol; 1993; 12:463.
114.
*Vlock D, Kalish L, Crouse C, Dutcher J, Adams G: Phase II trial of interferon alpha and chemotherapy
in locally recurrent or metastatic head and neck cancer. Preliminary results of ECOG trial EST 1390.
Proc Am Soc Clin Oncol; 1993; 12:284.
115.
Dutcher JP, Fisher RI, Weiss G, Aronson FR, Margolin K, Caliendo G, Louie A, Atkins M: An
outpatient regimen of subcutaneous interleukin-2 plus alpha-interferon in metastatic renal cell cancer.
Proc Am Soc Clin Oncol; 1993; 12:248.
116.
Dutcher JP and Wiernik PH: Mitoxantrone, Vinblastine and CCNU: A highly active regimen in poor
prognosis Hodgkin's disease. Proc Fifth International Conference on Malignant Lymphoma; Lugano,
Switzerland; 1993.
117.
*Dutcher JP, Wiernik PH, Todd M, Caliendo G, Benson L: Interleukin-2 as maintenance therapy for
acute myelogenous leukemia in second remission. Experimental Hematology; 1993; 21:1048
118.
*Dutcher JP, Wiernik PH, Einzig AI, Cassileth P: Mitoxantrone, vinblastine and CCNU (MVC): A
highly active regimen in poor prognosis Hodgkin's disease. Blood; 1993; 82 (Suppl 1):143a.
119.
*Dutcher JP, Leong T, Makary A, Paietta E, Bennett J, Cassileth P, Wiernik PH: Phase II study of
menogaril in patients with relapsed/refractory acute myeloid leukemia - EST 8490. Blood;
1993;
82(Suppl 1): 130a.
120.
Ciobanu N, Lazarus HM, DeBellis R, Ascensao J, Sparano JA, Gucalp R, Dutcher JP, Fox RM, Creger
RJ, Cooper BE, Berson SL, Nese M, Bello L, Wiernik PH: Autologous bone marrow transplantation using
ex-vivo etoposide purged marrow in patients with poor risk lymphomas and acute leukemias. Blood;
1993; 82(Suppl 1): 629a.
121.
*Fay JW, Collins R, Pineiro L, Dutcher J, Gucalp R, Grinblatt D, Lazarus HM, Williams S, Cooper BW,
Manfredo S, Issacs R: Concomitant administration of interleukin-6 and leucomax following autologous
bone marrow transplantation - a phase I trial. Blood; 1993; 82(Suppl 1):431a.
122.
*Sparano JA, Wiernik PH, Dutcher JP, Leaf A, Khalil A: Infusional cyclophosphamide, doxorubicin,
and etoposide in relapsed resistant and poor-prognosis non-Hodgkin's lymphoma. Blood; 1993;
82(Suppl 1):137a.
123.
Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E: Enhancement of platelet
aggregation by IL-6: Evidence for a direct effect on platelet function. Blood; 1993; 82(Suppl 1): 610a.
124.
*Mrowiec ZR, Oleksowicz L, Zuckerman D, Dutcher J, Lalezari P, Puszkin EG: Advantages of buffy
coat platelets stored at room temperature. Blood; 1993; 82(Suppl 1):400a.
125.
*Sparano JA, Wiernik PH, Dutcher JP, Sarta C, Strack M, Leaf A: Infusional cyclophosphamide,
doxorubicin, and etoposide in HIV-related non-Hodgkin's lymphoma: A followup report of a highly active
regimen. Blood; 1993; 82(Suppl 1):386a.
52
126.
*Sparano J, Lipsitz S, Wadler S, Hansen R, Benson AB, Dutcher JP: Clinical features predicting
development of toxicity in patients with pancreatic cancer treated with continuous infusion 5-fluorouracil
plus interferon-alpha. Proc Soc Biol Ther; 1993.
127.
*Sparano JA, Dutcher JP, Wiernik PH, Wadler S, Caliendo G, Nobile L: A phase II trial of low-dose
continuous infusion 5-fluorouracil plus interferon-alpha in patients with advanced renal cell carcinoma.
Proc Soc Biol Ther; 1993.
128.
*Zuckerman D, Oleksowicz L, Mrowiec Z, Korshidi M, Herz F, Dutcher J, Puszkin E: Role of GPIIb/IIIa
and GPIb in breast carcinoma-platelet interactions. Proc Exptl Biol; 1994.
129.
*O'Boyle K, Wang Y, Schwartz E, Einzig A, Regl D, Dutcher J, Wiernik P, Horwitz S: Detection of
taxol in human sera, cerebrospinal fluid, ascites, and pleural fluid using a novel monoclonal antibody and
two radioimmunoassay techniques. Proc Am Assoc Cancer Res; 1994; 35:241.
130.
*Oleksowicz L, Puszkin E, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J: Characterization of effects of
IL-6 on platelet activation and metabolic function in phase I clinical trials. Proc Am Assoc Cancer Res;
1994; 35:519.
131.
Caliendo G, Dutcher J, Lasala P, Mitnick R, Wiernik P: Phase II trial of merbarone in brain tumor
patients. Proc Am Soc Clin Oncol; 1994; 13:180.
132.
*Sznol M, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA: A phase II trial of a daily 1-hour
intravenous infusion of interleukin-6 for metastatic malignant melanoma. Proc Am Soc Clin Oncol;
1994; 13:396.
133.
*Sparano JA, Wiernik PH, Dutcher JP, Sarta C, Leaf A, Hu XP: A pilot trial of infusional
cyclophosphamide, doxorubicin and etoposide plus didanosine in HIV-related non-Hodgkin's lymphoma.
Proc Am Soc Clin Oncol; 1994; 13:51.
134.
*Einzig AI, Schuchter LM, Wadler S, Coatsworth S, Dutcher JP, Reci A, Mollman J, Wiernik PH: Phase
II trial of Taxotere (RP 56976) in patients with metastatic melanoma previously untreated with cytotoxic
chemotherapy. Proc Am Soc Clin Oncol; 1994; 13:395.
135.
Leaf A, Schwartz E, Ritch P, Dutcher J, Adams G: A phase II study of amonafide in carcinoma of the
head and neck. Proc Am Soc Clin Oncol; 1994; 13:286.
136.
Fay JW, Stein B, Collins R, Pineiro L, Dutcher J, Gucalp R, Grinblastt D, Lazarus HM, Williams S,
Cooper BW, Resta D, Issacs R: Concomitant administration of interleukin-6 (rhIL-6) and rhGM-CSF
following autologous bone marrow transplantation - A phase I trial update. Proc Am Soc Clin Oncol;
1994; 13:111.
137.
*Schuchter L, Neuberg D, Atkins M, Tester B, Reclo A, Sickles C, Moore J, Light B, Anderson T,
Chachoua A, Dutcher J: A phase I study of interleukin-1 alpha (IL-1) and high dose cyclophosphamide
(Cy) in patients with advanced cancer. Proc Am Soc Clin Oncol; 1994; 13:133.
138.
*Carlisle P, Gucalp R, Gialanella P, McKitrick J, Wiernik PH, Dutcher J: Amphotericin B resistant
paecilomyces fungal sinusitis. Proc 8th Internatl Symp Infections in Immunocompromized Host; 1994.
53
139.
*Oleksowicz L, Mrowiec Z, Isaacs R, Puszkin E, Dutcher J: Enhancement of platelet function by IL3 and
IL6 in myeloablated patients. Blood; 1994; 84(Suppl 1):29a.
140.
*Sparano JA, Wiernik PH, Leaf A, Henry D, Mason B, Sarta C, Hu X, Dutcher JP: Didanosine
ameliorates neutropenia in patients with HIV-related non-Hodgkin's lymphoma treated with infusional
cyclophosphamide, doxorubicin and etoposide (CDE). Proc Am Assoc Cancer Res; 1995; 36:203.
141.
*Sparano JA, Wiernik PH, Yu L, Sarta C, Dutcher JP, Leaf A: Central nervous system prophylaxis and
therapy in patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide,
doxorubicin, and etoposide. Proc Am Radium Society; 1995.
142.
Dutcher JP, Caliendo G, LaSala P, Sparano J, Oleksowicz L, O'Boyle K, Wiernik PH: Treatment and
course of brain metastases in patients with metastatic renal cell cancer. Proc Am Radium Society; 1995.
143.
*Dutcher JP, Wiernik PH, Markus S, Schiffer CA: 15-year follow-up of adult patients with acute
myeloid leukemia: Study BCRC 7802. Proc XXVI Annual meeting International Socieity Hematology,
1995.
144.
*Dutcher JP, Fisher R, Weiss G, Aronson F, Margolin K, Louie A, Atkins M: Outpatient subcutaneous
interleukin-2 plus alpha-interferon in metastatic renal cell cancer: 3 year follow-up of the cytokine
working group study. Proc Am Soc Clin Oncol; 1995; 14:332.
145.
*Sparano JA, Wiernik PH, Hu XP, Sarta C, Dutcher JP, Hanau L, Leaf A: Opportunistic infection in
patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide,
doxorubicin & etoposide: A case control study. Proc Am Soc Clin Oncol; 1995; 14:289.
146.
Vlock DR, Kalish L, Crouse C, Dutcher J, Adams G: Phase II trial of interferon alpha (IFN) and
chemotherapy in locally recurrent or metastatic head and neck cancer (SCCHN). Results of ECOG trial
EST 1390. Proc Am Soc Clin Oncol; 1995; 14:303.
147.
Mrowiec ZR, Oleksowicz L, Zuckerman D, Deleon-Fernandez M, Khorshidi M, Dutcher JP, Puszkin EG:
Buffy coat platelets stored in plasma containing apyrase, aprotinin and ascorbic acid. Transfusion; 1995;
35(Suppl 1):7S.
148.
Novik Y, Dutcher JP, Oleksowicz L: Interleukin-2 & Interleukin-11: Absence of an effect on in vitro
agonist-induced platelet aggregation and platelet GMP-140 expression. Blood; 1995; 86 (suppl 1):701a.
149.
Oleksowicz L, Dutcher JP, DeLeon M, Etkind P: GPIb is expressed by MCF-7 human breast carcinoma
cells. Blood; 1995; 86(Suppl 1):85a.
150.
Sparano JA, Wiernik PH, Hu X, Dutcher JP, Sarta C, Henry D, Mason B: Didanosine (ddI) ameliorates
neutropenia and thrombocytopenia in patients with HIV-associated non-Hodgkin's lymphoma (NHL)
treated with infusional cyclophosphamide (C), doxorubicin (D), and etoposide (E) plus granulocyte-colony
stimulating factor (G-CSF). Blood; 1995; 86(Suppl 1): 934a.
151.
Dutcher JP, Lee S, Paietta E, Bennett J, Stewart J, Wiernik PH: An ECOG phase II study of carboplatin
in blast crisis of chronic myelogenous leukemia (CML-BC) (E1992). Blood; 1995; 86 (Suppl 1):757a.
54
152.
*Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Atkins M. 5FU +
Subcutaneous (SC) interleukin-2 (IL2) plus SC Intron (IFN) in metastatic renal cell cancer (RCC) patients
(pts). A CWG Study. Proc Am Soc Clin Oncol; 1996; 15:272 (abst 725).
153.
*Margolin K, Atkins M, O'Boyle K, Sosman J, Weiss G, Lotze M, Dutcher J, Fisher R. Prospective
randomized trial of lisofylline (LSF) for the modulation of interleukin-2 (IL-2) toxicity. Proc Am Soc Clin
Oncol; 1996; 15:273 (abst 729).
154.
Small EJ, Weiss G, Dutcher J, Walther P, Johnson D, Wilding G, Kuzel T, Kralik C, Paton V.
Preliminary results from a multicenter open-label trial of ActimmuneR interferon gamma-1b injection
(rIFN-g) for the treatment of metastatic renal cell carcinoma: Favorable safety profile. Proc Am Soc Clin
Oncol; 1996; 15:259 (abst 674).
155.
*Schuster MW, Ackley L, Smith M, Doukas M, Pendergrass K, Dutcher J, Harris J, Levine J, Tubridy K,
Sherman M. Phase II open-label evaluation of recombinant human macrophage colony-stimulating factor
(rhM-CSF) in patients with non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL).
Proc Am Soc Clin Oncol; 1996; 15:273 (abst 730).
156.
O'Boyle K, Coatsworth S, Anthony G, Ramirez M, Greenwald E, Kaley R, Steinberg JJ, Wadler S,
Dutcher J, Wiernik P. Effects of desialylation of ovine submaxillary mucin (OSM) on humoral and
cellular immunity to Tn and sialylated Tn. Proc Am Assoc Cancer Res; 1996; 37:491 (abst 3352).
157.
Dutcher JP, Wiernik PH: Mitoxantrone, Vinblastine and CCNU (MVC): A highly active regimen in
poor prognosis Hodgkin's disease. Proc VI Internatl Conf on Malignant Lymphoma, Lugano; Ann Oncol
1996; 7:115.
158.
Dutcher JP: The emerging role of immunotherapy in non-Hodgkin's lymphoma. Proc VI Internatl Conf
on Malignant Lymphoma, Lugano, 1996. Satellite Symposium. Ann Oncol; 1996; 7:229.
159.
*Wiernik PH and Dutcher JP: Should maintenance therapy for acute leukemia be revisited? Expt
Hematol; 1996; 24:1123.
160.
*Oleksowicz L, Dutcher JP, DeLeon M, Etkind P: Platelet immunorelated GPIb is expressed by fresh
human tumor specimens. Blood; 1996; 88(Suppl 1):180a.
161.
*Dutcher J, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Lotze M, Gordon M. IL2-based
therapy in metastatic renal cell cancer: Cytokine Working Group Experience. Proc Am Soc Clin Oncol;
1997; 16:327a.
162.
Dutcher J, Lee S, Makary A, Hines J, Bennett J, Paietta E, Gallagher R, Rowe J, Wiernik PH: ECOG
phase II study (E1993) of all-trans retinoic acid (ATRA) in accelerated/blastic chronic myeloid leukemia.
Proc Am Soc Clin Oncol; 1997; 16:30a.
163.
Venkatraj U, Lee S, Logie K, Palackdharry C, Stewart J, Hamilton S, Wiernik PH, Cassileth P, Sznol M,
Dutcher JP. ECOG phase II trial of interleukin-4 in chronic lymphocytic leukemia and indolent nonHodgkin's lymphoma (E5Y92). Proc Am Soc Clin Oncol; 1997; 16:126a.
164.
Small EJ, Weiss G, Dutcher J, Walther P, Johnson D, Wilding G, Kuzel T, Kralik G, Paton V: A
multicenter open-label trial of ActimmuneR interferon-gamma-1b injection for the treatment of metastatic
55
renal cell carcinoma. Proc Am Soc Clin Oncol; 1997; 16 343a.
165.
Lotze M, Atkins M, Dutcher J, Fisher R, Margolin K, Weiss G, Abrams J, Sznol M, Parkinson D,
Hawkins M, Paradise C, Rosenberg SA. Melanoma patients with durable responses to IL-2 treatment:
Role of surgical salvage for persistent or recurrent disease. Proc 4th World Conference on Melanoma,
1997.
166.
*Dutcher JP, Wiernik PH: Pilot study of carboplatin and mitoxantrone as treatment for blast crisis of
chronic myeloid leukemia. Proc XIVth Meeting of Internatl Society Haematology, European & African
Division, 1997.
167.
*Flaherty L, Atkins M, Clark J, Dutcher JP, Gordon M, Lotze M, Margolin K, Sosman J, Weiss G:
Randomized phase II trial of chemotherapy and outpatient biotherapy in metastatic malignant melanoma.
Chemotherapy Foundation Annual Meeting, November 1997; Cancer Investigation 1997; 16(Suppl 1):
28-29.
168.
Malik UR, Challagalla JD, Sparano JA, Gucalp R, Wiernik PH, Dutcher JP: Decreased platelet
transfusion requirement in patients transplanted with peripheral blood stem cells. Proc Am Assoc Blood
Banks, Transfusion 1997; 37:167S.
169.
*Dutcher JP, Caliendo G, Oleksowicz L, Sparano J, Suh J, Novik Y, Wiernik PH: Phase II study of
moderate dose bolus IL2 plus GM-CSF in metastatic renal cell cancer. J Immunotherapy; 1997; 20:402.
170.
*Oleksowicz L, Dutcher JP, DeLeo-Fernandez M, Etkind P: Breast carcinoma GPIb -related protein
expression is regulated by a PKC-sensitive mechanism. Blood; 1997; 90(Suppl 1):425a.
171.
Bhagwati N, Dutcher JP. Fineberg S, Oleksowicz L: Tissue expression of a platelet-immunorelated GPIb
receptor correlates with breast malignancy and tissue invasion. Blood; 1997; 90(Suppl 1): 301a.
172.
*Dutcher JP, Wu J-J, Caliendo G, Hu X-P, Oleksowicz L, Sparano J, Wiernik PH: Mixed
sarcomatoid/clear cell renal cell cancer (RCC) has an improved prognosis over pure sarcomatoid RCC.
Proc Am Assoc Cancer Res; 1998; 39: 593(Abst 4036).
173.
Dutcher JP and Wiernik PH: Pilot study of carboplatin and mitoxantrone in blast crisis of chronic
myeloid leukemia. Proc Am Soc Clin Oncol; 1998; 17:23a (abst 89).
174.
*Oleksowicz L, Dutcher JP: A phase II pilot trial of dose-intensive interleukin-2 in metastatic renal cell
carcinoma. Proc Am Soc Clin Oncol; 1998; 17:318a (abst 1227).
175.
Plasse T, Goss T, Dutcher J, Logan T, Gordon M, Clark J, Weiss G, Margolin K, Atkins M: Quality of
life (QOL) assessment of renal cancer patients treated with interleukin-2, interferon-alpha, and 5fluorouracil. Proc Am Soc Clin Oncol; 1998; 17: 67a (abst 260).
176.
*Anand K, Sparano JA, Gucalp R, Malik U, Friedman K, Paietta E, Dutcher JP, Wiernik PH: Phase I
trial of high-dose paclitaxel plus cyclophosphamide, thiotepa, carboplatin and autologous stem cell
transplantation. Proc Am Soc Clin Oncol; 1998; 17:87a (abst 333).
177.
*Wiernik PH, Gallagher RE, Kim S, Paietta E, Dutcher JP: Pilot study of arsenic trioxide in acute
myeloid leukemia. Br J Haematol; 1998; 102:329.
56
178.
Moadel A, Morgan C, Fatone A, Grennan J, Carter J, LaRuffa G, Skummy A, Dutcher JP: Self-reported
spiritual and existential needs among an ethnically-diverse cancer patient population. Proc Soc Behavioral
Medicine; 1999.
179.
Dutcher JP, Caliendo G, Novik Y, Oleksowicz L, Sparano J, Wiernik PH: Phase II study of moderate
dose bolus or continuous infusion (CI) IL2 plus GM-CSF in metastatic renal cell cancer (MRCC). Proc
Am Soc Clin Oncol; 1999; 18:451a (#1740).
180.
Flaherty LE, Atkins M, Sosman J, Clark J, Margolin K, Dutcher J, Gordon M, Lotze M, Weiss G:
Randomized phase II trial of chemotherapy and outpatient biotherapy with interleukin-2 and interferon
alpha in metastatic malignant melanoma. Proc Am Soc Clin Oncol; 1999; 18:536a (#2070).
181.
Oleksowicz L and Dutcher JP: Thirty two month follow-up analysis of a phase II trial of dose-intensive
interleukin-2 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol; 1999; 18:350a (#1348).
182.
Novik Y, Dutcher JP, Caliendo CG, Wiernik P: Phase II study of moderate dose bolus or continuous
infusion IL2 plus GM-CSF in metastatic renal cell cancer. Proc First International Kidney Cancer
Symposium; 1999.
183.
Caliendo G, Dutcher JP, Wu JJ, Hu XP, Wiernik PH: Mixed sarcomatoid/clear cell renal cell cancer has
an improved prognosis over pure sarcomatoid RCC. Proc First International Kidney Cancer Symposium;
1999.
184.
*Wiernik PH, Dutcher JP, Gallagher R, Caliendo G, Garl S, Paietta E: Phase II trial of arsenic trioxide in
patients with relapsed/refractory acute myeloid leukemia, blast crisis of CML, or myelodysplasia. Blood;
1999; 94 (Suppl 1): 510a (#2283).
185.
*Vonderheide RH, Dutcher J, Eckhardt G, Gribben JG, Perry V, Caron D, Ghalie R: Phase I study of
rhuCD40 Ligand in cancer patients. Blood; 1999; 94(Suppl 1):63a (#270).
186.
Armitage R, Ulrich D, Macduff B, Vonderheide RH, Dutcher J, Eckhardt G, Gribben JG, Perry V, Bell A,
Caron D, Ghalie R, Fanslow W: Analysis of circulating mononuclear cell, antibody and cytokine levels in
phase I cancer patients treated with recombinant human CD40 Ligand. Blood; 1999; 94(Suppl 1): 66a
(#284).
187.
Novik Y, Paietta E, Dutcher JP, Wiernik PH: Idarubicin and standard dose Ara-c ((I+A) for refractory and
relapsed adult ALL. Blood; 1999; 94(Suppl 1): 234b (#4252).
188.
*Unnikrishnan D, Dutcher JP, Varshneya N, Choragudi N, Api M, Garl S, Wiernik PH, Chiaramida S:
Torsades de pointes in two patients on treatment with arsenic trioxide. Exptl Hematol; 2000; 28
(Suppl 1):44 (abst # 42).
189.
Dutcher JP, Wiernik PH, Novik Y, Garl S, Hughes J, Arezzo J: Major hematologic response in a patient
with myelodysplasia to arsenic trioxide. Blood; 2000; 96 (Suppl 1): 260b (Abstract 4856).
190.
*Unnikrishnan D, Varshneya N, Lucariello R, Dutcher JP, Wiernik PH, Chiaramida S: Torsade de
Pointes associated with arsenic trioxide treatment for hematological malignancies. Proc Am Col
Cardiology; 2001; 37(Suppl A):118 (abstract 1027).
57
191.
*Dutcher JP, Smith JW, Merriman R, Olson S, Bycott P, Burns T, Bender JF: A phase I trial of DENSPM
(n1,n11-diethylnorspermine) in combination with interleukin-2. Proc Am Assoc Cancer Res; 2001;
42:540, (abstract 2907).
192.
*Novik Y, Dutcher JP, Larkin M, Wiernik PH: Phase II study of thalidomide in advanced refractory
metastatic renal cell cancer: A single institution experience. Proc Am Soc Clin Oncol; 2001; 20: 265a
(abst 1057).
193.
*Margolin KA, Thompson JA, Clark J, Flaherty L, Atkins M, Sosman J, Weiss G, Ernstoff M, Weber J,
Dutcher J, Smith J: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A
phase II Cytokine Working Group Trial. Proc Am Soc Clin Oncol; 2001; 20: 359a (Abst 1432).
194.
*Margolin K, Atkins MB, Weber J, Dutcher JP, Ernstoff M, Smith J, Clark J, O’Day S, Flaherty L, Baar
J, Sosman J, Weiss G, Thompson JA, Lathia C, Smith J, Martell RE: Evaluation of the interleukin-2
selective agonist BAY 50-4798 in patients with advanced melanoma and renal cell carcinoma, a phase I
study. Proc AACR/NCI/EORTC Conf on Targeted Therapy; 2001.
195.
*Margolin K, Atkins MB, Weber J, Dutcher JP, Ernstoff M, Smith J, Clark J, O=Day S, Flaherty L, Baar
J, Sosman J, Weiss G, Thompson JA, Lathia C, Smith J, Martell RE: Evaluation of the interleukin-2
selective agonist BAY 50-4798 in patients with advanced melanoma and renal cell carcinoma, a phase I
study. J Immunotherapy; 2001; 24:S15.
196.
*McDermott D, Flaherty L, Clark J, Weiss G, Logan T, Gordon M, Sosman J, Ernstoff M, Urba W,
Margolin K, Dutcher J, Atkins M: A randomized phase III trial of high-dose interleukin-2 (HDIL2) versus
subcutaneous IL2/Interferon in patients with metatstatic renal cell carcinoma. J Immunotherapy; 2001;
24:S15.
197.
*Moadel A, Dutcher J: Psychosocial needs assessment of cancer patients in Bronx, New York. Proc of
Soc Behavioral Medicine; 2002.
198.
*Adiga, K, Dutcher JP, Larkin M, Wiseman E, Garl S, Koo J, Beatty K: Characterization of bone disease
in patients with metastatic renal cell cancer. Proc Third North American Symposium on Skeletal
Complications of Malignancy; 2002.
199.
Friedland D, Leon L, Manola J, Dutcher JP, Roth B, Wilding G: Carboxyamidotriazole (CAI) in patients
with advanced renal cell cancer refractory to immunotherapy: An ECOG phase II trial. Proc Am Soc Clin
Oncol; 2002; 21:152b (Abst # 2424).
200.
*Margolin KA, Atkins MB, Weber J, Dutcher JP, Ernstoff MS, Smith J, Clark J, O=Day S, Baar J,
Sosman J, Lathia C, Humphrey R, Martell RE, Schwartz B: Phase I study of interleukin-2 selective agonist
BAY-50-4798 (BAY) in patient with advanced melanoma and renal cell cancer. Proc Am Soc Clin
Oncol; 2002; 21:12a (Abst # 46).
201.
*Atkins M, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Park Y, Marshall B, Boni J, Dukart G:
A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with
advanced renal cell carcinoma.
Proc Am Soc Clin Oncol; 2002; 21:10a (abst 36).
202.
*Schwartz G, Dutcher JP, Vogelzang NJ, Gollob J, Thompson J, Bukowski RM, Figlin RA, Lohner M,
58
Roskos L, Hwang CC, Foon KA, Schwab G, Rowinsky E: Phase 2 clinical trial evaluating the safety and
effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol; 2002; 21:24a (abst 91).
203.
*Logan TF, Dutcher JP, Flaherty LE, Sosman JA, Ernstoff MS, Clark JI, Atkins MB: A Cytokine
Working Group (CWG) phase II study of intermediate dose bolus interleukin-2 (IL-2) for renal cell
carcinoma patients ineligible to receive high dose IL-2 due to inadequate organ function. Proc Am Soc
Clin Oncol; 2002; 21:15a (abst #57).
204.
Clark JI, Gollob J, Sosman J, Margolin K, Dutcher JP, Urba W, Fisher S: Phase I trial of polyethylene
glycol (PEG) in
-2b (IFN) + interleukin-2 (IL-2) in renal cell cancer. Proc Am Soc Clin Oncol;
2002; 21:151b (Abst # 2419).
205.
Weiner L, Figlin R, Belldegrun A, Schwartz G, Dutcher J, Vogelzang N, Gollob J, Thompson J,
Bukowski R, Crawford J, Foon KA, Schwab G, Rowinsky E: ABX-EGF, a fully human anti-epidermal
growth factor receptor (EGFr) monoclonal antibody : Preliminary results of phase 1 and 2 studies. Proc
ASCO Molecular Therapeutics Symposium, 2002.
206.
Adiga GU, Dharmarajan TS, Kandker FA, Reddy RM, Dutcher JP: Magnitude and factors contributing to
iatrogenic anemia in elderly. Blood; 2002; 100(Suppl Part II):12b (abst # 3497).
207.
DuHamel KN, Smith M, Egert J, Diaz-Wionczek, Holness D, Raptis G, Dutcher J, Winkel G: The impact
of a pain education/communication skills intervention on Latina women with breast cancer related pain.
Proc 6th World Congress of Psycho-Oncology; 2003.
208.
Mannam P, Dutcher JP, Eapen J, O’Boyle K, Marcoullis G, Malik S, Khairkhan N, Sivadas H, Garino A,
Wiernik PH: Role of prognostic factors in patients with metastatic renal cell carcinoma (MRCC) eligible
for treatment with interleukin-2 (IL2). Proc Am Soc Clin Oncol; 2003; 22:441 (Abst # 1770).
209.
Unnikrishnan D, Dutcher JP, Garl S, Varshneya N, Lucariello R, Wiernik PH; Cardiac monitoring of
patients on arsenic trioxide therapy. Proc Am Soc Clin Oncol; 2003; 22:609 (Abst # 2449).
210.
*Dutcher JP, Hudes G, Motzer R, Ko YJ, Smith JW, Zonno K, Marshall B, Dukart G, Liou SH:
Preliminary report of a phase I study of intravenous CCI-779 given in combination with interferon-alpha to
patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol; 22:213 (Abst # 854).
211.
*Clark JI, Atkins M, Urba W, Figlin R, Dutcher J, Flaherty L, Sosman J, Logan T, White R, Margolin K
for the Cytokine Working Group: Adjuvant high dose-bolus interleukin-2 for patients with high-risk renal
cell carcinoma – A Cytokine Working Group randomized trial. Proc Am Soc Clin Oncol;
2003;
22:164 (Abst # 659).
212.
*Thompson J, Swedloff J, Escudier B, Dutcher J, Bukowski R, Vaishampayan U, Hussain A, Negrier S,
Chitale K, Rothermel J: Phase II trial evaluating the safety and efficacy of EPO906 in patients with
advanced renal cell carcinoma: Prognostic factor analysis. Proc Am Soc Clin Oncol; 2003; 22:408, (Abst
# 1628).
213.
*Hidalgo M, Atkins MB, Stadler WM, Logan T, Dutcher J, Hudes G, Marshall B, Liou-SH, Dukart G: A
randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with
advanced renal cell carcinoma: Prognostic factor analysis. Proc Am Soc Clin Oncol; 2003; 22:201 (Abst
# 804).
59
214.
*Nanus DM, Garino A, Milowsky MI, Rosmarin A, Larkin M, Dutcher JP: Active chemotherapy for
aggressive renal cell carcinoma. Proc Am Soc Clin Oncol; 2003; 22:407 (Abst # 1635).
215.
*Adiga G, Dutcher JP, Dharmarajan TS: Iatrogenic anemia in hospitalized older adults: Impact on
mortality. J Am Geriatric Soc; 2003; 51:S212-213 (Abst # P505).
216.
Jain D, Dutcher JP, Wiernik PH: Complete clinical response with single agent high dose rituximab in
mantle cell lymphoma. Blood; 2003; 102 (Suppl 1): 305b (Abst # 4943).
217.
Jain D, Dutcher JP, Wiernik PH: High dose rituximab in Chronic lymphocytic leukemia. Blood;
102 (Suppl 1): 359b (Abst # 5164).
218.
Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer:
Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Proc Am
Assoc Cancer Res 2004; 477-478.
2003;
218.
*Smith JW, Ko YJ, Dutcher JP, Hudes G, Escudier B, Motzer R, Negrier S, Duclos B, Galand L,
Strauss L: Update of a phase I study of intravenous CCI-779 given in combination with interferon- to
patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol; 2004; 23:384 (Abst # 4513).
219.
*Gordon MS, Manola J, Fairclough D, Cella D, Richardson R, Sosman J, Kasimir B, Dutcher JP,
Wilding G: Low dose interferon-2b + thalidomide in patients with previously untreated renal cell
cancer: Improvement in progression-free survival but not quality of life or overall survival. A phase III
study of the Eastern Cooperative Oncology Group (E2898). Proc Am Soc Clin Oncol 2004; 23:384
(Abst # 4516).
220.
*Raftopoulos H, Escudier B, Renshaw G, Lara PN, Dutcher J, Nanus D, Petrylak DP, Sacris L: A
phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with
(Abst
# 4629).
221.
Escudier B, Raftopoulos H, Lara Jr. PN, Dutcher JP, Nanus D, Renshaw G: A phase II multicenter
study of the anti-cancer sulfonamide indisulam in patients with progressive inoperable and/or
metastatic renal cell carcinoma. Proc European Soc Medical Oncology (ESMO); 2004.
222.
*Mehrabi J, Atkins M, Sosman J, Loagan T, Margolin K, Dutcher J, Urba W, Lau-Schwabe A, Clark
J: Phase I/II trial of outpatient PEG-Intron® with interleukin-2 (IL-2) in advanced renal cell
carcinoma (RCC): A Cytokine Working Group Study. Proc Internatl Soc Biol Therapy; 2004.
223.
*Dorai T, Sawczuk I, Wiernik PH, Dutcher JP: Biological significance of overexpression of carbonic
anhydrase IX in renal cell carcinoma. Proc 3rd Internatl Kidney Cancer Symposium; 2004.
224.
*Alexandrescu DT, Karri S, Dutcher JP, Wiernik PH: Mitoxantrone, vinblastine and lomustine
(MVC): Long-term follow-up of patients treated for Hodgkin’s disease. Blood 2004; 104: 369a
(Abst # 1312).
225.
Dorai T, Sawczuk I, Wiernik PH, Dutcher JP: Biological significance of overexpression of
carbonic anhydrase IX in renal cell carcinoma. Proc Am Assoc Cancer Res; 2005: 241.
60
226.
Escudier B, Raftopoulos H, Lara PN, Dutcher J, Nanus D, Renshaw G: A phase II multicenter study
of the anticancer sulfonamide indisulam in patients with progressive inoperable and/or metastatic
renal cell carcinoma (RCC). Proc ESMO; 2005.
227.
*Atkins MB, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Margolin
K, Weiss G, Urba W: A Cytokine Working Group phase II study of temozolomide (Tmz), thalidomide
(Thal) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma.
Proc Am Soc Clin Oncol; 2005; 23:723s (abst # 7552).
228.
*Sosman J, Carrillo C, Urba W, Ernstoff M, Flaherty L, Atkins M, Clark J, Dutcher J, Margolin K,
Weiss G, Kirkwood: A Cytokine Working Group 3-arm phase II trial of gp100 209-2M peptide and
high dose interleukin-2 in HLA-A2+ advanced melanoma patients. Proc Am Soc Clin Oncology;
2005; 23:711s (abst # 7504).
229.
*Elson PJ, Manola JB, Mazumdar M, Bacik JM, Supers SJ for the International Kidney Cancer
Working Group. Prognostic factors for survival in patients with metastatic renal cell carcinoma: A
study from the International Kidney Cancer Working Group (IKCWG). Proc Am Soc Clin Oncology;
2005; 23:386s (abst # 4533).
230.
Natali LC, Maddukuri P, Lucariello R, Malik S, Bhagwati N, Fernaine G, Wiernik P, Dutcher JP:
Significant arrhythmias associated with IL-2 therapy. . Proc Am Soc Clin Oncology; 2005; 23:
187s (abst # 2588).
231.
Hugec V, Koulova L, Garino A, Wiernik PH, Dutcher JP: Gemcitabine in treatment of metastatic
renal cell cancer. Proc Am Soc Clin Oncology; 2005; 23:452s (abst # 4798).
232.
Margolin K, Lara PN, Quinn DI, Dutcher J, Frankel P, Doroshow JH, Gandara D, Synold T, Lacey.
Genasense (G3139) plus -interferon (IFN) in metastatic renal cancer (RCC): A phase II study of the
California Cancer Consortium. Proc Am Soc Clin Oncology 2005; 23:426s (abst # 4694).
233.
*Figlin R, Bukowski R,Srinivas S, McDermott D, Dutcher J, Takimoto C, Haas N, Ryan C, Hauke R,
Clark J, Arends R, Patel M, Lockbaum P, Huang S, Schwab G: A phase II trial of panitumumab
(ABX-EGF) in the treatment of patients with metastatic renal cell carcinoma (mRCC). Proc 4th
Internat’l Kidney Cancer Symposium; 2005.
234.
*Alexandrescu DT, Hugec VS, Dutcher JP, Wiernik PH: Serum globulins as marker of immunologic
restoration in chronic lymphocytic leukemia after treatment with high dose rituximab.
XI
International Workshop on CLL, 2005.
235.
*Alexandrescu DT, Hugec VS, Dutcher JP, Wiernik PH: Serum globulins as marker of immunologic
restoration in chronic lymphocytic leukemia after treatment with high dose rituximab. Proc Internatl
Soc for Biological Therapy, J Immunotherapy 2005; 28: 628-629.
236.
*Alexandrescu DT, Hugec VS, Dutcher JP, Wiernik PH: Serum globulins as marker of immunologic
restoration in chronic lymphocytic leukemia after treatment with high dose rituximab. ECOG Fall
Meeting; 2005; Young Investigators Symposium, Tampa FL.
237.
*Alexandrescu DT, Karri S, Dutcher JP, Wiernik PH: Mitoxantrone, vinblastine and lomustine
(MVC): Long-term follow-up of patients treated for Hodgkin’s disease. ECOG Fall Meeting; 2005,
61
Young Investigators Symposium, Tampa FL.
238.
Koi P, Ghevamian R, Hugec V, Dutcher J: Renal medullary carcinoma: A single institution
experience and review of the clinical cases in the literature. Proc Am Urological Assoc; 2006.
239.
*Bukowski R, McDermott D, Kabbinavar F, Figlin R, Flaherty K, Srinivas S, Vaishampayan U,
Drabkin H, Dutcher J, Scappaticci F: Phase II study of erlotinib (E) plus bevacizamab (B) vs B alone
in metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol; 2006; 24:222s (Abst # 4523).
240.
*Hudes G, Carducci M, Tomzak P, Dutcher J, Figlin R, Kapoor A,Staroslawska E, O’Toole T, Park
Y, Moore L: A phase III, randomized,3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN)
of the combination of TEMSR + IFN in the treatment of first-line,poor-prognosis patients (pts) with
advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol; 2006; 24: 2s,(Abst # LBA4)
241.
Farray D, Clark JI, Kuzel T, Dutcher JP: A multicenter phase II study of thalidomide in combination
with interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma
(MRCC). Proc Am Soc Clin Oncol; 2006. Abst # 14636.
242.
Muniswamy H, Dutcher JP, Mannam P, Malik S, Rusciano V, Paul L, Wiernik PH: Role of
prognostic factors in patients with metastatic renal cell carcionoma eligible for treatment with
interleukin-2. Proc Am Soc Clin Oncol; 2006; Abst # 14514
243.
*Alexandrescu DT, Brown K, Dasanu CA, Dutcher JP, Wiernik PH: Influence of parent age and
gender on anticipation in familial B-cell malignancies. Proc Am Soc Clin Oncol; 2006; 24:435s
(abst # 7553).
244.
Dutcher JP, Dasanu C, Codreanu I, Yeddu M, Muniswamy H, Wiernik PH, Alexandrescu DT:
Correlation between hemodynamic parameters and response to high dose IL-2 in metastatic
melanoma. Proc Am Soc Clin Oncol; 2006; 24:online. Abst # 18012
245.
*Elson PJ, Bacik JM, Manola JB, Mazumdar M, for the International Kidney Cancer Working Group.
Prognostic factors for survival in metastatic renal cell carcinoma: A Kidney Cancer Association’s
International Kidney Cancer Working Group (IKCWG) study. Renal Cancer Symposium – Proc
ESMO; 2006.
246.
*Lee SH, Dasanu C, Dutcher J: Eosinophilia and pruritus with interleukin-2 treatment in patients
with metastatic renal cell carcinoma. J Immunotherapy 2006; 29:639.
247.
*Darabi K, Yeddu M, Dutcher JP: Immune thrombocytopenic purpura (ITP)-like syndrome in
carcinoma. Transfusion 2006; 46 (suppl):160A.
248.
*Dorai T, Pastorek J, Wiernik P, Dutcher J: Non-traditional roles of carbonic anhydrase IX in renal
cell carcinoma. Proc Am Assoc Cancer Res; 2007; 3745.
249.
*Rusciano V, Lee S, Dutcher JP: Efficacy of gabapentin on pruiritus induced by interleukin-2
treatment in patients with metastatic renal cell carcinoma and melanoma Proc Oncology Nurse
Society; 2007.
250.
*Graham S, Dutcher JP, Rosal-Grief V, Sacris L, Koo J: Incidence and nursing management of hand
62
foot skin reaction in patients treated with oral tyrosine kinase inhibitors for metastatic renal cell
carcinoma. Proc Onco, Nursing Soc; 2007; abst 2165.
251.
*Dutcher JP, Rustine A, Koo J, Sacris L, Graham S, Rosal V, Casquete N, Wiernik PH:
Radiotherapy administered concurrently with oral tyrosine kinase inhibitors (TKIs) in patients with
metastatic renal cell cancer. Proc Am Radium Soc , Oncology; 2007; 21 (Suppl 2): 48.
252.
*Ryan C, Bukowski R, Figlin RA, Knox J, Hutson T, Dutcher J, George J, Kirshner J, Humphrey J,
Stadler WM: on behalf of ARCCS Investigators: The Advanced Renal Cell Carcinoma Sorafenib
(ARCCS) expanded access trial: Long term outcome in 1st line patients . J Clin Oncol; 2007; 25
(Suppl 18):258s (Abst 5096).
253.
Henderson C, Bukowski R, Stadler WM, Dutcher J, Kindwall-Keller T, Hotte S, Logie K, Baltz B,
Wilson K, Figlin RA on behalf of ARCCS Investigators. The Advanced Renal Cell Carcnioma
Sorafinib (ARCCS) expanded access trial: Subset analysis of patients with brain metastases. Proc
ASCO (online); 2007; abst 15506.
254.
*Lee S, Rusciano V, Dutcher JP: Efficacy of gabapentin on pruiritus induced by interleukin-2
treatment in patients with metastatic renal cell carcinoma and melanoma. J Clin Oncol; 2007; 25
(Suppl 18):131s (abst 3056).
255.
*Rini B, Wilding GT, Hudes G, Stadler WM, Kim S, Tarazi JC, Bycott PW, Liau KF, Dutcher JP:
Axitinib (AG-013736; AG) in patients with metastatic clear cell renal cell cancer refractory to
sorafinib. J Clin Oncol; 2007; 25 (Suppl 18): 242s (abst 5032).
256.
Pan C, Hussey M, Lara P, Mack PC, Nagle RB, Dutcher J, Samlowski W, Clark J, Crawford ED,
Gordon MS: Phase II trial of epidermal growth factor receptor (EGFR) inhibiot erlotinib (E) in
patients with advanced papillary renal cell carcinoma, SWOG S0317. Proc ASCO (online) 2007;
abst 15516.
257.
*Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A,
Feingold J: Correlation of survival with tumor histology, age and prognostic-risk group for previously
untreated patients with advanced renal cell canrciona (adv RCC) receiving temsiorlimus (TEMSR) or
interferon alpha (IFN). Proc ASCO, J Clin Oncol; 2007; 25 (Suppl 18): 243s, abst 5033.
258.
*Royston P, Bacik J, Elson P, Manola JB, Mazumdar M for the IKCWG: A consensus prognostic
factor model for survival in patients with metastatic renal cell carcinoma: A Kidney Cancer
Association’s International Kidney Cancer Working Group (IKCWG) Study. J Clin Oncol; 2007;
25 (Suppl 18): 262s (abst 5109).
259.
Ernstoff MS, Regan MM, McDermott DF, Sosman JA, Dutcher JP, Clark JI, Crocenzi TS, Ochoa
AC, Atkins MB for the Cytokine Working Group. First Line Treatment with Bevacizumab and high
dose bolus Aldesleukin (IL2) in metastatic renal cell carcinoma patients. Proc ASCO (online);
2007; abst 15524.
260.
*Bojanapally PR, Alexandrescu DT, Rusciano V, Wiernik PH, Dutcher JP: Phase II single institution
study of sequential biochemotherapy for patients with stage IV melanoma. J Clin Oncol; 2007;
(Suppl 18): 492s (abst 8580).
63
261.
*Dutcher J, Szczylik C, Tannir N, Benedetto P, Ruff P, Berkenblit A, Thiele A, Strahs A, Feingold J,
Hudes G: Effect of temsirolimus vs interferon alpha on overall and progression-free survival based on
tumor histology in patients with previously untreated renal cell carcinoma. Proc 6th International
Kidney Cancer Symposium, Chicago, IL Oct 2007.
262.
*Dutcher JP, for all participating investigators: Renal Cell Cancer: Expanded access evaluation of
Sunitinib and Sorafenib. Proc Chemotherapy Foundation, 2007.
263.
*Bardy-Bouxin N, Galand L, Dutcher J, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A,
Berkenblit A, Thiele A, Strahs A, Feingold J: Correlation of overall survival with tumor histology for
patients with advanced renal cell carcinoma treated with temsirolimus or interferon alpha. Proc
French Assoc Urology; 2007.
264.
*Rini B, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Bycott P, Liau K, Dutcher J: Axitinib
(AG-013736; AG) in patients with metastatic clear cell renal cell cancer refractory to sorafenib. Proc
ECCO; 2007.
265.
*Rini BI, Halabi S,Rosenberg J, Stadler W, Dutcher J, Pcius J, Tanguay S, Vaena DA, Atkins JN,
Taylor J, Ou S-S, Archer L, Small for the CALGB: CALGB 90206: A phase III trial of bevacizumab
plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell cancer. Proc
ASCO GU; 2008.
266.
*Dutcher J, De Souza P, Figlin RA, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J,
Hudes G: Effect of temsirolimus verus interferon-α on survival of patients with advanced renal cell
carcinoma of different tumor histologies. Proc ASCO GU; 2008.
267.
*Henderson CA, Bukowski RM, Stadler WM, Dutcher JP, Kindwall-Keller T, Hotte SJ, Logie K,
Baltz B, Wilson K, Figlin RA, on behalf of the ARCCS investigators. Sorafenib therapy in the
management of advanced renal cell carcinoma with brain metastases: Results from an expanded
access program. Presented by Andrea Rustine, PA-C, MS Proc EAU; 2008.
268.
*Figlin RA, deSousa P, McDermott D, Dutcher J, Berkenblit A, Thiele A, Krygwski M, Strahs A, Fei
ngold J, Hudes G: Analysis of PTEN and HIF1- α and correlation with efficacy in patients with
advanced renal cell carcinoma treated with temsirolimus or interferon-α. Proc Am Assoc Cancer Res;
2008; 4477.
269.
*deSouza P, Radulovic S, Beck J, Pendergrass K, Siddique N, Dutcher J, Berkenblit A, Thiele A,
Krygowski M, Hudes G:
Characterization of hyperglycemia, hypercholesterolemia and
hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferonα. J Clin Oncol 2008; 26 (Suppl 15S): 278S. (abstract # 5116 )
.
270.
*Logan T, McDermott D, Dutcher J, Makhson A, Mikulas J, Berkenblit A, Galand L, Krygowski M,
Hudes G: Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in
patients with advanced renal cell carcinoma and poor-risk features. J Clin Oncol 2008; 26(Suppl
15S): 262S. (abstract # 5050 )
271.
*Dutcher JP, Wilding G, Hudes GR, Stadler WM, Kim S, Tarazi JC, Rosbrook B, Rini BI:
Sequential axitinib (AG-013736) therapy of patients with metastatic clear cell renal cell cancer (RCC)
64
refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone.
2008; 26 (Suppl 15S): 281S. (abstract # 5127 )
J Clin Oncol
272.
*Pan C, Hussey M, Lara P, Mack P, Nagle R, Dutcher J, Samlowski W, Clark J, Gordon M, Crawford
E: Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final
results from Southwest Oncology Group study 0317. J Clin Oncol 2008; 26 (Suppl 15S): 262S.
(abstract # 5051 )
273.
Bojanapally PR, Graham S, Rustine AL, Sacris LA, Dutcher JP: Temsirolimus for advanced renal
cell carcinoma: Compassionate versus commercial use. Proc ASCO Annual Meeting 2008 online.
274.
*Dutcher J, Rixe O, Motzer R, Wilding G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Rini BI:
Levothyroxin treatment of hypothyroidsim and axitinib (AG-013736) efficacy in patients with
metastatic renal cell carcinoma. Proc ESMO Annual Meeting, Ann Oncol 2008; 19 (Suppl 8):
viii194. (Abst 600P)
275.
*Trask P, Mardekian J, Tarazi J, Bycott P, Kim S, Dutcher J, Wilding G, Hudes G, Stadler WM, Rini
B: Disease-related symptoms in sorafenib-refractory metastatic renal cell cancer (mRCC) patients
treated with axitinib (AG-013736). Proc ESMO, Annual Meeting, Ann Oncol 2008; 19 (Suppl 8):
viii192. (Abst 594P)
276.
*Rixe O, Dutcher J, Motzer R, Wilding G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Rini BI:
Association between diastolic bllod pressure (dBP) > 90 mmHg and efficacy in patients with
metastatic renal cell carcinoma receiving axitinib (AG-013736). Proc ESMO, Annual Meeting, Ann
Onc 2008; 19 (Suppl 8): viii189. (Abst 587 PD)
277.
*Lee SH, Rusciano V, Dutcher JP: IL-2 induced pruritus: Investigation of its mechanism and novel
treatment options in patients treated with IL-2 for metastatic renal cell carcinoma and malignant
melanoma. Proc Kidney Cancer Association, 2008.
278.
*Pendergrass K, Hudes G, Radulovic S, Beck J, Dutcher J, Berkenblit A, Thiele A, Krygowski M,
deSouza P: Characterization of hyperglycemia, hypercholesterolemia and hyperlipidemia in patients
with advanced renal cell carcinoma treted with temsirolimus or interferon-α. Proc ASCO GU
Symposium, 2009.
279.
*Logan T, McDermott D, Dutcher J, Makhson A, Mikulas J, Berkenblit A, Galand L, Krygowski M,
Hudes G: Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in
patients with advanced renal cell carcinoma and poor-rist features. Proc ASCO GU Symposium,
2009.
280.
*Haas N, Manola J, Pins M, Liu D, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J: ECOG
8802: Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with
sarcomatoid features. Proc ASCO GU Symposium 2009.
281.
*Rixe O, Dutcher J, Motzer R, Wildng G, Stadler WM, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini
BI: Diastolic blood pressure and pharamcokinetics as predictors of axitinib efficacy in metastic renal
cell carcinoma. J Clin Oncol 2009; 27 (Suppl 15S): 245s, 2009. (abstract # 5045)
282.
*Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher
65
J, Small EJ: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with
metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;
27 (Suppl 15S): 798s. (abstract # LBA5019)
283.
*Haas N, Manola J, Pins M, Liu D, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J: ECOG
8802: Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with
sarcomatoid features. J Clin Oncol 2009; 27(Suppl 15S): 243s. (abstract # 5038)
284.
Lee S, Baig M,Rusciano V, Gao Y,Malik S, Wiernik PH, Dutcher JP. Survival advantage in patient
treated with high dose Interleukin-2 (HDIL2) for metastatic renal cell carcinoma. Proc Am Soc Clin
Oncol, 2009. (abst E16039, online).
285.
*Maroto P, Hudes G, Dutcher J, White C, Krygowski M, Cincotta M, Ohata J, Duran I, Berkenblit A:
Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced
renal cell carcinoma treated with temsirolimus. Proc ESMO/ECCO, 2009.
286.
*Rini BI, Bair AH, Chen I, Dutcher J: A phase II evaluation of axitinib with our without dose
titration in patients with metastatic renal cell carcinoma. Proc Kidney Cancer Association, Annual
meeting, Chicago, Sept 2009.
287.
*Kuzel T, Dutcher J, Ebbinghaus S, Gordon M, Grubbs SS, Khan K, Lipton A, McDermott D,
Millard F, Quinn D, Sullivan T: A phase 2 multi-center, randomized, open-label study of two dose
levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma. Proc Kidney Cancer
Association, Annual meeting, Chicago, Sept 2009.
288.
*Lee SH, Baig M, Rusciano V, Malik S, Dutcher JP: Relation of pruritis and eosinophilia to survival
in patients treated with high dose interleukin-2 for metastatic renal cell carcinoma. Proc Kidney
Cancer Association, Annual meeting, Chicago, Sept 2009.
289.
*Adiga GU, Dutcher JP, Wiernik PH: Prevalence and characterization of various cancers among
Hepatitis C infected patients. Proc Am Soc Gastroenterology, 2009; S127.
290.
*Dutcher JP, Garrett M, Motzer R, Wilding G, Stadler WM, Pithavala Y, Kim S, Tarazi J, Rixe O,
Rini BI: Pharmacokinetics and efficacy of axitinib in patients with sorafenib-refractory metastatic
renal cell carcinoma. Proc AACR-NCI-EORTC Meeting, Nov 2009.
291.
*Harzstark AL, Halabi S, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher JP,
Rini BI,Small EJ: Hypertension is associated with clinical outcome fo rpatinets with metastatic renal
cell carcinoma treated with interferon and bevacizumab on CALGB 90206. Proc GU ASCO, 2010;
(abst 30798)
292.
*McDermott DF, Ghebremichael MS, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP,
Logan T, Figlin RA, Atkins MB: The high-dose aldesleukin (HD-IL2) “Select” trial in patients with
metastatic renal cellcarcinoma. Proc GU ASCO; 2010; (abst 48229).
293.
*Dandamudi UB, Ghebremichael MS, Sosman JA, Regan MM, Atkins MB, Clark J, Dutcher JP,
Curti BD, Vaishampayan UN, Ernstoff MS: A phase II study of bevacizumab and high dose
aldesleukin (IL2) in patients with metastatic renal cell carcinoma. Proc GU ASCO; 2010; (Abst
50953).
66
294.
*McDermott DF, Ghebremichael MS, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP,
Logan T, Figlin RA, Atkins MB: The high-dose aldesleukin (HD-IL2) “Select” trial in patients with
metastatic renal cell carcinoma. J Clin Oncol 2010; 28:15S: 345s. (abst 4514).
295.
*Dandamudi UB, Ghebremichael MS, Sosman JA, Regan MM, Atkins MB, Clark J, Dutcher JP,
Curti BD, Vaishampayan UN, Ernstoff MS: A phase II study of bevacizumab and high dose
aldesleukin (IL2) in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28:15S:349s.
(abst 4530).
296.
*Gunturu S, Adiga GU, Dutcher JP: Lactobacillus jensenii bacteremia while on probiotic therapy.
Am J Gastro 2010; 105 (Suppl 1): S 227. (abstr # 628)
297.
*Procopio G, Bellmunt J, Dutcher JP, Bracarda S, Knox J, Brueckner A, Kalmus J, Escudier B,
Hutson TE. Sorafenib in older patients with advanced renal cell carcinoma: Subanalysis by age of an
integrated database of 8 company-sponsored clinical trials. Proc ESMO, 2010.
298.
*Eisen T, Hutson TE, Gore M, Quinn DI, Bokemeyer C, Dutcher JP, Brueckner A, Kalmus J,
Bukowski RM, Escudier B. Sorafenib safety over time in >4600 patients with renal cell carcinoma
RCC): Insights from an integrated database of 8 company-sponsored trials. Proc ESMO, 2010.
299.
*McDermott D, Ghebremichael M, Signoretti S, Margolin K, Clark J, Sosman J, Dutcher J, Logan T,
Appleman L, Atkins: The high dose aldesleukin (HD IL-2) “Select” trial in patients with metastatic
renal cell carcinoma; J Immunotherapy; 2010; 33:903-904.
300.
*Nanus DM, Tagawa ST, Dutcher JP, Akhtar NH, Saran A, Mazumdar M, Milowsky MI, Gudas LJ:
NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the
treatment of patients with advanced renal cell carcinoma (RCC). Proc GU ASCO, 2011; Abst 72337.
301.
*Bracarda S, Bokemeyer C, Procopio G, Eisen T, Bellmunt J, Szczylik C, Know J, Dutcher JP,
Brueckner A, Escudier B, Hutson T: Sorafenib dosage patterns in older patients with advanced renal
cell carcinoma (RCC): A subanalysis by age of an integrated database of 8 company-sponsored
clinical trials. Proc EAU, 2011.
302.
*Dutcher JP, Wiernik PH: Renal cell carcinoma and hematologic malignancy in the same patients.
Proc Am Fed Clin Res (Eastern Division), Wash DC, April 2011. J Invest Med 2011; 59:634.
303.
Choueri TK, Pal SK, Cabanillas ME, Ramieis DA,Tseng JS, Holland JS, Morrissey S, Dutcher JP:
Antitumor ativity observed in an ongoing phase I drug-drug interaction study of cabozntinib (XL 184)
and rosiglitazone in patients with renal cell carcinoma and differentiated thyroid cancer. Proc Am Soc
Clin Oncol 2011; Abst e13042.
304.
*Keilholz U, Procopio G, Bellmunt J, Dutcher JP, Bracaarda S, Knox J, Bruekner A, Strauss UP,
Escudier B, Hutson TE: Sorafenib dosage patterns in older patients with advanced renal cell
carcinoma (RCC): A subanalysis by age of an integrated database of 8 company-sponsored clinical
trials. Proc German Oncology Meeting, Sept 2011.
305.
*Choueri TK, Pal SK, McDermott DF, Ramies DA, Morrissey S, Lee Y, Miles D, Holland JS,
Dutcher JP: Activity of cabozntinib (XL 184) in patients with metastatic, refractory renal cell
67
carcinoma. Proc GU ASCO 2012.
J Clin Oncol 30 (Suppl 5) 2012 Abst 364.
306.
*Choueri TK, Pal SK, McDermott DF, Ramies DA, Morrissey S, Lee Y, Miles D, Holland JS,
Dutcher JP: Efficacy of cabozntinib (XL 184) in patients with metastatic, refractory renal cell
carcinoma. Proc ASCO 2012. J Clin Oncol 30 (Suppl) 2012 Abst 4504.
307.
*Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Wood CG, Kane CJ, Jewette MAS, Atkins MB,
Dutcher JP, DiPaola RS, Eastern Cooperative Oncology Group: Cardiac safety analysis for a phase
III trial of sunitinib or sorafenib or placebo in patienst with resected renal cell carcinoma. Proc ASCO
2012. J Clin Oncol 30 (Suppl) 2012. Abst 4500
308.
*Varella L, Chintapatla R, Wiernik PH, Dutcher JP: Association of renal cell carcinoma and
hematologic malignancy. Proc Internatl Kidney Cancer Association, Chicago, Oct 2012. Br J Urol
2012; 110 (Suppl 2):: 10-11.
309.
Chintapatla R, Varella L, Wiernik P, Rusciano V, Dutcher JP: Association of renal cell carcinoma
and B-cell hematologic malignancy. Proc Am Soc Hematol, 2012. Epub
310.
*McDermott D, Flaherty K, Manola J, …Dutcher JP, DiPaola R: The BEST Trial (ECOG 2804): A
randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy with
bevacizumab, sorafenib, and temsiroimus in advanced renal cell carcinoma. Proc GU ASCO 2013, p
178 (Abstr # 345)..
311.
*Varella L, Chintapatla R, Wiernik PH, Rusciano V, Dutcher J: Association of renal cell carcinoma
and hematological malignancy. Proc GU ASCO 2013, p 204 (abst # 449)
312.
* Nixon AB, Halabi S, Shterev I, Starr MD, Brady JC, Dutcher JP, Hopkins J, Hurwitz HI, Small E,
Rini B, Febbo PG, George D for the Alliance for Clinical Trials in Oncology. Identifiecation of
predictive biomarkers of overall survival in patients with advanced renal cell Crcinoma treated with
interferon alpha +/- bevacizumab: Results from CALGB 90206. Proc ASCO 2013
313. * Bailey AS, Cheng SC, Kwon ED, Leibovich BC, Signoretti S, Dutcher JP, Appleman LJ, Sosman
JA, Margloin KA, Clark J, Khushalani NI, Curti BD, Ernstoff MS, Pantuck AJ, Vaishampayan UN,
McDermott DF, Atkins MB: PDL-1/PDL-3 (Programmed Death Ligand 1/3) tissue expression and
response to treatment with IL2 and antiangiogenic therapies. J Clin Oncol 31, 2013 (suppl; Abst 4521).
314.
* Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Dutcher J, Wiernik P,
Palomba L, Portlock C, Murali R, Klein RJ, Coleman J, Stadler Z, Offit K, Vijai J: Renal cell
carcinoma and non-Hodgkin’s lymphoma: Genomic approaches to identification of shared
succeptibility. Proc Soc Urol Oncol, Dec 2013
315.
Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Dutcher J, Wiernik P,
Palomba L, Portlock C, Murali R, Klein RJ, Coleman J, Stadler Z, Offit K, Vijai J: Renal cell
carcinoma and non-Hodgkin’s lymphoma: Genomic approaches to identification of shared
succeptibility. Proc Am Urol Assoc, 2014
316.
*Wiernik PH, Dutcher JP: Families with both Hodgkin’s lymphoma and myeloma: Anticipation and
male transmission. J Invest Med 2014; 760, (Abst 3).
68
317.
*Chen Y, Garrett M, Rini B, Motzer RJ, Dutcher JP, Rixe O, Wilding G, Stadler WM, Tarazi J,
Pithavala YK: Effect of renal impairment on the pharmacokinetics and safety of axitinib. Proc
ASCPT, 2015.
318.
*Haas N, et al: Results from ASSURE (E2805): Adjuvant Sorafenib or Sunitinib for Unfavorable
Renal Carcinoma, and ECOG-ACRIN-led NCTN Phase 3 Trial. Proc GU ASCO, 2015. Abst 41765
319.
Pili R, Manola J, Craducci MA, Dutcher JJ, Appleman LL, Groteluschen DL, DiPaola RS: A
randomized phase II study to determine the effect of 2 different doses of AVE0005 (VEGF trap) in
patients with metastatic renal cell carcinoma: A trial of the ECOG-ACRIN Cancer Research Group
(E4805). Proc ASCO, 2015.
320.
*Haas N, et al: Dose analysis of ASSURE (E2805): Adjuvant Sorafenib or Sunitinib for unfavorable
renal carcinoma, an ECOG-ACRIN-led NCTN phase 3 Trial. Proc ASCO, 2015.
69
SELECTED INVITED PRESENTATIONS:
1.
Congressos Integrados Latino-Americanos de Cancerologia. Sao Paulo, Brazil, May 10-15, 1981.
"Present-Day Management of Hodgkins Disease".
2.
Congressos Integrados Latino-Americanos Cancerologia. Sao Paulo, Brazil, May 10-15, 1981.
"Treatment of Acute Leukemia".
3.
6th Annual Symposium on Advances in Cancer Treatment Research, Baltimore Cancer Research
Center and the University of Maryland School of Medicine, September 24-26, 1981. "Hematologic
Support of the Cancer Patient".
4.
Phagocyte Workshop, Washington, D.C., May 11, 1982. "The Effect of Alloimmunization on the
Migration of 111In-labeled Granulocytes to Infected Sites".
5.
Cancer Management Symposium, University of Maryland, Baltimore, May 21-22, 1982. "Ethiodized
Oil Emulsion (EOE) 13 for CT Scanning of the Liver and Spleen".
6.
Annual Meeting - Michigan Blood Bank Association, Detroit, Michigan, October 1, 1982.
"Indications for Platelet Transfusion".
7.
Guest Lecturer, State Hospital of St. Gallen, Switzerland, Dec. 1982. "New Approaches in the
Treatment of Acute Leukemia".
8.
Phagocytologists Workshop, Washington D.C., April 29, l983. "Pulmonary Retention of Indium-111Labeled Granulocytes".
9.
Symposium - The Controversial Platelet - sponsored by the American Red Cross Blood Services,
Central Ohio Region, Columbus, Ohio, May 5, 1983. "Clinical Approach to Platelet Transfusion
Therapy".
10.
I Latin American Congress of Clinical Oncology of the UICC, Lima, Peru, Sept 18-22, 1983.
"Management of Acute Leukemia".
11.
I Latin American Congress of Clinical Oncology of the UICC, Lima, Peru. Sept. 18-22, 1983.
"Present Status of the Treatment of Acute Non-Lymphocytic Leukemia".
12.
I Latin American Congress of Clinical Oncology of the UICC, Lima, Peru, Sept. 18-22, 1983.
"Neutropenia and Infections in Cancer".
13.
Co-Chairman, Session I on Leukemia and Myeloproliferative Disorders, American Society of
Hematology, 1983.
14.
Symposium on Advances in Cancer Treatment Research, Sponsored by Albert Einstein College of
Medicine/Montefiore Medical Center, Manhattan, N.Y. March 16-17, 1984. "Transfusion Supportive
Care".
15.
Co-Chairman, Session of Leukocytes, International Society of Hematology, 1984.
70
16.
Advances in Nuclear Medicine, 1985, Sponsored by Albert Einstein College of Medicine/Montefiore
Medical Center, Manhattan, NY. April 29-May 2, 1985. "Labeled Cells for Abscess and Thrombus
Localization".
17.
VIIIth Meeting of International Society of Haematology, European and African Division. Warsaw,
Poland. September 8-13, 1985. "A Clinical Program Of Platelet Cryopreservation".
18.
Oncology Grand Rounds, Long Island Jewish Hospital, New York, NY , February 1986. "Transfusion
Supportive Care".
19.
Oncology Grand Rounds, Mercy Hospital, Pittsburgh, PA, March, 1986. "Methotrexate, Leukovorin
Interactions".
20.
Oncology Grand Rounds, University of Maryland Cancer Center, Baltimore, Md, June, 1986.
"Leukemia Treatment in the Elderly".
21.
Oncology Grand Rounds, Mt. Sinai Hospital and Medical Center, New York, NY, July, 1986.
"Management of Acute Non-Lymphocytic Leukemia".
22.
Medical Grand Rounds, Bronx Lebanon Hospital, New York, NY, August, 1986. "New Approaches
in Oncology: Interleukin-2 and Bone Marrow Transplantation".
23.
Oncology Grand Rounds, Wilford Hall Air Force Medical Center, San Antonio, TX, October 2, 1986.
"High Dose Methotrexate Therapy - Is More Better?"
24.
San Antonio Blood Club, San Antonio, TX, October 2, 1986. "Platelet Transfusion Therapy in
Oncology Patients".
25.
Co-Chairman, Session on Transfusion, American Society of Hematology Meeting, 1986.
26.
The Melanoma Letter, Skin Cancer Foundation, December, 1986. "Experimental Therapy for
Melanoma: Interleukin-2 and Taxol".
27.
Medical Grand Rounds, "Infection Management in Patients with Malignancy", Our Lady of Mercy
Hospital, Bronx, NY, January 7, 1987.
28.
Invited presentation, "Hematologic Complications of Malignancy", Riverside Hospital, Red Bank, NJ,
March 4, 1987.
29.
Medical Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA, March 31, 1987.
"Granulocyte Transfusions and the Febrile Neutropenic Patient".
30.
Annual Symposium of Maine Society of Hospital Pharmacists, Sugarloaf, ME, June 6, 1987.
"Leukovorin and Chemotherapy Interactions".
31.
Invited participant, Hammer Workshop on The Nature of LAK Cells, Salk Institute, San Diego, CA,
July 24, 1987.
32.
Invited presentation, "Granulocyte Transfusion Therapy in Neutropenic Patients", symposium at
71
Abbott Laboratories, Chicago, IL, November 2, 1987.
33.
Invited presentation, "Management of the Neutropenic Patient", Westchester Hospital Pharmacy
Association, November 17, 1987.
34.
Study Section Participant, NCI-RFP on Biologic Response Modifiers in Cancer Research, Bethesda,
MD, December 2-3, 1987.
35.
Section on Oncology, World Book Encyclopedia Volume 14, page 767, 1989 edition.
36.
Invited participant, Hammer Workshop on Biologic Response Modifiers. Salk Institute, San Diego,
CA, January 4-5, 1988.
37.
Medical Grand Rounds, "Interleukin-2 and Interferon in Clinical Oncology", St. Barnabas Hospital,
Bronx, NY January 14, 1988.
38.
Medical Grand Rounds, "Clinical Trials with Interleukin-2", New York University School of
Medicine, January 20, 1988.
39.
Invited participant, Cetus Corporation Brainstorming Session on IL-2 in Melanoma, Emeryville, CA,
February 4, 1988.
40.
Current Trends in Cancer Diagnostics and Therapeutics, American Cancer Society and Quiller-Dishner
College of Medicine, East Tennessee State University, Johnson City, TN, April 8-9, 1988.
"Interleukin-2"; "Platelet Transfusion Therapy".
41.
Interleukin 2: Clinical and Biological Update. Roswell Park Memorial Institute, Buffalo, NY, April
20, 1988. "Current Status of NCI Extramural Trials".
42.
Co-Chairman, Session on AIDS and Epidemiology, American Society of Clinical Oncology, New
Orleans, LA, May 23-25, 1988.
43.
Medical Grand Rounds, "Hematologic Complications of Malignancy", Long Island College Hospital,
Brooklyn, NY June 2, 1988.
44.
Co-Chairman, Session on Chronic Myelogenous Leukemia, International Society of Hematology,
Milan, Italy, August 28-September 2, 1988.
45.
Participant, NCI-Extramural Working Group on Adoptive Immunotherapy - Work Session, Sept 2930, 1988, Bethesda, MD.
46.
Invited Participant, Workshop on Transfusion Medicine Applications for Growth Factors and Biologic
Response Modifiers, "Interleukin-2". American Association of Blood Banks National Meeting,
Kansas City, MO, October 8-12, 1988.
47.
Invited Participant in Rap Session on Cytokines and Adoptive Immunotherapy, AABB National
Meeting, Kansas City, MO, October 10, 1988.
48.
Participant, NCI Phase I/II Working Group Meeting, Feb 28-Mar 1, 1989, Bethesda, MD.
72
49.
Participant, Symposium on Plasma and Cytapheresis and Autologous Transfusion. South Central
Association of Blood Banks, 31st Annual Meeting, March 11, 1989, Houston, TX. "Mononuclear Cell
Separation, Improved Technology".
50.
Participant, Symposium: 6th Annual Advances in Cancer Treatment Research, Albert Einstein Cancer
Center, Manhattan, NY March 16-18, 1989, "Interleukin-2/LAK Cell Therapy".
51.
Medical Grand Rounds, Booth Memorial Hospital, Flushing, NY, April 4, 1989.
Applications of Biologic Response Modifiers".
52.
Invited Participant, American Society for Apheresis, April 6-8, 1989, Jacksonville, FL. "Controversies
in Apheresis - IL2/LAK/TIL Therapy, Efficacy, Toxicity, Controversies".
53.
Medical Grand Rounds, Brookdale Hospital, Brooklyn, NY, April 19, 1989. "Interleukin-2/LAK Cell
Therapy".
54.
Book Review of Thoracic Oncology, by Roth JA, Ruckdeschel JC, Weisenburger TH (eds), WB
Saunders, Philadelphia, PA, 1988; In Heart and Lung, the Journal of Critical Care, 1989.
55.
Medical Grand Rounds, Montefiore Medical Center, Bronx, NY, September 7, 1989. "Update of
Cancer Therapy with Interleukin-2".
56.
Oncology Grand Rounds, New York University Medical Center, NY, NY, September 21, 1989.
"Update of Cancer Therapy with Interleukin-2".
57.
Medical Grand Rounds, Bronx Municipal Hospital (Jacobi Hospital), Bronx, NY, September28, 1989,
"Update on Therapy of Adult Acute Non-lymphocytic Leukemia".
58.
Invited Participant, American College of Physicians, Workshop on the Role of Newer Drugs in the
Treatment of Common Diseases, New York, NY, September 29, 1989. "Adjuvant Therapy in Early
Breast Cancer".
59.
Invited Participant, Workshop on Transfusion Medicine Applications for Growth Factors and Biologic
Response Modifiers, "Interleukin-2". American Association of Blood Banks, National Meeting, New
Orleans, LA, October 20-26, 1989.
60.
Invited Participant, Management of Hematologic Malignancies in the 90s, "Transfusion therapy in
acute leukemia", The Annual Carolyn Standish Memorial Symposium. Allegheny General Hospital,
Pittsburgh, PA, February 16, 1990.
61.
Invited Participant, Medical Therapy into the 90s and Beyond, "Interleukins", American College of
Physicians, New York Downstate Scientific Meeting. New York, NY, March 31, 1990.
62.
Invited Speaker, Scientific Seminar of the Medical Advisory Council of the New Jersey Blood
Services. "Platelet transfusion therapy in oncology" New Brunswick, NJ May 15, 1990.
63.
Invited participant, Your Patient and Cancer, "Cancer and vitamins", August 1990.
73
"Clinical
64.
Invited Speaker and Participant, II Congreso Uruguayo de Trasplantes, "Tratamiento de apoyo del
trasplante de medula osea", Montevideo, Uruguay. October 29-Nov 1, 1990.
65.
Invited Speaker, Medical Grand Rounds, Jamaica Hospital, "Colony Stimulating Factors", Jamaica,
NY November 7, 1990.
66.
Invited Speaker and Participant, Second Symposium in memory of Marianna Lordos, The Cyprus
Anti-Cancer Society, "Recent advances in the prevention and management of Gynaecological cancer,
urological cancer, lung cancer." Larnaca, Cyprus, November 24-25, 1990.
67.
Invited Speaker, Oncology Update, Our Lady of Mercy Medical Center, Second Annual Symposium,
"A New Look at Hodgkin's Disease, December 11, 1990.
68.
Invited Speaker, Symposium on the Future of Treatment and Diagnosis of Acute Myelogenous
Leukemia. Presented at the combined annual meeting of the American Society of Hematology and
International Society of Hematology, November 30, 1990, Boston MA.
69.
Invited Participant, Progress in AML Treatment. Videoconference sponsored by the Leukemia Society
of America, January 31, 1991.
70.
Section on Sarcoidosis, World Book Encyclopedia Vol 17, page 123, 1992.
71.
Invited Speaker, American Cancer Society Symposium on New Pharmacologic Agents, Symposium of
Interleukin-2, Dallas, Texas, February 5-7, 1991.
72.
Invited Speaker, Eighth Annual Advances in Cancer Treatment Research, Manhattan, NY "Future
Directions of Biologic Response Modifiers in Cancer Therapy", March 14, 1991.
73.
Invited Speaker, American College of Physicians, "Workshop on the Role of Newer Drugs in the
Treatment of Common Diseases" "New Drugs in the Treatment of Cancer", Manhattan, NY, May 17,
1991.
74.
Invited Speaker, Fox Chase Cancer Center Network Meeting, "Biologic Response Modifiers in Acute
Leukemia” Philadelphia, PA, June 17, 1991.
75.
Invited Speaker, Hackensack Medical Center, "Problems of Clinical Alloimmunization to Platelets",
Hackensack, NJ, June 20, 1991.
76.
Invited Speaker, University of Michigan Cancer Center, "New Directions in Acute Leukemia", Ann
Arbor, Michigan, June 21, 1991.
77.
Invited Speaker, Toronto Hematology/Oncology Seminar, "Advances and Future in the treatment of
Acute Myeloblastic Leukemia", Toronto, Canada, August 21, 1991.
78.
Invited Speaker, Hematology Grand Rounds, Princess Margaret Hospital, "Biologic therapy in
hematologic malignancies", Toronto, Canada, August 21, 1991.
79.
Invited Speaker, Weiler Hospital of the Albert Einstein College of Medicine, State of the Art Medical
Grand Rounds, "Biologic Treatment of Neoplastic Disease", New York, NY October 8, 1991.
74
80.
Chairman, Session III, Albert Einstein Cancer Center Annual Retreat: "Biologic and Clinical Aspects
of Breast Cancer", "Discussion of Human Breast Cancer - Definition of the Problem", Oct 27-28,
1991.
81.
Chairman, Session on Adult Acute Lymphocytic Leukemia, 5th International Symposium on Therapy
of Acute Leukemias, Roma Italy, November 1-6, 1991.
82.
Invited Speaker, First Department of Oncology, University of Vienna, "New Treatments in Acute
Leukemia", Nov 6, 1991.
83.
Invited Speaker, Free University of Berlin, "Treatment of Adult Acute Leukemia", Berlin, Germany,
Nov 8, 1991.
84.
Invited Speaker, University of Freiberg, "Management of Acute Non-lymphocytic Leukemia",
Freiberg, Germany, Nov 9, 1991.
85.
Invited Speaker, Department of Hematology, Catholic Hospital, Seoul, Korea, "Management of Adult
Acute Leukemia", Nov 11, 1991.
86.
Invited Speaker, Second International Symposium on Management of Renal Cell Carcinoma. "High
dose Interleukin-2 Alone in Renal Cell Cancer", Cleveland Clinic Symposium, Cleveland, Ohio,
November 20-21, 1991.
87.
Invited Speaker, Carolyn Standish Memorial Symposium, Advances in Hematologic Malignancies,
"Acute Nonlymphocytic Leukemia", Allegheny General Hospital, Pittsburgh, PA, January 17, 1992.
88.
Invited Speaker, Leukemia Society of America Symposium, Orlando chapter, "Treatment of Acute
Non-lymphocytic Leukemia", Orlando, FL, March 12, 1992.
89.
Invited Speaker, 9th Annual Advances in Cancer Treatment Research, " Update of Biologic Response
Modifiers", Albert Einstein Cancer Center, New York, NY March 18, 1992.
90.
Cancer Consultation, "Management of CML", Primary Care and Cancer, March-April 1992.
91.
Invited Speaker, Simposio Idarubicina en Leucemias agudas mieloblasticas, "North American
Experience with Idarubicin in the Treatment of AML” National Hematology Society of Mexico,
Guanajuato, Mexico, April 24-25, 1992.
92.
Invited Speaker, Tumor Conference, Mary Immaculate Hospital, Queens, NY
Carcinoma", April 30, 1992.
93.
Invited Speaker, ECOG Education Symposium, ECOG semi-annual meeting, Baltimore, MD, "Growth
Factors: Use, Abuse, and Challenges", June 8, 1992.
94.
Chairperson and Speaker, Symposium on Advances in Metastatic Renal Cell Carcinoma:
Recombinant Interleukin-2 Therapy; New York, New York, "Experience with High Dose Interleukin2 Therapy", June 29, 1992.
75
"Renal Cell
95.
Chairperson, Session on Treatment of Adult Acute Lymphoblastic Leukemia: Present and Future.
Second International Meeting, LEUKAEMIA 1992. July 5, 1992, Genoa Italy.
96.
Consultant, Cetus - sponsored Management Guidelines in the Treatment of Metastatic Renal Cell
Carcinoma with Proleukin IL2. 1992.
97.
Sections on Oncology and Leukemia, World Book Encyclopedia, 1993.
98.
Invited speaker, Medical Oncology Grand Rounds, "Use and Future of Interleukin-2” Yale University,
New Haven, CT, September 22, 1992.
99.
Invited speaker, 1992 Medical Oncology Grand Rounds Symposium, University of Florida,
Gainesville, FL "Update and Future of Interleukin-2 in Cancer Therapy", Jacksonville, FL,
September 25, 1992.
100.
Invited speaker, Medical Oncology Grand Rounds, "Use and Future of Interleukin-2 in Cancer
Therapy", Medical College of Virginia, Richmond, VA, September 29, 1992.
101.
Invited speaker, National Meeting of the German and Austrian Hematology and Oncology Society,
"New agents and approaches in acute myeloid leukemia", Symposium, Berlin, Germany, October 4-7,
1992.
102.
Invited speaker, Chemotherapy Foundation Symposium X, "Clinical Applications of IL2". New York,
NY November 13, 1992.
103.
Division of Medical Oncology, Grand Rounds, "Prospects for Interleukin-2 Therapy", Northwestern
University School of Medicine, Chicago, IL. January 26, 1993.
104.
Department of Urology Grand Rounds, "Interleukin-2 in Renal Cell Cancer". University of Virginia
School of Medicine, Charlottesville, VA, January 28, 1993.
105.
Invited speaker, Joint Oncology Conference, "IL-2: A Biologic Response Modifier in Cancer
Therapy", Rhode Island Hospital , Providence, Rhode Island, February 19, 1993.
106.
Invited speaker, Dermatology Grand Rounds, "Treatment of Metastatic Melanoma” Albert Einstein
College of Medicine, New York, March 17, 1993.
107.
Invited faculty, Cobe Spectra User Conference, Apheresis Graduate School, "Cancer Treatments and
Cures - How Effective Are They in 1993?. Am Soc Apheresis Annual Meeting, Boston, MA, April
14, 1993.
108.
Oncology Grand Rounds, NYU Medical Center, "Interleukin-2 in Cancer Therapy", June 23, 1993.
109.
MedEdNet Teleconference: Diagnosis and Treatment of Melanoma. July 14, 1993.
110.
Advisory Committee, Sandoz Cytokine Development Unit, 1992-.
111.
Advisory Committee, Lederle Pharmaceuticals, Mitoxantrone, 1993.
76
112.
V Congresso Uruguayo de Hematologia, Sociedad de Hematologica del Uruguay. 27, 28, 29 de
Octubre de 1993.
113.
Venkatraj U and Dutcher JP: Case Studies in Oncology: GM-CSF in Metastatic Breast Cancer.
Promedica Pub. 1994.
114.
Basic Sciences Foundation of Clinical Oncology and Hematology Lecture Series, Long Island College
Hospital, Brooklyn, NY "Interleukins and Adoptive Cellular Immunotherapy of Cancer", May 5,
1994.
115.
Seminar, Frontiers in Medical Research Series, Senior Graduate Class, Albert Einstein College of
Medicine, "Applications of Basic Research to Clinical Problems", May 5, 1994.
116.
Symposium, Innovative New Therapies in Breast Cancer, Lymphoma and Leukemia, University
Ireland Cancer Center, Case Western Reserve, "Biologic Response Modifiers", Sept 21, 1994.
117.
International Symposium: Oncology '94. The Israel Cancer Association and The European School of
Oncology; Herzlia, Israel; October 17-20, 1994. "High Dose Chemotherapy in the Treatment of Breast
Cancer and Lymphoma" and Biologic Response Modifiers in Cancer Therapy"
118.
Dutcher JP: Defense Against Infection: An Overview of the Immune System and Cytokine Network.
CME Monograph, Albert Einstein College of Medicine. January 1995.
119.
Dutcher JP and Wiernik PH: Commentary on Acute Lymphoblastic Leukemia in Adults by Ong and
Larson, Oncology, 9:442-444, 1995.
120.
Invited Speaker, New Developments in Cancer Biotherapy: The Second Decade. "Cytokines in Cancer
Therapy". Presbyterian/St. Luke's Medical Center, Denver Colorado. March 30, 1995.
121.
Invited Participant American College of Physicians Midwest Board Review Course, organized by
Rush Medical College. Lectures on Genitourinary Cancer, Gynecologic Cancer and Oncologic
Emergencies. Chicago, IL. May 25, 1995.
122.
Invited Participant, NCI-Japanese Joint Seminar on therapy of acute leukemia, Oakland, CA, March 23, 1996.
123.
Book Review, Multiple Myeloma, G. Gahrton and BGM Durie (eds), Arnold, London GB, Pub and
copub Oxford University Press, NY 1996; In Medical Oncology, 1997.
124.
Invited Participant, Congressos Oncologicos en el Uruguay, Round Table on Non-Hodgkin's
Lymphoma, "Perspectives in Treatment of Low-Grade non-Hodgkin's Lymphoma", December 12,
1996.
125.
Book Review: Multiple Myeloma Edited by Gahrton & Durie, Published by Arnold, London GB and
copublished by Oxford University Press. in Medical Oncology 13:243-244, 1996.
126.
Invited Commentary: Tumor Board, Oncology Times, 1997.
127.
Faculty, 2nd Annual AACR/ASCO Workshop on Clinical Trials Methodology; Vail Colorado, July
77
1997.
128.
Co-Moderator and Invited Speaker, Memorial Regional Cancer Center, Annual Oncology Update for
Primary Care Physicians, Hollywood, Fla, February 5-7, 1997.
129.
Invited Speaker, AACR Educational Session, Cancer Research and the FDA, discussion of FDA
Advisory Committees, March 28, 1998.
130.
Invited Speaker, Second Annual Albert P Sutton Visiting Professor Conference on Genitourinary
Oncology, Long Island Jewish Medical Center, April 3, 1998.
131.
Invited Speaker, New York Roentgen Society Spring Conference, Leukemia for Non-Medical
Oncologists, April 24, 1998, New York.
132.
Invited Participant, American Society for Clinical Oncology, Fellows Breakfast at Annual Meeting:
Strategies for a Successful Career in Academic Oncology. May 15-16, 1999 Atlanta, GA
133.
Book Review, Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunization, edited
by Kickler and Herman, AABB Press, 1999; In AABB Weekly Report, 2000.
134.
Invited Participant, University of Bochum Dept of Dermatology Symposium on Melanoma.
Presentation of ECOG 1684 and 1690 studies. Bochum Germany, Jan 29, 2000.
135.
Invited Speaker, 7th Annual Cancer Symposium, New Millenium Strategies and Developments in
Multimodality Cancer Therapy, March 31, 2000, Tarrytown, NY. Talks on Chemotherapy in Brain
Tumors; Adjuvant Therapy in Breast Cancer, and Medical Oncology Clinical Trials.
136.
Invited Speaker, Cancer Genetics Symposium, Annual Meeting of Society of Experimental Biology,
American Federation for Medical Research, Familial Prostate Cancer. April 15, 2000, San Diego, Ca.
137.
Visiting Professor and Lecturer, Mayo Clinic, Rochester MN. April 20, 2000. Three Lymphoma
Stories.
138.
Invited participant, Reflections in Courage, Web Discussion of Treatment of Melanoma. Sponsored
by Cancer Care and cancer education.com. May 25, 2000.
139.
Book Review, Transfusion Therapy: Clinical Principles and Practice, P.D. Mintz (ed), AABB Press,
2000. In Annals of Internal Medicine, 133:572, 2000.
Book Review, Aplastic Anemia: Pathophysiology and Treatment. H. Schrezenmeier, A Bacigalupo
(eds) Cambridge University Press, 2000.. In Medical Oncology 2000; 17:248.
140.
141.
Lecturer, Medical Oncology Grand Rounds, MD Anderson Cancer Center, October 9, 2001. Biology
and Management of Renal Cell Cancer.
142.
Visiting Professor and Lecturer, Dept Oncology, Johns Hopkins University Medical Center, October
24, 2001. Biology and Management of Renal Cell Cancer.
143.
Visiting Professor and Lecturer, Dept of Urology, New York Medical College. January 17, 2002.
Role of Chemotherapy in Bladder Cancer and Role of Immunotherapy in Metastatic Renal Cell
78
Cancer.
144.
Invited Speaker, Conference on the Role of Intraoperative Radiotherapy, Department of Radiation
Oncology, New York Medical College. March 8, 2002.
Current Status of Neoadjuvant
Chemotherapy in Prostate Cancer. Risks and Benefits of Adjuvant Hormonal Therapy in Breast
Cancer.
145.
Invited Speaker, Conference of the Society of Oncology Pharmacists. Interleukin-2 Therapy. St
Petersburg, FL. April 2002.
146.
Invited Speaker, ASCO Symposium, IL2-Based Therapy for Kidney Cancer and Melanoma. Chicago,
IL May 2003.
147.
Invited Speaker, ASCO Educational Program: Methods: Phase I and II Trials. Chicago, IL May
2003.
148.
149.
Invited Discussant, Session on New Therapy in Renal Cell Cancer, ASCO Annual Meeting, 2004.
Invited Discussant, Session on Health Policy – FDA Drug Approval Process, ASCO Annual Meeting,
2004
Invited Speaker, Noon Conference, State University of New York, Syracuse. Update on the
Treatment of Metastatic Renal Cell Carcinoma. September 30, 2004.
150.
Invited Speaker, Van Andel Reasearch Institute, Han-Mo Koo Memorial Seminar Series: “Clinical
Features and Treatment of Metastatic Renal Cell Cancer” October 6, 2004
151.
Invited Speaker, Renal Cancer Symposium, Mayo Clinic, Jacksonville FL, August 2004.
152.
Invited Speaker, Kidney Cancer Association Scientific Meeting, Chicago, IL, November 2005.
153.
Invited Speaker, Cancer 2006, Preferred Treatment and Management Options, Hoag Cancer
Center, Newport Beach, CA. Adjuvant Treatment and Treatment of Advanced Melanoma,
January 27, 2006.
154.
Invited Speaker, Clinical Hematology and Oncology, Scripps Cancer Center, La Jolla, CA,
Targeted Therapy for Renal Cancer, February 20, 2006.
155.
Invited Speaker, ONS 31st Annual Congress Symposium: Renal Cell Cearcinoma: Today’s
Targeted Therapies Improving Tomorrow’s Outcomes. Renal Cell Cancer: Risk, Diagnosis, and
Staging. May 5, 2006.
156.
Discussant, Clinical Science Symposium, 2006 ASCO, Renal Cell Cancer, Non-Clear Cell Renal
Cell Cancer. June 3, 2006.
157.
Invited Speaker, PER Kidney and Bladder Cancer Symposium, August 2006, Florida. Topic –
Long term treatment of Metastatic Renal Cell Cancer with Tyrosine Kinase Inhibitors; Update of
whatever information exists.
79
158.
Invited Speaker, 2006, International Kidney Cancer Association meeting, Chicago, Sept 23, 2006.
Topic – Update on the Expanded Access Sunitinib Trial.
159.
Invited Speaker, 10th Aniversary Joint Cancer Conference of the Florida Universities. Sept 28-Oct
1, 2006. Topic – Targeting mTOR and applications of chemotherapy and immunotherapy in
metastatic renal cell cancer.
160.
Invited Speaker, 4th International Congress on Kidney and Bladder Cancer, August 3-5, 2007,
Orlando, FL. Novel Agents for Targeting Non-Clear Cell Carcinoma.
161.
Invited Speaker, 7th International Congress on Monoclonal Antibodies in Cancer, August 17-19,
2007, Quebec, Canada. Combinations with Anti-VEGF Antibodies. Emerging Antibodies –
Rencarex in Renal Cell Cancer.
162.
Invited Speaker, 2nd Inter – American Oncology Conference – Targeted Therapies.
12-14, 2007. Buenos Aires, AR. Targeted Therapies in Renal Cell Cancer.
163.
Invited Speaker, Chemotherapy Foundation Symposium, XXV: Expanded Access Therapy of
Renal Cell Cancer (Sunitinib and Sorafenib). November 2007, New York, NY.
164.
Invited Speaker, Consensus Conference: Evolving Strategies for the Management of Cutaneous
Toxicites Associated with Multitargeted Kinase Inhibitors. “ Survival Data and Correlation with
Toxicities” - OLM data base. Chicago, IL, January 21, 2008.
165.
Invited Speaker, Eighth International Congress on Genitourinary Malignancies. “Chromophobe
Renal Cell Carcinoma/ Collecting Duct Carcinoma”, Washington DC, July 17-19, 2008.
166.
Invited Speaker, Seventh International Kidney Cancer Association Symposium. “ Management of
Patients with Impaired Organ Function” Chicago, IL Sept 26-27, 2008.
167.
Invited Speaker, Japanese Society of Oncology, Targeted Therapy in Renal Cell Cancer, Nagoya,
Japan, November 3, 2008.
168.
Invited Speaker, Japanese Society of Renal Cancer, mTOR inhibition in Renal Cell Cancer,
Nagoya, Japan, November 4, 2008.
169.
Invited Speaker, Novartis Oncology Emerging Gloal Market RCC Forum – Advances in the
Treatment of Renal Cell Cancer. Singapore, March 14-15, 2009.
170.
Invited Speaker, New York Cancer Consortium, Review of GU ASCO 2009, Manhattan, NY
March 20, 2009.
171.
Invited Speaker, Mayo Clinic Jacksonville, Review Of Oncology, Update on Treatment of Renal
Cell Carcinoma, Amelia Island, FL, August 2009.
172.
Invited Speaker, Kidney Cancer Association, Annual Meeting, Chemotherapy for Sarcomatoid
80
September
Renal Cell Cancer, Chicago, IL, September 25-27, 2009.
173.
Invited speaker: International RCC Expertise Exchange: November 13, 2009 New York
174.
Invited Speaker, Seventh Annual Current Trends in Genitourinary Malignancies: October 16,
2010; New York, Sponsored by New York Presbyterian Hospital/Weill Cornell Medical Center/
Columbia University Medical Center. “Management of non-Clear Cell Renal Cell Carcinoma.
175.
Medical Grand Rounds, Renal Cancer, Beth Israel Medical Center, NY NY 2011
176.
Urology Grand Rounds, Renal Cancer, Beth Israel Medical Center, NY NY 2011
177.
Moderator, Session on Symptom Management, International Kidney Cancer Association, Annual
Meeting, Chicago, IL, October 2011.
178.
Urology Grand Rounds, Brookdale Hospital Center, Brooklyn NY 2011
179.
Medical Oncology Grand Rounds, Methodist Hospital Center, Brooklyn NY 2012
180.
Medical Oncology Grand Rounds, Newark Veterans Hospital, East Orange, NJ 2012
181.
Urology Grand Rounds, Long Island College Hospital, Brooklyn NY, 2012.
182.
Citywide Annual Meeting of Tumor Registrars, Renal Cell Cancer, held at Roosevelt Hospital,
March 2012.
183.
Medicine Grand Rounds, St Luke’s Roosevelt Hospital Center, NY NY April 2012
184.
Chair, Session I, American Federation of Clinical Research, Eastern Division, April 2012
185.
ECOG Fall Meeting Pharmacy/Nursing/CRA Education Symposium – Invited Presentation –
Renal Cell Carcinoma Update. November 10, 2012.
186.
Dept Urology Grand Rounds, Long-Island Jewish/North Shore Medical Center, March 2013
187.
Dept Urology Grand Rounds, Columbia University Medical Center, April 2013.
188.
Upstate Urology Conference sponsored by Dept Urology, Albany Medical Center, Lake Placid NY
August 17, 2013.
189.
Dept Medicine Grand Rounds, Update on Renal Cell Cancer, Winthrop University Hospital, LI
NY October 2013
190,
Dept Medicine Grand Rounds, Update on Renal Cell Cancer, St Barnabas Hospital, Bronx NY
October 2013
191.
Kidney Cancer Association Annual Meeting – Newer TKI Agents in Front Line Setting: Con
Discussant - Chicago, Novermber 2013
81
Cabozantinib – An active agent in prostate and renal cell
192.
Chemotherapy Foundation, NY, NY
cancer. November 2013
193.
Dept Medicine Grand Rounds, Update of IL-2 based Immunotherapy; University of Cincinnati,
Cincinnati OH, February 21, 2014
194.
Dept Medicine Grand Rounds, Update on Renal Cell Cancer, Jacobi Hospital, Bronx NY
February 25, 2014
195.
Dept Melanoma Grand Rounds, MD Anderson Cancer Center, Houston TX, Immuotherapy of
Melanoma, 2014; July 14, 2014
196.
Upstate Urology Conference sponsored by Dept Urology, Albany Medical Center, Lake Placid NY
August 16, 2014.
197.
Rome International Meeting on Geriatric Oncology, Universita de Siena and Sapienza Universita
de Roma, Dec 4-5, 2014, Chair, session on Kidney Cancer
198.
Kidney Cancer Association: 2015 Patient and Survivor Workshop – New York, Update on
Immunotherapy; Jan 10, 2015.
199.
Eastern Regional Meeting, American Federation for Medical Research, Washington DC, April 16,
2015. Co-Chair, Symposium I: Update: Primary Immune Deficiency Disorders Associated with
Chronic Rhinosinusitis and Malignancy.
200.
International Kidney Cancer Coalition (IKCC) - 5th International Conference for Organizations
Representing Patinets with Kidney Cancer, April 16-18, 2015, Morristown NJ, USA; April 18 Speaker - Advances in Immuno-Oncology for Kidney Cancer.
82
STUDENTS AND HOUSESTAFF PRECEPTED
STUDENTS
1983 Shoshanah Pollock - Summary of patients studied with ethiodized oil emulsion-13. (abstract).
1984 Jack Catanese - a) follow-up of AECOM Hodgkin's disease patients for long-term toxicity 1985b)
case report of Hodgkin's disease patient developing osteosarcoma in irradiated tissue (published).
1986 Vicki Weiss - Interleukin-2 clinical project: Nutritional abnormalities in such patients.
1988 Craig Shalmi - Mechanism of renal failure in patients treated with IL2 (abstract presented; paper
published - JCO).
1989 David Merer - a) case report of patient with melanoma metastatic to heart (published) b)
Evaluation of tryptophan depletion therapy in patients with advanced malignancy.
1989 Tara Solomon - Evaluation of the coagulopathy associated with IL2 therapy (published).
1997 Jing-Jing Wu - Evaluation of sarcomatoid histology of renal cell cancer impact on prognosis vs
mixed sarcomatoid/clear cell (presented AACR - 1998; published).
1998 Stephen Huang - IL6 in metastatic ocular melanoma.
1998 Boris Kuzinsky - HPV in renal cell cancer
2004 – Ellice Wong – Cardiovascular toxicity of chemotherapy
HOUSESTAFF
1986 Stuart Marcus - Evaluation of nutritional deficiencies in patients treated with IL2; (published)
evaluation of catecholamines in patients treated with IL2. (Abstract).
1987 Daniel Petrylak - Evaluation of micronutrient changes in patients treated with IL2. (published).
1989 Steven Werfel - case report of a patient with renal insufficiency treated with IL2 and resembling
graft versus host reaction (paper published - Am J Nephrol 1992).
1989 Craig Moskowitz - Thyroid dysfunction associated with acute leukemia. (Abstract presented 1990;
paper published, Am J Heme 1991).
1991 Bruce Gaynor - Phase II study of carboplatin and mitoxantrone in relapsed/refractory leukemia.
(abstract presented ASH 1991; manuscript published Medical Oncology 2010, epub 2009).
2000-2001
D. Unnikrishnan - Torsades de pointes in three patients on treatment with arsenic
trioxide and other cardiologic features. (Abstracts presented at ISEH, 2000 and Am Col Cardiol, 2001;
published in Blood.
83
2001-2002
Giridhar Adiga - Characterization of bone metastases in patients with renal cell cancer.
(Abstract presented at meeting on bone metastases, NIH, Bethesda MD 2002; manuscript
published)
2002-2003 Giridhar Adiga – Evaluation of iatrogenic anemia in hospitalized elderly. Abstract submitted
to ASH and presented at Am Geriatric Society annual meeting 2003.
2002-2003 Prashant Mannam – Review of outcome of patients with metastatic renal cell cancer and
evaluation of prognostic factors in those treated with interleukin-2 based therapy. Abstract submitted to
ASCO 2003.
2002-2003 A .Kunther – Association of renal cell cancer and non-Hodgkin’s lymphoma. (manuscript
published, Am J. Heme.)
2003- R.Karri – Update of MVC in Relapsed Hodgkin’s disease, with Doru Alexandrescu. Abstract
presented at ASH.
2003- Evelyn Morris - Mitoxantrone and Carboplatin in Blast Crisis of CML (manuscript published,
Medical Oncology, 2010, epub 2009.).
2004 – Luis Natali – Arrhythmias in patients receiving IL2. Abstract submitted.
2006 - Sung Lee – Eosinophilia in patients undergoing high dose IL2 therapy. Abstract presented at
Int Soc Biological Therapy.
2007 - Sung Lee – Pruritis responding to gabapentin in patients undergoing high dose IL2 therapy.
Abstract presented at ASCO.
2007 – Padmaja Bojanopally – Taxol and High dose IL2 Sequential biochemotherapy in melanoma.
Abstract presented at ASCO.
2008 - Padmaja Bojanopally/ Mohammed Mowla - Temsirolimus – experience with compassionate
and commercially available agent in patients with metastatic RCC. Abstract presented at ASCO 2008;
Manuscript submitted, Medical Oncology.
2008 – Sung Lee - Pruritis and Eosinophilia mechanisms - Abstract presented at Kidney Cancer
Association meeting , 2008. Paper published J Immunotherapy
2009 - Mahadi Baig - Sung Lee, Mahadi Baig - Long term remission of CML in Blast Crisis treated
with IFN, plicamycin, and finally imatinib. Published, 2009.
2010 – Mahadi Baig, Sung Lee - Eosinophilia and Pruiritis in RCC treated with IL2, use of
Gabapentin, published J immunotherapy, 2010
2009 - S Gunturu - *Gunturu S, Adiga GU, Dutcher JP: Lactobacillus jensenii bacteremia while on
probiotic therapy. Am J Gastro 105 (Suppl 1): S 227 (abstr # 628), 2010
2009 – Amin – toxicity of Sorafenib and correlation with response
84
2010 - Ravi - Castlemans’s Disease - Diagnosis in Oncology (submitted)
2011 – Mowla and Padmaja - Temsiroimus – non-trial experience (in preapartion)
2012 - Varella - RCC and Lymphoma in families – abstract submitted KCA, GU Oncology
FELLOWS
1987 Karen Simon - case report of adenocarcinoma arising in vulvar breast tissue (published).
1989 Margery Strack - Evaluation of coagulopathy associated with IL2 therapy. (abstract presented;
published).
1990 Grace Sagayadan - Therapy of acute leukemia in elderly patients.
1990 Fabio Volterra - Lymphoma in association with breast cancer.(abstract presented, manuscript
published).
1991 Sreenivas Rao - Role of biologic response modifiers in hematologic malignancies (published).
1992 Deborah Colletti - Alpha interferon and plicamycin for accelerated phase chronic myelogenous
leukemia (abstract presented; manuscript published).
2003- Alexandrescu Doru and Lydia Koulova – Rituxan in treatment of TTP and ITP (manuscript
published)
2003- Alexandrescu Doru – Case studies of high dose and low dose IL2 (monograph published)
2003 – Alexandrescu Doru – Fatal intra-alveolar hemorrhage in a patient receiving Rituxan (manuscript
published)
2003- Alexandrescu Doru – IV gamma globulin and risk of Stroke (published)
2004 – Lydia Koulova - Phase II study of IL2 amd GMCSF in metastatic RCC (manuscript published)
2004 – Alexandrescu Doru – Chapter, Chemotherapy Toxicities and Complications, In Clinical
Hematology, (Ed) S. Gerson, et al: In press, 2005.
2004 – Alexandrescu Doru – Update of MVC for Hodgkin’s disease with Dr. Karri – presented at ASH,
manucript in preparation.
2004 – Vladimir Hugec and Lydia Koulova – Gemcitabine in advanced renal cancer. Abstract
published.
2005 – Vladimir Hugec – Chapter, Management of non-Clear Cell renal cell cancer In Clinical
Management of Renal Tumors, (Eds) R Bukowski, A Novick, 2008
2006 - Constantine Dasanu – Skin Changes in patients receiving tyrosine Kinase inhibitors – articles
published.
85
2006- Merat Esfahani – Review of treatment of CML- Blast Crisis – published Current Treatment
Options.
2009 – Sung Lee, Mahadi Baig - Long term remission of CML in Blast Crisis treated with IFN,
plicamycin, and finally imatinib. Published, 2009.
2006-9 – Sung Lee - Eosinophilia and Pruiritis in RCC treated with IL2, presented, Kidney Cancer
Meeting, Chicago. Published, J Immunotherapy, 7/2010.
2009-2010 - Giridhar U. Adiga - *Gunturu S, Adiga GU, Dutcher JP: Lactobacillus jensenii
bacteremia while on probiotic therapy. Am J Gastro 105 (Suppl 1): S 227 (abstr # 628), 2010
2010-2011- Giridhar U. Adiga - Colorectal Cancer In Geriatric Gastroenterology, C Pitchumoni and
TS Dhamarajan (eds). IN press 2011
2012-2013 - Rangaswamy Chintapatla - RCC and lymphoma in families – abstract at GU oncology
and KCA 2012.
86